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ABSTRACT: The commercial macrolide antibiotic fidaxomicin was synthesized in a highly convergent manner. Salient features of 
this synthesis include a β-selective noviosylation, a β-selective rhamnosylation, a ring closing metathesis, a Suzuki coupling and a 
vinylogous Mukaiyama aldol reaction. Careful choice of protecting groups and fine tuning of the glycosylation reactions led to the 
first total synthesis of fidaxomicin. In addition, a relay synthesis of fidaxomicin was established, which gives access to a conveniently 




Fidaxomicin (1, Figure 1), also known as tiacumicin B and 
lipiarmycin A3, constitutes a macrolide antibiotic used for the 
treatment of Clostridium difficile infections (CDI),1 which are 
considered responsible for a significant number of hospital-ac-
quired infections, resulting in over 29’000 deaths each year in 
the USA.2 While vancomycin and metronidazole are generally 
prescribed for this condition as first-line treatment,3 the intro-
duction of fidaxomicin (1) in the USA and the EU in 2011 pre-
sented a new therapeutic option.4 Currently, it is recommended 
for the treatment of severe or moderate cases of CDI and lower 
recurrence rates than the standard vancomycin control have 
been reported.5 Upon oral administration, fidaxomicin (1) 
shows selective bactericidal activity without being absorbed 
into the blood stream.6 The mechanism of action includes bind-
ing to RNA polymerase7 at a different binding site compared to 
other RNA polymerase inhibitors. Binding of fidaxomicin pre-
vents formation of the RNA polymerase open complex and ini-
tiation of transcription.8 For these reasons, fidaxomicin (1) pre-
sents a first-in-class drug with a validated mechanism of action. 
Interestingly, fidaxomicin (1) was also reported to be active 
against Mycobacterium tuberculosis, including drug resistant 
strains,9 thus attracting further biological interest to this class of 
antibiotics. 
Over the last four decades, over forty members of the tiacum-
icin family of natural products have been reported from several 
sources of bacteria.10 The first isolation of fidaxomicin (1) from 
Actinoplanes deccanensis by Gruppo Lepetit scientists dates 
back to 1972.11 The only structural element they could elucidate 
at that time however, was the dichlorohomoorsellinic acid frag-
ment, probably due to the complex structure of the macrolide. 
In 1986, tiacumicins A, B and C were isolated from Dactylo-
sporangium aurantiacum, as were the clostomicins from Mi-
cromonospora echinospora, and the relative configuration was 
elucidated.12 At this point, it remained unclear if tiacumicin B, 
clostomicin B1, and lipiarmycin A3 shared an identical consti-
tution and configuration. The complete structure of tiacumicin 
B was unambiguously established by X-ray crystallographic 
analysis in 2006.13 Currently, lipiarmycin A3 and tiacumicin B 
(fidaxomicin, 1) as well as clostomicin B1 have been estab-
lished to be identical.13 Further isolation of fidaxomicin deriva-
tives was recently achieved in a biosynthetic study by Zhang 
and co-workers,14 where the genes responsible for the biosynthe-
sis were also investigated. 



























































Concerning its molecular architecture, fidaxomicin (1) dis-
plays a number of remarkable features. The 18-membered mac-
rocycle features five stereogenic centers and five double bonds 
arranged in two different diene moieties. Additionally, one of 
the two carbohydrate segments, 4-demethyl-D-noviose, is rarely 
found in natural products, rendering fidaxomicin (1) a unique 
antibiotic. Moreover, the two glycosidic linkages are arranged 
in β-fashion. Therefore, the major synthetic challenges for the 
synthesis of fidaxomicin (1) are associated with (1) the selective 
installation of the two glycosidic linkages (the cis–1,2 diol link-
age, cf. the β-mannose problem)15 between the macrocycle and 
the two carbohydrate segments as well as (2) convergent con-
struction of the highly unsaturated macrocycle domains. Up to 
date, four synthetic studies of the 18-membered macrocycle of 
fidaxomicin (1) have been reported by Zhu,16 Altmann,17 
Roulland18 and our research group.19 Furthermore, the synthesis 
of noviose,20 rhamnose21 and a resorcinol domain22 have been re-
ported. As is demonstrated in the synthesis of β-lactams or 
erythromycin derivatives,23 we support the notion that both total 
chemical synthesis as well as semisynthesis can offer a pivotal 
platform for the discovery of new antibiotics. Consequently, we 
have published the first total synthesis of fidaxomicin (1, ti-
acumicin B, lipiarmycin A3) in a preliminary communication.24 
In this study, we report (1) on the second generation total syn-
thesis of fidaxomicin (1) leading to a 72-fold increase in overall 
yield; (2) on a successful relay synthesis of the target, which 
enables the preparation of semisynthetic analogs from the natu-
ral material; (3) degradation studies of this drug under a variety 
of conditions and (4) document the first total synthesis of the 
related congener, tiacumicin A (2).  
RESULTS AND DISCUSSION 
Stability Analysis of Fidaxomicin (1). Although fidax-
omicin (1) is a commercialized antibiotic, little about the chem-
ical stability nor semisynthetic studies had been reported at the 
start of our synthetic endeavor.25 Therefore, we decided to em-
bark on evaluating the stability of fidaxomicin under a series of 
conditions. Specifically, we determined the pKa of 1, examined 
the sensitivity of 1 towards acidic conditions and basic condi-
tions and identified the degradation products.  
For determination of the pKa value, an aqueous solution of 
NaOH (0.01 M) was added portionwise to a solution of fidax-
omicin (1) in a MeOH/H2O solvent mixture, as fidaxomicin is 
hardly soluble in pure water at neutral pH. The pH was deter-
mined after each addition of NaOH solution. The pKa value of 
fidaxomicin in this MeOH/H2O mixture was determined by 
identification of the titration’s mid-point to be pK
aw
s = 6.6. This 
is in accordance with the value given in the literature, pK
aw
s = 
6.8, in a solvent mixture 2-methoxyethanol/H2O 4/1.26 However, 
the pKa value in pure H2O, which was not experimentally deter-
mined due to the low solubility of fidaxomicin (1) in H2O, is of 
higher interest for reasons of comparability. With the help of 
empirical parameters specific for phenols as acids, the corre-
sponding value was calculated to be pK
aw
w = 5.6.27 The very high 
acidity of the dichlorohomoorsellinic acid group in fidaxomicin 
can be rationalized by the electron withdrawing effect of the es-
ter substituent at para-position and the inductive effects by the 
chloro substituents at the ortho-positions. 
 
Scheme 1. Stability Analysis of Fidaxomicin (1) 
 
Next, we examined the sensitivity of 1 towards acidic condi-
tions (Scheme 1). Treatment of 1 with hydrochloric acid under 
anhydrous conditions in dichloromethane led to a formation of 
tetrahydrofuran derivatives (15R)-6 and its epimer.28 This par-
ticular reaction was supposed to have occurred via an intramo-
lecular oxy-SN2´ type attack of the hydroxy group at C18. Alter-
natively, when hydrochloric acid was added to fidaxomicin (1) 
in protic solvents such as MeOH, the corresponding methoxy-
adducts were formed as methanol attacks the diene system in-
stead of the hydroxy group at C18 (not shown). With only ten 
equivalents of HCl in MeOH at room temperature, fidaxomicin 
(1) slowly degraded. However, with 100 equivalents of HCl, 
nearly complete degradation was observed within four hours 
with the main degradation product resulting from nucleophilic 
attack of methanol (m/z = 863 for [M+Na]+) and loss of the no-
viose segment. These results are consistent with the regulatory 
information for fidaxomicin, where fidaxomicin is reported 
chemically unstable outside of pH range from 4 to 8.29 
Next, the stability of fidaxomicin (1) was investigated under 
basic conditions. When 1 was treated with NaOH in MeOH and 
water, the isobutyrate group of noviose segment migrated from 
the C4´´ to the C3´´ position to provide tiacumicin F (3) and 
from the C4´´ to the C2´´ position to provide tiacumicin C (4). 
Under even stronger basic conditions or prolonged exposure to 
base, the isobutyrate was hydrolyzed to give alcohol 5, which is 
the main metabolite of fidaxomicin, OP-1118.4, 30 Therefore, the 
choice of cleavable protecting groups under very mild and or-
thogonal conditions was critically important for the total syn-













































































































To identify the optimal protecting groups for the sensitive 
groups in fidaxomicin (1), a series of protection and deprotec-
tion experiments was performed (Scheme 2). First, we protected 
the aromatic hydroxy groups on the resorcylate moiety as allyl 
ethers which could be cleaved under standard Pd catalysis con-
ditions. Next, the 1,2-syn-diol on the noviose moiety was suc-
cess protected as a cyclic carbonate using CDI (carbonyl diim-
idazole). At this point, the carbonate was the best protecting 
group for the diol, as it offered fast hydrolysis. Additionally, the 
electron withdrawing effect was expected to contribute to the β-
selective glycosylation as it destabilizes the oxacarbenium ions 
and should therefore prevent the non-selective SN1 process (vide 
infra). Other protecting groups, such as di-tert-butylsilylene or 
dimethylsilylene could not be implemented. Finally, the two re-
maining hydroxy groups on the macrocycle were protected as 
TBS ethers using TBSOTf and 2,6-lutidine, to provide pro-
tected fidaxomicin 7. The C3 hydroxy group on the rhamnose 
fragment was not protected under these conditions, presumably 
due to steric reasons. 
The deprotections were initiated by treatment with 3HF·NEt3 
at 50 °C to cleave the two TBS groups, which led to the clean 
formation of the corresponding alcohol. By the careful monitor-
ing of the deprotection reactions, we observed the quick cleav-
age of C18 TBS ether at room temperature. However, the TBS 
group at C7 was found to be very stable reflecting the steric 
bulkiness of the surrounding environment, requiring harsher 
deprotection conditions. As it was expected, subsequent car-
bonate deprotection turned out to be troublesome due to the mi-
gration of the C4´´ ester group on the noviose segment: DBU, 
K2CO3, DMAP, or DABCO led to the formation of tiacumicin F 
(3), tiacumicin C (4) and 5. Finally, the desired product was iso-
lated by the treatment with Barton´s base31 at room temperature 
in wet dichloromethane, although isobutyrate migration reac-
tions could still not be completely suppressed. Further improve-
ment for the selective hydrolysis was achieved by the treatment 
with NaH and ethylene glycol in dry tetrahydrofurane at 0 °C. 
Finally, the allyl groups were removed under Pd (0) catalysis to 
provide fidaxomicin (1). 
Scheme 2. Semisynthetic Approach for the Selection of Pro-
tecting Groupsa 
 
aReagents and conditions: a) allyl bromide, K2CO3, DMF, 45 °C, 
3 h, 89%; b) CDI, Et3N, CH2Cl2, rt, 24 h, 90%; c) TBSOTf, 2,6-lut., 
CH2Cl2, 0 °C to rt, 5 h, 52%; d) 3HF·NEt3, THF, 50 °C, 2 d, > 99%; e) 
NaH, (CH2OH)2, THF, 0 °C, 15 min; RP-HPLC, 46%; f) Pd(PPh3)4, mor-
pholine, THF, 0 °C, 30 min, 86%. DMF = N,N-dimethyl formamide, 
CDI = 1,1-carbonyldiimidazole, TBS = tert-butyldimethylsilyl, 2,6-
lut. = 2,6-lutidine, THF = tetrahydrofuran. 
Scheme 3. Retrosynthetic Analysis 
Retrosynthetic Analysis. Based on the preliminary stability 
assessment and the evaluation of protecting groups, we identi-
fied a retrosynthetic strategy outlined in Scheme 3. Cleavage of 
the two b-glycosidic bonds and the orsellinic ester bond would 
give the four segments 8, 9, 10 and 11. The macrocycle 10 could 
be accessed via Yamaguchi esterification, Pd catalyzed Suzuki 
or Stille cross coupling and a ring closing metathesis from frag-
ments 12, 13 and 14. Although Zhu and co-workers utilized ex-
tensive Evans aldol reactions,16 we propose that a vinylogous 
Mukaiyama aldol reaction of the silyl ketene aminal 15 and the 
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Rhamnose Segment Synthesis. The synthesis commenced 
with the preparation of the rhamnose segment. For the prepara-
tion of a protected resorcylate, we applied the biomimetic cas-
cade reactions established by Barrett and co-workers (Scheme 
4).32 First, the known keto dioxinone 1833a was treated with 
freshly prepared propionyl imidazole 1733c to provide diketone 
19, which was then treated with excess Et3N at room tempera-
ture to trigger a spontaneous cyclization and aromatization and 
provide phenol 20 in 57% yield. The obtained electron rich phe-
nol 20 was treated with sulfuryl chloride to convert it to the di-
chloride, 34 which was then protected with allyl bromide to yield 
the acylation precursor 21 in 95% yield.  
Scheme 4. Synthesis of Acylation Precursor 21a 
 
aReagents and conditions: a) LDA (4.2 equiv), ketone 18 (2.1 
equiv), THF, −78 °C, 1.5 h; propionyl imidazole 17, 2.5 h, −78 °C; 
Et3N (excess), CH2Cl2, rt, 16 h, 57%; b) SO2Cl2, CH2Cl2, reflux, 1.5 h, 
98%; c) allyl bromide, K2CO3, DMF, rt, 4 h, 95%. LDA = lithium diiso-
propylamide. 
The next key steps towards the synthesis of rhamnoside seg-
ment were the selective introduction of the C2´ methyl group 
and C4´ ester on the unusual monosaccharide (Scheme 5). First, 
the two equatorial hydroxy groups at C3´ and C4´ of known 2235 
was protected as the butane-2,3-diacetal. After methylation at 
the C2´ hydroxy group with MeI and the hydrolysis of the tem-
porary acetal protecting group (72% over 3 steps), the resulting 
diol 23 was advanced to the thioglycoside 24 by the treatment 
with TMSSPh in the presence of ZnI2. Next, we performed an 
acylation of diol 24 with the resorcylate 21. Although the C4´ 
hydroxy group was expected to be less reactive than C3´,36 we 
were very satisfied to obtain the desired C4´ acylated product 
26 with an excellent regioselectivity ratio (10:1). Upon careful 
observation, we found that the acylation of the C3´ hydroxy 
group is indeed kinetically favored and this regioisomer was ob-
tained as a single product after stirring for 30 min at room tem-
perature (judged by 1H NMR analysis). With longer reaction 
times, the aromatic ester migrates from C3´ to C4´ to give the 
desired regioisomer 26. Subsequent protection of the aromatic 
hydroxy group with allyl bromide and oxidative hydrolysis of 
the thioglycoside by treatment with aqueous NBS resulted in 
the formation of hemiacetal in 95% yield. Considering the ther-
modynamic stability of the ester at C4´ and the steric bulkiness 
of the surrounding functionality, the remaining C3´ hydroxy 
group was not protected. Finally, the resulting hemiacetal was 
treated with N-phenyl trifluorochloroacetimidate37 to afford 
acetimidate 27 suitable for glycosylation. 
 
 
Scheme 5. Synthesis of Rhamnoside Donor 27a 
 
aReagents and conditions: a) HC(OMe)3, (MeCO)2, CSA (6 mol%), 
MeOH, 90 °C (sealed tube), 24 h; b) NaH, MeI, THF, 0 °C to rt, 3.5 
h; c) TFA, H2O, CH2Cl2, rt, 1 h, 72% (3 steps); d) TBAI, ZnI, TMSSPh, 
ClCH2CH2Cl, 65 °C, 2.5 h, 73%; e) 21 (1.0 equiv) NaH (5 equiv), THF, 
0 °C, 30 min; rt, 16 h, 25:26 = 1:10, 26: 83%; f) allyl bromide, K2CO3, 
DMF, 50 °C, 3 h, 96%; g) NBS, acetone/H2O 10:1, 0 °C to rt, 95%, 
α:β = 5:1; h) ClC(=NPh)CF3, acetone, K2CO3, rt, 3 h, 98%. CSA = cam-
phorsulfonic acid, NBS = N-bromosuccinimide, TBAI = tetrabu-
tylammonium iodide, TFA = trifluoroacetic acid, TMS = trimethylsi-
lyl. 
Noviose Segment Synthesis. The key steps in the synthesis 
of the noviose fragment include the incorporation of the addi-
tional methyl group at the C5´ position and appropriate func-
tionalization of the neighboring hydroxy group so that the β-
selective glycosylation proceeds with reasonable selectivity. As 
was briefly mentioned above in the context of fidaxomicin (1) 
protections, we decided to use the carbonate group for the pro-
tection of the 1,2-syn alcohol. The synthesis of the noviosyl do-
nor started with the ring contraction reaction of iodide 2838a to 
provide furanoside 2938b in 91% yield under modified Vasella 
conditions39 (Scheme 6). Next, the terminal olefin 29 was di-
rectly oxidized to the corresponding methyl ester 30 by employ-
ing Marshall’s ozonolysis protocol40 in NaOMe solution. The 
major side product isolated was an aldehyde intermediate 31, 
which was transformed into the desired ester 30 under mild ox-
idation with bromine (92%).41 Subsequent introduction of the 
additional methyl group at the C5´´ position using the Grignard 
reagent and isomerization of the obtained tertiary alcohol 32 un-
der acidic conditions gave access to pyranoside 33. Unfortu-
nately, the equilibrium between furanose 32 and pyranose 33 in 
TFA in MeOH turned out to be only 2:1 in favor of the desired 
pyranose. The minor furanoside product 32 could be converted 
to pyranoside 33 by resubjection to the same acidic conditions. 
After three cycles of acid treatment and separation, the desired 
pyranoside 33 was obtained in 81% overall yield as an anomeric 
mixture (α:β = 2:1). The introduction of the carbonate group 
using CDI, followed by the treatment with isobutyryl chloride, 
resulted in formation of the fully functionalized noviose 34 in 
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Finally, the acetal 34 was converted to the desired glycosyl bro-
mide donor 35 using HBr in acetic acid. It is worth noting that 
this glycosyl bromide 35 was isolated as a mixture with glyco-
syl acetate, and it was sensitive to silica gel when it had been 
concentrated at room temperature. Therefore, two equivalents 
of glycosyl bromide 35 were prepared immediately before the 
noviosylation reaction and used immediately after aqueous 
workup and concentration at low temperature. 
Scheme 6. Synthesis of Noviosyl Bromide 35a 
  
aReagents and conditions: a) Zn (10 equiv), NH4Cl (0.4 equiv), 
MeOH, 60 °C, 91%; b) CSA (20 mol%), 2,2-DMP, MeOH, 55 °C, 18 
h, 99%; c) O3, NaOH in 2.5 M MeOH, CH2Cl2, −78 °C, 30: 62%, 31: 
11%; d) Br2, NaHCO3, MeOH, H2O, 40 °C, 92%; e) MeMgBr (2.4 
equiv), Et2O, 35 °C, 30 min, 99%; f) TFA (excess), MeOH, 100 °C 
(µw), 3 h, 81% (3 cycles), α:β = 2:1; g) CDI, ClCH2CH2Cl, reflux, 3 h; 
h) isobutyryl chloride, Et3N, CH2Cl2, rt, 1 h, 67% (2 steps) α:β = 2:1; 
i) 33% HBr in AcOH, CH2Cl2, 0 °C to rt, 2 h. 2,2-DMP = 2,2-dimethox-
ypropane. 
Synthesis of Vinyl Iodide via VMAR. Our initial efforts for 
macrocycle construction are depicted in Scheme 7. The synthe-
sis of the macrocycle fragment began with the synthesis of silyl 
ketene aminal 15 from 38 through γ-deprotonation.42 The other 
key component, aldehyde 16, was synthesized either from pro-
pargyl alcohol 36 through methylzirconation or from diethyl 
methylmalonate 37 in four steps through a decarboxylative 
elimination.43 Next, the key vinylogous Mukaiyama aldol reac-
tion (VMAR) between 15 and the α,β-unsaturated aldehyde 16 
was investigated. All the initial investigations to yield syn-aldol 
adduct using excess Lewis acid failed.44 The reason for this can 
be ascribed to the combination of electron rich and bulky α,β-
unsaturated aldehyde and sterically more demanding ethyl sub-
stituted silyl ketene aminal 15 compared to the standard methyl 
group. Actually, VMAR is quite sensitive to electronic and ste-
ric properties of the electrophiles and nucleophiles.45 In our ear-
lier investigation towards the synthesis of JBIR-02, for exam-
ple, we failed to achieve a reaction with electron rich unsatu-
rated aldehyde substrates.46 As there are many more successful 
applications of anti-selective VMAR in polyketide natural 
product synthesis, we next investigated anti-selective VMAR,47 
expecting the hydroxy group to be invertible by Mitsunobu re-
action (vide infra). After extensive experimentation, the best 
conditions to cleanly obtain the desired product were identified: 
TiCl4 was slowly added to the aldehyde 16, followed by syringe 
pump addition of aminal 15 at –78 °C over 20 min; then the 
reaction mixture was slowly warmed to –37 °C and stirred over-
night at the same temperature for 18 h. The reaction mixture had 
to be kept at –37 °C to observe a reasonable reaction rate and 
selectivity. In addition, the purification of aminal 15 and alde-
hyde 16 had to be performed thoroughly as the contamination 
of TBSOH and water accelerated the reaction.48 The obtained 
anti-39 was then transformed into the syn-nitrobenzoate by em-
ploying the Mitsunobu protocol. Cleavage of the Evans auxil-
iary in the presence of para-nitrobenzoate was performed selec-
tively under reductive conditions to provide primary alcohol 40. 
(78%)49 Although some overreaction led to the formation of diol 
41 in 22% yield (based on 1H NMR) as a mixture with nitroben-
zyl alcohol, the material throughput of this reaction was im-
proved by transforming the diol side product 41 into 40 by a 
three-step sequence. First, the primary hydroxy group was pro-
tected as TBS ether in the presence of the secondary hydroxy 
group. Second, the obtained TBS ether was transformed into the 
para-nitrobenzoate under standard esterification conditions and 
finally treated with HF in MeCN to provide the alcohol 40. The 
obtained allylic alcohol 40 was oxidized with MnO2 to provide 
the corresponding α,β-unsaturated aldehyde in 92% yield. At 
this stage, the absolute configuration of this α,β-unsaturated al-
dehyde was unambiguously confirmed by a single crystal X-ray 
analysis of its bromide derivative. Subsequent diastereoselec-
tive Brown allylation of aldehyde with (–)-allyl-diisopinocam-
pheylborane50 established the C7 hydroxy group and gave the al-
cohol in 70% yield. The separation of the desired product from 
isopinocampheol was difficult at this point, however, the pure 
TBS ether 42 was easily separable by silica gel column chro-
matography after TBS protection of the mixture. Subsequent 
deprotection of the nitrobenzoyl ester cleanly provided the de-
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Scheme 7. Synthesis of Vinyl Iodide 43 and 44 via Vinylogous Mukaiyama Aldol Reaction (VMAR)a 
 
aReagents and conditions: a) Cp2ZrCl2, AlMe3, CH2Cl2, rt, 12 h; I2, 60%; b) MnO2, CH2Cl2, > 99%; c) NaH, CHI3, Et2O, reflux; d) KOH, H2O, 
EtOH, reflux, 75% (2 steps); e) LiAlH4, Et2O, 86%; g) NaHMDS, THF, −78 °C; TBSCl, E:Z = 20:1, 97%; g) 16 (2.0 equiv), TiCl4 (1.0 equiv), CH2Cl2, 
−78 °C; 15 via syringe pump for 20 min; −78 to −37 °C; −37 °C, 18 h, 39: 75%, d.r. > 50 :1, 38: ca. 20%; h) PNBOH, DEAD, PPh3, THF, 0 °C to 
rt, 40: 78%, 41: 22%; i) NaBH4 (3.0 equiv), THF/H2O, 0 to 15 °C, 3 h; j) TBSCl, imid., CH2Cl2, rt, 10 min; k) PNBCl, DIPEA, DMAP, CH2Cl2, rt, 6 
h; l) 48% HF, MeCN, rt, 3 h, > 99% (3 steps); m) MnO2, CH2Cl2, 92%; n) (−)-Ipc2B(allyl) (1.5 equiv), Et2O, −78 °C; aq. NaBO3·4H2O, 70%, d.r. = 
20:1; o) TBSOTf, 2,6-lut., CH2Cl2, 93%; p) DIBAL, PhMe, CH2Cl2, −40 °C, 43: > 99%.; q) K2CO3, MeOH/H2O; r) TESOTf, 2,6-lut., CH2Cl2, 44: 95% 
(2 steps). Cp = cyclopentadienyl, DEAD = diethyl azodicarboxylate, NaHMDS = sodium bis(trimethylsilyl)amide, Ipc = isopinocampheyl, PNB 
= para-nitrobenzoyl, imid. = imidazole, DMAP = 4-dimethyl-aminopyridine, TES = triethylsilyl, DIBAL = diisobutylaluminum hydride. 
Conjugated Ester Synthesis. The carboxylic acid fragment 
49 was prepared from commercially available ethyl 3-hydroxy-
propanoate 45 (Scheme 8). First, the dianion of ester 45 was 
condensed with freshly distilled acrolein to furnish the corre-
sponding aldol adduct 46. The obtained crude mixture of diol 
46 was directly treated with TBSCl and Et3N in the presence of 
SnMe2Cl251 to give primary TBS ether 47. Acetylation of the re-
maining secondary hydroxy group and the subsequent E1cB 
elimination using DBU as a base furnished the unsaturated ester 
(E)-48 (E:Z 5.5:1). 
aScheme 8. Synthesis of α,β,γ,δ-Unsaturated Carboxylic Acid 
49a 
  
aReagents and conditions: a) LDA (3.5 equiv), THF, −78 to −30 
°C; acrolein (1.2 equiv), −78 to −10 °C; b) Me2SnCl2 (10 mol%), 
TBSCl, Et3N, CH2Cl2, rt, 75 % (2 steps) d.r. = 3:2; c) Ac2O, Et3N, 
DMAP, CH2Cl2, rt; d) DBU, CH2Cl2, rt, E:Z = 5.5:1, (E,E)-48: 78%, 
(Z,E)-48: 14% (2 steps); e) DIBAL (2.5 equiv), CH2Cl2, −78 °C; −10 °C; 
f) MnO2, CH2Cl2, rt; g) NaClO2, KH2PO4, 2-methyl-2-butene, t-
BuOH/H2O 1:1, rt, 70% (3 steps). DBU = 1,8-diazabicycloun-dec-7-
ene. 
The following hydrolysis proved to be troublesome due to the 
formation of side products probably via spontaneous TBS 
deprotection and / or (hetero-) Diels Alder reactions. Fortu-
nately, the desired carboxylic acid 49 was obtained by formal 
hydrolysis of the delicate substrate. It should also be noted that 
the ester 48 and carboxylic acid 49 were relatively unstable at 
room temperature. Therefore, it is recommended to store 48 in 
frozen benzene at –20 °C when it is kept for more than a day. 
Synthesis of Coupling Partners 52 and 55. The coupling 
partners for iodide 44 were synthesized in three steps from the 
known epoxide 5052 (Scheme 9). First, the TBS ether was pre-
pared from epoxy alcohol 50, which was obtained through a ki-
netic resolution of 3-buten-2-ol through a Sharpless epoxida-
tion.52b Regioselective alkylation with propynyllithium in the 
presence of BF3·OEt2 provided the desired secondary alcohol 
51.53 Pd-catalyzed hydrostannylation gave access to the stannane 
52, along with the undesired regio isomer 53. Other approaches 
such as hydrozirconation54 and stannyl-cupration55 gave a com-
plex mixture of products. Alternatively, the alcohol 51 was sub-
jected to copper-catalyzed hydroboration using bis(pinaco-
lato)diborane to provide boronic ester 54 as a single regioiso-
mer using the protocol developed by Altmann and co-workers.17 
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Scheme 9. Synthesis of Stannane 52 and Boronic Ester 55a 
 
aReagents and conditions: a) TBSCl, imid., CH2Cl2, 93%; b) 
propyne, n-BuLi, BF3·OEt2, THF, −78 to 0 °C, 90%; c) Pd(OAc)2 (5 
mol%), PCy3 (10 mol%), n-Bu3SnH, n-hexane, 52: 51%, 53: 45%; d) 
B2Pin2 (1.1 equiv), CuCl (5 mol%), PPh3 (6 mol%), KOt-Bu (20 
mol%), THF, rt, 26 h, 91%; e) 49 (1.2 equiv) TCBC (1.25 equiv), 
DMAP, Et3N, PhMe, 61%, Cy = cyclohexyl, Pin = pinacolato, TCBC = 
2,4,6-trichlorobenzoyl chloride. 
Synthesis of the Macrocycle 10. With the three key frag-
ments in hand, the planned Pd-catalyzed cross coupling was ex-
plored (Scheme 10). The first approach employing a Stille cou-
pling was found to be very challenging due to the steric hin-
drance of the methyl groups of stannane 52 and iodide 44, re-
sulting only in side product formation. To our delight, the de-
sired coupled product 56 was obtained in 77% yield by applying 
the Pd/Cu-mediated cross coupling conditions reported by 
Fürstner and co-workers.56 Interestingly, the alcohol at C11 
needed to be protected as TES ether, otherwise the reaction did 
not proceed even under Fürstner´s conditions. Later, we also 
found that this reaction could be replaced by a TlOEt promoted 
Suzuki coupling between 44 and 54 (not shown). The use of 
TlOEt as a base was essential57 to accelerate this reaction to 
reach the best results. Next, the obtained alcohol 56 was con-
densed with carboxylic acid 49 using the Yamaguchi protocol 
to give rise to polyene 57. The obtained polyene 57 was cy-
clized using second generation Grubbs catalyst (15 mol%) to 
provide macrocycle 58.58 Interestingly, when this reaction was 
performed at room temperature, Z isomer was exclusively 
formed after 30 min (not shown), probably due to the confor-
mational restriction during the cyclization. However, by heating 
this reaction mixture for an additional 18 hours at 100 °C, (Z)-
58 was partially converted to (E)-58 to give a 2:1 mixture in 
favor of the E isomer. It is worth noting that this isomerization 
did not occur only with heat and, neither light-induced59 nor 
Morita-Baylis-Hillman type isomerization provided complex 
mixtures. Alternatively, the cyclization was performed at 
100 °C for 2 h to yield the same results.16 Fortunately, the two 
isomers could be separated by silica gel column chromatog-
raphy, which in turn allowed for recycling of the undesired Z 
isomer by subjecting it to the same metathesis conditions with 
the aim to convert it into the E isomer. Finally, the primary TBS 
and TES groups were cleaved using 3HF·NEt3. As the TBS 
group at the C18 position was also sensitive under these condi-
tions, the reaction was not allowed to proceed to complete con-
version in order to avoid over-deprotection. The desired diol 10 
was obtained in 65% yield along with the TES deprotected in-
termediate 59 in 32% yield. The latter could be further depro-
tected under the same conditions to afford diol 10. With this, 
the synthesis of the protected fidaxomicin aglycon was com-
pleted with the appropriate hydroxy groups available for the 
subsequent glycosylation reactions.  
Scheme 10. Synthesis of Macrocycle 10a 
 
aReagents and conditions: a) 52 (1.7 equiv), CuTC (3.0 equiv), Pd(PPh3)4 (70 mol%), [n-Bu4N]+[Ph2PO2]- (3.9 equiv), DMF, 2.5 h, rt, 77%; 
b) 49 (2.0 equiv), TCBC (1.95 equiv), DMAP, Et3N, PhMe, rt, 1.5 h, 86%; c) Grubbs II (20 mol%), PhMe, 40 °C, 10 min; 100 °C, 18 h, E:Z = 2:1, 
(E)-58: 60%, (Z)-58: 30%; d) Grubbs II (20 mol%), PhMe, 100 °C, 18 h, 92%, E:Z = 2:1; e) 3HF·NEt3, THF, MeCN, 0 °C to rt, 8 h, 10: 65%, 59: 
32%. CuTC = Copper(I) 2-thiophenecarboxylate. 
b-Selective Glycosylations. We were now poised to explore 
the final glycosylations (Scheme 11). We started exploration of 
the rhamnosylation60 using model substrates with similar func-
tional groups (see supporting information for screening results). 
Searching for the best reaction conditions, we found that using 
trifluoroacetimidate 27 and TBSOTf as an activator at cryo-
genic temperature37 led to the best yield and diastereoselectiv-
ity.61 Therefore, we applied these optimized conditions with the 
primary alcohol 10 and obtained the desired glycoside 61 in 
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this particular reaction is ascribed to the formation of oxocarbe-
nium cation intermediate 60, which was selectively attacked by 
the glycosyl acceptor 10 from the β-face.62 
 
Scheme 11. Successful β-Selective Rhamnosylation and Failed β-Selective Noviosylationa 
 
aReagents and conditions: Imidate 27 (4.2 equiv), TBSOTf (20 mol%), CH2Cl2, MS 4Å, –78 to –20 °C, 2.5 h, α:β = 1:3, β-61: 16%.
Having succeeded with the rhamnosylation, we then explored 
noviosylation of 61. Applying several glycosylation conditions, 
it was found that the reactivity of the glycosyl acceptor 61 was 
much lower than we had initially expected. All the attempts to 
obtain the desired glycoside 7 failed after screening various gly-
cosyl donors and activation conditions, probably due to the fol-
lowing two reasons: (1) steric bulkiness of substituents close to 
the hydroxy group; and (2) rigidity of the macrocycle and an 
allylic strain of the double bond system. Additionally, the ma-
terial supply for noviosylation hampered the investigation, as 
the previous rhamnosylation reaction only gave 16% of prod-
uct. Therefore, we concluded not to investigate this strategy any 
further and established a new synthetic strategy. Based on the 
results obtained with 61, we hypothesized that glycosylation 
might succeed if we employed a more flexible acceptor. There-
fore, we decided to use alcohol 43 as a glycosyl acceptor, ex-
pecting it to offer increased conformational flexibility, good 
material availability and compatibility of the following reac-
tions to the glycosylated product (e.g. Suzuki coupling and 
RCM). 
β-Selective Noviosylation and Completion of the Total 
Synthesis. With this new strategy, β-selective noviosylation of 
alcohol 43 was screened under various reaction conditions. Alt-
hough this transformation was still challenging owing to the ste-
rically demanding nature of glycosyl acceptor 43, we identified 
that the use of HgO in combination with HgBr2 would lead to 
the smooth formation of the desired β-glycoside 62 (Scheme 
12). 
Scheme 12. Total Synthesis of Fidaxomicin (1)a 
 
aReagents and conditions: a) Bromide 35 (2.8 equiv), HgO (6.5 equiv), HgBr2 (15 mol%), MS 4Å, CH2Cl2, 1 h, α:β = 1:3, β-62: 54%; b) 55 
(1.5 equiv), Pd(PPh3)4 (20 mol%), TlOEt (1.6 equiv), THF/H2O 3:1, 0 °C to rt, 30 min, 82%; c) Grubbs II (20 mol%), PhMe, 100 °C, 1 h, E:Z = 
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equiv), TBSOTf (20 mol%), CH2Cl2, MS 3Å, –78 to –30 °C, 1 h, α:β = 1:4, β-7: 62%; g) 3HF·NEt3 (excess), THF, 50 °C, 24 h, 60%; h) Barton’s 
base, CH2Cl2, H2O, rt, 3 h; i) Pd(PPh3)4 (10 mol%), morpholine (excess), THF, 0 °C, 30 min; RP-HPLC, 10% (2 steps). Barton`s base = 2-tert-
butyl-1,1,3,3-tetramethylguanidine.
The configuration of the glycosidic bonding was determined 
by extensive 1H and 2D NMR studies, which confirmed the se-
lective formation of the desired β-anomer 62. We assume the 
reaction proceeds via an SN2-like mechanism under classical 
Helferich’s conditions63 to provide the desired anomer. The ob-
tained β-glycoside was further transformed into the macrocycle 
in three steps. First, the iodide 62 was coupled with boronate 55 
under the previously described Suzuki coupling conditions.17 
Next, the polyene 63 was cyclized to yield the desired macro-
cycle 64 as a mixture of E and Z isomers. Fortunately, in this 
case, both stereoisomers were separable using preparative thin 
layer chromatography (PTLC). After selective removal of the 
primary TBS group, the rhamnosylation reaction was per-
formed. Gratifyingly, we confirmed the formation of fully pro-
tected fidaxomicin 7 with a diastereomeric ratio of 4:1 at the 
rhamnose linkage, thereby accomplishing a relay synthesis of 
fidaxomicin (1). The identity of a semisynthetic and a totally 
synthetic sample of 7 was confirmed by comparing the spectro-
scopic data of both (i.e. 1H NMR, see detailed comparison re-
sults listed in supporting information). We further converted 
fully protected fidaxomicin 7 to synthetic 1 by employing the 
deprotection conditions investigated in the early stage of this 
synthetic program. TBS deprotection with 3HF·NEt3, carbonate 
deprotection with Barton’s base and allyl deprotection under 
palladium catalyzed conditions delivered the desired fully syn-
thetic fidaxomicin (1). As the relay synthesis conditions pre-
sented in Scheme 2 were only identified after the successful to-
tal synthesis, we think that the yield of this transformation under 
the new conditions (e.g. NaH instead of Barton’s base) should 
be much higher. 1H NMR analysis confirmed the identity of syn-
thetic and natural fidaxomicin (1). 
Total Synthesis of Tiacumicin A (2). The synthesis of Ti-
acumicin A (2) started with the alkylation of commercially 
available epoxide 65 with propynyllithium (Scheme 13). Tak-
ing the volatility of the resulting secondary alcohol into account, 
it was immediately borylated to give boronate 66. This boronate 
was further advanced to ester 68 via Yamaguchi esterification 
with known carboxylic acid 67.64 As tiacumicin A (2) contains 
an acetate instead of the isobutyrate on the noviose moiety, we 
prepared the corresponding glycosyl bromide 69 from the com-
mon intermediate 33 via acetylation with Ac2O in THF. This 
bromide 69 was subsequently reacted with alcohol 43 and the 
desired β-glycoside 70 was obtained in 44% yield. The diastere-
oselectivity (1:4) was slightly better than in the corresponding 
reactions of fidaxomicin total synthesis (1:3) however, the yield 
was lower. Next, iodide 70 was coupled with the separately syn-
thesized boronate 68 under Suzuki coupling conditions. Ring 
closing metathesis of the polyene 71 proceeded smoothly under 
the same conditions as for fidaxomicin. Although the separation 
of the stereoisomers turned out to be difficult by silica gel col-
umn chromatography, separation of the desired E isomer was 
achieved by HPLC on a chiral stationary phase (DAICEL, Chi-
ralpack-IA column). The (E) isomer was then treated with 
3HF·NEt3 at 50 °C providing C7 alcohol. Finally, the carbonate 
group was cleaved to give tiacumicin A (2) together with an-
other natural product, 4´-deacetyl tiacumicin (not shown).14a 
During hydrolysis, the prevention of transacylation was more 
difficult than in the case for fidaxomicin due to the smaller ac-
etate group when compared to the isobutyrate. We separated all 
the isomers by reversed phase HPLC to provide four com-
pounds. The spectroscopic data for tiacumicin A (2) was iden-
tical to the one reported for the natural sample,14a concluding the 
first total synthesis of this natural product. With these success-
ful syntheses, we demonstrated the versatility of our synthetic 
strategy for the synthesis of tiacumicin class natural products. 
We are currently working on other members of this class of an-




Scheme 13. Total Synthesis of Tiacumicin A (2)a 
  
O
a) MeCCLi, BF3·Et2O, 53%
b) (BPin)2, CuCl, PPh3
    KOt-Bu, 86% (2 steps)
(R)-butylene oxide (65)
d) CDI, 80 °C
e) Ac2O, Py.























i) Grubbs II, 92%, E:Z = 1:0.8, 42% (E)
j) 3HF·NEt3, 98%
k) (CH2OH)2, NaH, 18% (RSM: 27%)
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aReagents and conditions: a) propyne, t-BuLi, BF3·OEt2, THF, –78 °C to 0 °C, 2 h, 53%; b) B2Pin2, CuCl (5 mol%), PPh3 (6 mol%), KOt-Bu (20 
mol%), THF, 20 h, 86%; c) 67 (1.3 equiv), TCBC (1.3 equiv), Et3N, DMAP, PhMe, 5 h, 81%; d) CDI, THF, 80 °C, 3.5 h; 6 N HCl, 2 h, rt; e) Ac2O, 
Py., CH2Cl2, 68% (2 steps); f) 33% HBr in AcOH, CH2Cl2, 0 °C to rt; g) 69 (1.8 equiv), HgO, HgBr2, MS 4Å, CH2Cl2, 44% (β), α:β = 1:4; h) 68 (1.7 
equiv), Pd(PPh3)4, (10 mol%), TlOEt (1.5 equiv.), THF, H2O, 88%; i) Grubbs II (20 mol%), PhMe, 100 °C, 92%, E:Z = 1:0.8; HPLC purification 
DAICEL, Chiralpack-IA, 42% (E); j) 3HF·NEt3, THF, 50 °C, 98%; k) NaH, (CH2OH)2, CH2Cl2, 0 °C, Tiacumicin A: 18%, RSM: 27%. RSM = recovery 
of starting material. 
Conclusion. A first total synthesis of the antibiotic natural 
product, fidaxomicin (1, tiacumicin B, lipiarmycin A3) was ac-
complished in a highly convergent manner. The developed pro-
tocol gives access to the conveniently protected 18-membered 
macrocycle in 15 steps from commercially available starting 
material. The macrocycle synthesis is highly convergent and 
high yielding. The modular strategy of the synthesis as well as 
the judicious design of the glycosyl donors and glycosylation 
point allowed β-selective rhamnosylation and β-selective novi-
osylation. Finally, removal of carefully chosen and validated 
protecting groups cumulated in the total synthesis of fidax-
omicin (1). With this strategy, we are well equipped for the 
preparation of other tiacumicin class natural products, as exem-
plified by the preparation of tiacumicin A (2) reported herein. 
Further synthetic endeavors as well as the results from biologi-
cal assays will be disclosed in due course. 
 
EXPERIMENTAL SECTION 
General Information, Materials and Equipment: Unless otherwise 
stated, all chemicals were of reagent grade and purchased from 
Sigma-Aldrich-Merck, Acros Organics, Honeywell, Fluorochem or 
Tront. Fidaxomicin was obtained by fermentation from Actinoplanes 
deccanensis (DSM 43806; ATCC 21983).  Reactions were carried out 
under protecting gas (N2 or Ar) in oven-dried (120 °C) glass equipment 
and monitored for completion by TLC or UHPLC-MS (ESI). Solvents for 
reactions were of analytical grade. Evaporation of solvents in vacuo 
was done with the rotary evaporator at 40 °C bath temperature and 
appropriate pressure. Thin layer chromatography (TLC): Merck TLC 
plates silica gel 60 F254 on glass plate with the indicated solvent sys-
tem; the spots were visualized by UV light (254 nm), I2, anisaldehyde, 
ninhydrin, ceric ammonium molybdate (CAM) or KMnO4 stain. Prepar-
ative Thin layer chromatography (PTLC): Merck PTLC plates silica gel 
60 F254 0.5 mm on glass plate. For purification, ca. 5 -10 mg of sample 
was loaded on 20 x 10 cm plate and separated using indicated solvent. 
Flash Chromatography: Silica gel column chromatography was per-
formed using silica gel 60 (230-400 Mesh) purchased from Sigma-Al-
drich with solvent mixture indicated. Ultra high-performance liquid 
chromatography coupled to mass spectrometry (UHPLC-MS): Ulti-
mate 3000 LC instrument (Thermo Fisher Scientific) coupled to a triple 
quadrupole Quantum Ultra EMR MS (Thermo Fisher Scientific) using a 
reversed-phase column (Kinetex® EVO C18; 1.7 μm; 100 Å, 50 x 2.1 
mm; Phenomenex). The LC was equipped with a HPG-3400RS pump, a 
WPS-3000TRS autosampler, a TCC-3000RS column oven and a Van-
quish DAD detector (all Thermo Fisher Scientific). The following sol-
vents were applied: H2O+0.1% HCO2H (A), MeCN+0.1% HCO2H (B). The 
MS was equipped with an H-ESI II ion source. The source temperature 
was 250 °C, the capillary temperature 270 °C and capillary voltage 
3500 V, and datasets were acquired at resolution 0.7 on Q3 in centroid 
mode. High-performance liquid chromatography (HPLC): Prominence 
modular HPLC instrument (Shimadzu) coupled to a SPD-20A UV/Vis 
detector (Shimadzu) using a reversed-phase column (Gemini C18, 3 
μm,10 Å, 150 mm x 4.6 mm; Phenomenex) for analytical HPLC and a 
reversed-phase column (Gemini, 10 μm, 110 Å, 150 mm x 10.0 mm) 
for preparative HPLC. The LC was equipped with a CBM-20A system 
controller, LC-20A solvent delivery unit, SIL-20A auto-sampler, CTO-
20A column oven, and DGU-20A online degassing unit (all Shimadzu). 
The following solvents were used: H2O+0.1% HCO2H (A), MeCN + 0.1% 
HCO2H (B). Specific optical rotation [𝛼]$
% : Jasco P-2000 Polarimeter; 
measured at the indicated temperature T. Infrared spectra (IR): Spec-
trumTwo FT-IR Spectrometer (Perkin–Elmer) equipped with a Specac 
Golden GateTM ATR (attenuated total reflection) accessory; applied 
as neat samples or as films; 1/l in cm–1. Nuclear magnetic resonance 
spectra (NMR): 1H NMR spectra were recorded in CDCl3, CD2Cl2, ace-
tone-d6, CD3OD or C6D6 at 298 K on the instruments Bruker 
AvanceNeo-600 (600 MHz with Cryo-TCI probe), AvanceII or III-500 
(500 MHz with Cryo-BBO, TXI, BBI or BBO probe) or AvanceII-400 (400 
MHz with QNP, BBO or BBFO probe); δ in ppm relative to solvent sig-
nals (δ = 7.26 ppm for CDCl3, 5.32 ppm for CD2Cl2, 2.05 for acetone-d6, 
3.31 ppm for CD3OD and 7.16 ppm for C6D6); J is given in Hz. 13C NMR 
spectra were recorded in the indicated solvents and on the same in-
struments; δ in ppm relative to solvent signals (δ = 77.16 ppm for 
CDCl3, 53.84 ppm for CD2Cl2, 49.00 ppm for CD3OD and 128.06 ppm 
for C6D6); Data is reported as follow: chemical shift (δ, ppm), multiplic-
ity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet or not re-
solved signal; br, broad signal), coupling constant(s) (J, Hz), integra-
tion. High-resolution electrospray ionization mass spectra (HRMS): 
QExactive (Thermo Fisher Scientific) with a heated ESI source con-
nected to a Dionex Ultimate 3000 UHPLC system. Samples dissolved 
in MeOH at ca. 50 g mL-1; injection of 1 µL on-flow with an auto-sam-
pler (mobile phase: MeOH+0.1% HCO2H or MeCN/H2O 2:8 + 0.1% 
HCO2H; flow rate: 120 µL/min); ion source parameters: spray voltage 
3.0 kV, capillary temperature 320°, sheath gas rate: 5 l min-1, s-lens RF 
level 55.0; full scan MS in alternating (+)/(–)-ESI mode; mass ranges 
80–1200, 133–2000, or 200–3000 amu; resolution (full width half-
maximum) 70’000; automatic gain control (AGC) target 3.00·106; max-
imum allowed ion transfer time (IT) 30 ms; mass calibration <2 ppm 
accuracy for m/z 130.06619–1621.96509 in (+)-ESI and for m/z 
265.14790–1779.96528 in (–)-ESI with Pierce® ESI calibration solu-
tions (Thermo Fisher Scientific); lock masses: ubiquitous erucamide 
(m/z 338.34174, (+)-ESI) and palmitic acid (m/z 255.23295, (–)-ESI). 
 






4,6-dihydroxybenzoate (6).  To a solution of fidaxomicin (1, 34.2 mg, 
32.3 µmol) in CH2Cl2 (dry, 2.0 mL) was added HCl solution (4.0 M in 
dioxane, 16 µL, 64.6 µmol, 2.0 equiv.) was added and stirred. After 60 
min, HPLC-MS indicated full conversion of fidaxomicin (1). The reac-
tion mixture was diluted with CH2Cl2 (10 mL) and brine (15 mL), and 
aqueous phase was extracted with CH2Cl2 (3 x 20 mL). The combined 
organic phases were dried over MgSO4, filtered and concentrated. Pu-
rification by preparative RP-HPLC (75% B, isocratic (Phenomenex Luna, 
C18(2), 100 Å, 250 mm x 21.2 mm, 5 µm). H2O + 0.1% HCOOH (A) and 
MeCN + 0.1% HCOOH (B) were used for separation with the flow rate 
of 20 mL/min.) and concentration provided (15R)-6 (tR = 17.713 min; 
17.2 mg, 66%) and (15S)-6 (tR = 20.859 min; 3.8 mg, 14.5%) as colour-
less solids. The structure was elucidated based on the 1H and 2D NMR. 
The stereocenter at C15 was determined by NOESY experiment of 
both compounds. (15R)-6 showed strong correlation between H15 
and H19, but (15S)-6 did not. Major isomer (15R)-6: Rf = 0.66 (ace-
tone/pentane = 3/2); [α]D25 = –71° (c 0.76, CHCl3); 1H NMR (500 MHz, 
acetone-d6) δ 7.05 (d, J = 11.3 Hz, 1H, H3), 6.55 (dd, J = 15.1, 11.4 Hz, 
1H, H4), 6.02 (dt, J = 14.8, 7.2 Hz, 1H, H5), 5.95 (s, 1H, H13), 5.37 (d, J 
= 10.4 Hz, 1H, H9), 5.13 (d, J = 9.2 Hz, 1H, H11), 5.10 (t, J = 9.8 Hz, 1H, 
H4’), 4.98 (d, J = 5.6 Hz, 1H, H17), 4.65 (s, 1H, H1’), 4.60 (d, J = 9.6 Hz, 
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1H, H15), 4.57 (d, J = 11.4 Hz, 1H, H20a), 4.42 (d, J = 11.4 Hz, 1H, H20b), 
4.29 (s, 1H, H7), 4.23 (q, J = 6.6 Hz, 1H, H18), 3.81 (dd, J = 9.9, 3.4 Hz, 
1H, H3’), 3.63 – 3.55 (m, 2H, H2’, H5’), 3.52 (s, 3H, H7’), 3.23 (p, J = 7.6 
Hz, 1H, H10), 3.01 (qd, J = 7.3, 2.1 Hz, 2H, H8’’’), 2.62 (ddd, J = 15.5, 
7.0, 3.3 Hz, 1H, H6a), 2.46 (ddt, J = 14.5, 9.0, 4.9 Hz, 2H, H6b, H16a), 
2.13 (d, J = 14.1 Hz, 1H, H16b), 1.78 (s, 3H, H25), 1.68 (s, 3H, H24), 1.64 
(s, 3H, H21), 1.42 (dt, J = 18.5, 7.0 Hz, 2H, H22), 1.30 (d, J = 6.2 Hz, 3H, 
H6’), 1.21 (dt, J = 7.4, 4.1 Hz, 6H, H19, H9’’’), 0.89 (t, J = 7.3 Hz, 3H, 
H23); 13C NMR (126 MHz, acetone-d6) δ 169.7 (C1’’’), 167.2 (C1), 156.2 
(C3’’’ or 5’’’), 154.5 (C3’’’ or 5’’’), 145.8 (C3), 144.0 (C5), 142.7 (C7’’’), 
136.1 (C12 or 14), 133.6 (C11), 133.5 (C8), 131.2 (C12 or 14), 128.2 
(C9), 127.6 (C4), 126.0 (C13), 125.1 (C2), 114.9 (C6’’’), 110.2 (C2’’’), 
108.4 (C4’’’), 101.6 (C1’), 82.2 (C15), 82.0 (C18), 81.8 (C2’), 80.4 (C17), 
79.3 (C17), 77.7 (C4’), 73.0 (C7), 72.4 (C3’), 70.7 (C5’), 63.0 (C20), 61.8 
(C7’), 40.2 (C10), 38.2 (C6), 35.6 (C16), 29.6 (C22), 26.4 (C8’’’), 20.1 
(C19), 18.8 (C24), 18.3 (C6’), 16.2 (C25), 15.3 (C21), 14.5 (C9’’’), 12.4 
(C23); IR (cm-1) ν 2967, 2930, 2872, 1693, 1641, 1591, 1445, 1405, 
1375, 1313, 1241, 1198, 1144, 1112, 1067, 1021, 985, 917, 871, 855, 
798, 760, 735, 691. HRMS was measured as a mixture of (15R)-6 and 
(15S)-6: HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C41H54Cl2O12Na 
831.2885; Found 831.2893: Minor isomer (15S)-6: Rf = 0.66 (ace-
tone/pentane = 3/2); [α]D25 = –38° (c 0.26, CHCl3); 1H NMR (600 MHz, 
acetone-d6) δ 7.39 (d, J = 11.3 Hz, 1H, H3), 6.68 (dd, J = 15.1, 11.4 Hz, 
1H, H4), 6.19 (ddd, J = 14.8, 9.3, 5.1 Hz, 1H, H5), 6.12 (s, 1H, H13), 5.34 
(d, J = 9.9 Hz, 1H, H9), 5.28 (d, J = 7.8 Hz, 1H, H11), 5.11 (t, J = 9.7 Hz, 
1H, H4´), 5.10 (d, J = 4.0 Hz, 1H, H15), 5.00 (dd, J = 11.6, 3.9 Hz, 1H, 
H17), 4.70 (d, J = 0.9 Hz, 1H, H1´), 4.60 (d, J = 11.7 Hz, 1H, H20), 4.45 
(d, J = 11.7 Hz, 1H, H20), 4.33 (s, 1H, H7), 4.07 (q, J = 6.6 Hz, 1H, H18), 
3.82 (dd, J = 9.9, 3.4 Hz, 1H, H3´), 3.66 – 3.56 (m, 2H, H2´ H5´), 3.53 (s, 
3H, H(OMe)), 3.21 (dq, J = 10.0, 7.3 Hz, 1H, H10), 3.01 (qd, J = 7.4, 4.6 
Hz, 2H, H8´´´), 2.73 (d, J = 15.3 Hz, 1H, H6), 2.50 (ddd, J = 15.1, 9.3, 3.7 
Hz, 1H, H6), 2.13 (ddd, J = 13.2, 11.7, 4.1 Hz, 1H, H16), 1.91 (s, 3H, H21), 
1.75 (d, J = 1.5 Hz, 3H, H24), 1.72 – 1.68 (m, 1H, H16), 1.69 (s, 3H, H25), 
1.42 (dt, J = 13.3, 7.2 Hz, 1H, H22), 1.38 – 1.31 (m, 1H, H22), 1.30 (d, J 
= 6.1 Hz, 3H, H6´), 1.22 (d, J = 6.6 Hz, 3H, H19), 1.21 (t, J = 7.5 Hz, 3H, 
H9´´´), 0.86 (t, J = 7.4 Hz, 3H, H23); 13C NMR (151 MHz, acetone-d6) δ 
169.78 (C1´´´), 166.91 (C1), 156.38 (C3´´´), 154.85 (C5´´´), 146.97 (C3), 
145.45 (C5), 142.74 (C7´´´), 136.27 (C11), 136.10 (C13), 134.81 (C8), 
133.74 (C12), 133.28 (C14), 127.92 (C4), 127.28 (C9), 125.13 (C2), 
115.04 (C6´´´), 109.74 (C2´´´), 108.36 (C4´´´), 101.75 (C1´), 81.85 (C5´), 
80.91 (C15), 80.36 (C18), 77.63 (C4´), 77.35 (C17), 73.06 (C7), 72.42 
(C3´), 70.79 (C2´), 63.11 (C20), 61.82 (C-OMe), 39.76 (C10), 36.79 (C6), 
35.93 (C16), 30.64 (C22), 26.42 (C8´´´), 20.80 (C19), 18.64 (C24), 18.33 
(C6´), 18.23 (C25), 14.82 (C21), 14.54 (C9´´´), 12.06 (C23); IR (cm-1) ν 
2969, 2932, 2873, 1698, 1638, 1590, 1449, 1367, 1311, 1240, 1198, 
1167, 1142, 1110, 1088, 1063, 1023, 1003, 943, 902, 858, 884, 858, 
799. 
 







pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (Allyl pro-
tected fidaxomicin, 7a). To a solution of natural fidaxomicin (1) 
(400 mg, 0.38 mmol) in DMF (10 mL), K2CO3 (209 mg, 1.51 mmol, 4.0 
equiv) was added. To the suspension, allyl bromide (82 µL, 0.95 mmol, 
2.5 equiv) was added and the colourless reaction mixture was stirred 
at 45 °C for 3 h. The orange-red reaction mixture was quenched with 
sat. NH4Cl and the mixture was extracted with AcOEt 3 times. The or-
ganic layers were washed with brine, dried over MgSO4, filtered and 
concentrated. Purification by column chromatography (acetone/pen-
tane = 2/3) gave the allylated fidaxomicin 7a (384 mg, 89%) as a col-
ourless, amorphous solid; Rf = 0.2 (acetone/pentane = 2/3); [α]D26 = –
43.3° (c 0.58, CHCl3); IR (cm-1) ν 3472, 2976, 2934, 2878, 1701, 1642, 
1382, 1247, 1067, 1024; 1H NMR (400 MHz, acetone-d6) δ 7.22 (d, J = 
11.4 Hz, 1H), 6.62 (dd, J = 15.2, 11.5 Hz, 1H), 6.13 (dddt, J = 32.0, 17.2, 
10.4, 5.8 Hz, 2H), 5.96 (ddd, J = 14.7, 9.6, 4.7 Hz, 1H), 5.83 (s, 1H), 5.62 
(t, J = 8.2 Hz, 1H), 5.43 (ddq, J = 20.4, 17.2, 1.6 Hz, 2H), 5.33–5.23 (m, 
2H), 5.21 (dt, J = 10.5, 1.6 Hz, 1H), 5.02 (t, J = 9.7 Hz, 1H), 4.99 (d, J = 
10.1 Hz, 1H), 4.77 (d, J = 1.3 Hz, 1H), 4.76–4.69 (m, 1H), 4.64 (d, J = 0.8 
Hz, 1H), 4.63–4.58 (m, 4H), 4.53 (ddt, J = 11.8, 5.8, 1.4 Hz, 1H), 4.40 (d, 
J = 11.5 Hz, 1H), 4.26 (br s, 1H), 4.02 (p, J = 6.4 Hz, 1H), 3.95 (dd, J = 
3.4, 1.2 Hz, 1H), 3.75–3.66 (m, 3H), 3.59 (ddd, J = 3.1, 2.3, 1.3 Hz, 1H), 
3.55 (dd, J = 3.6, 0.8 Hz, 1H), 3.52 (s, 3H), 2.94–2.59 (m, 6H), 2.56 (p, J 
= 7.0 Hz, 1H), 2.52–2.38 (m, 1H), 1.99–1.87 (m, 1H), 1.81 (d, J = 1.4 Hz, 
3H), 1.73 (d, J = 1.4 Hz, 3H), 1.66 (dd, J = 1.4, 0.7 Hz, 3H), 1.33 (d, J = 
6.1 Hz, 3H), 1.30–1.21 (m, 1H), 1.19–1.12 (m, 15H), 1.09 (d, J = 0.6 Hz, 
3H), 0.82 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, acetone-d6) δ 176.7, 
167.8, 166.4, 153.8, 151.9, 145.2, 143.3, 139.9, 136.8, 136.8, 136.0, 
134.1, 134.0, 133.7, 128.6, 128.1, 126.3, 125.9, 125.4, 123.9, 122.2, 
118.7, 118.7, 101.8, 96.7, 93.2, 81.8, 78.2, 77.4, 77.4, 76.3, 75.6, 74.9, 
73.7, 72.8, 72.7, 72.6, 72.3, 72.2, 70.7, 70.1, 70.0, 69.9, 69.6, 67.7, 
67.5, 63.4, 61.7, 55.5, 55.4, 42.0, 37.2, 34.7, 32.0, 30.6, 28.7, 28.3, 
26.5, 25.6, 20.7, 19.4, 19.1, 18.6, 18.3, 17.4, 15.2, 14.4, 13.8, 11.1; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C58H82Cl2O18Na 1159.4770; 






pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (carbonate 
and allyl protected fidaxomicin, 7b). To a solution of allyl protected, 
semisynthetic fidaxomicin 7a (130 mg, 0.11 mmol) in CH2Cl2 (5.0 mL) 
at room temperature, Et3N (0.32 mL, 2.3 mmol, 21 equiv) and 1,1’-car-
bonyldiimidazole (28 mg, 0.17 mmol, 1.5 equiv) were added and the 
mixture was stirred for 24 h. Then it was quenched with sat. NH4Cl 
(10 mL) and extracted with CH2Cl2 (1 x 10 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated. Purification 
by column chromatography (Et2O only) gave the desired carbonate 
and allyl protected fidaxomicin 7b (120 mg, 90%). Rf = 0.85 (ace-
tone/pentane = 2/3); [α]D25 = –55.3° (c 0.02, MeOH); IR (cm-1) ν 3485, 
2976, 2935, 1813, 1738, 1701, 1247, 1066, 1023, 734; 1H NMR (400 
MHz, acetone-d6) δ 7.19 (d, J = 11.4 Hz, 1H), 6.63 (dd, 14.4, 12.0 1H), 
6.17 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 6.09 (ddt, J = 17.1, 10.4, 5.8 Hz, 
1H), 6.00–5.90 (m, 1H) 5.93 (s, 1H), 5.74 (d, J = 6.9 Hz, 1H), 5.61 (dd, J 
= 8.1, 8.1 Hz, 1H), 5.43 (ap ddq, J = 20.4, 17.2, 1.6 Hz, 1H), 5.31–5.23 
(m, 2H), 5.21–5.16 (m, 2H), 5.18 (d, J = 3.2 Hz, 1H), 5.12–4.99 (m, 3H), 
4.72–4.67 (m, 1H), 4.64 (s, 1H), 4.64–4.57 (m, 4H), 4.53 (dddd, J = 11.7, 
5.8, 1.4, 1.4 Hz, 1H), 4.39 (d, J = 11.5 Hz, 1H), 4.29–4.24 (m, 1H), 4.07–
4.00 (m, 2H), 3.86 (d, J = 10.1 Hz, 1H), 3.80 (d, J = 9.8 Hz, 1H), 3.75 (d, 
J = 4.2 Hz, 1H), 3.73–3.66 (m, 1H), 3.55 (d, J = 3.3 Hz, 1H), 3.55–3.50 
(m, 1H), 3.52 (s, 3H), 2.92–2.62 (m, 6H), 2.50 (ddd, J = 14.7, 9.6, 4.4 Hz, 
1H), 2.40 (ddd, J = 13.7, 8.3, 4.4 Hz, 1H), 1.96–1.90 (m, 1H), 1.89 (ap s, 
3H), 1.79 (ap s, 3H), 1.68 (ap s, 3H), 1.33 (d, J = 6.2 Hz, 3H), 1.25–1.12 
(m, 19H), 0.82 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, acetone-d6) δ 
176.0, 168.1, 166.5, 154.7, 153.9, 152.0, 145.1, 143.1, 140.0, 137.3, 
136.0, 135.5, 134.7, 134.1, 134.1, 128.7, 128.4, 127.5, 126.0, 125.6, 
123.8, 122.3, 118.8, 118.7, 101.9, 95.3, 93.0, 81.9, 78.5, 77.5, 76.4, 
76.4, 75.4, 75.0, 73.3, 73.1, 72.9, 72.4, 70.7, 66.1, 63.5, 61.8, 42.8, 
37.4, 34.6, 28.5, 28.4, 26.0, 25.6, 23.9, 20.4, 19.2, 19.0, 18.3, 17.4, 
15.3, 14.4, 13.8, 11.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 







lyloxy)-3,5-dichloro-6-ethylbenzoate (fully protected fidaxomicin, 7). 
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To a solution of carbonate and allyl protected, semisynthetic fidax-
omicin 7b (23 mg, 18 μmol) in CH2Cl2 (0.5 mL) at 0 °C, 2,6-lutidine (20 
μL, 0.18 mmol, 10 equiv) and TBSOTf (24 μL, 90 μmol, 5 equiv) were 
added. The solution was stirred at room temperature for 5 h. Then it 
was quenched with sat. NH4Cl (5 mL) and extracted with AcOEt (3 x 3 
mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated. Purification by column chromatography (Et2O/pentane 
= 1/1) gave the fully protected fidaxomicin 7 (13 mg, 52%). Rf = 0.32 
(AcOEt/cyclohexane = 1/4), 0.45 (Et2O/pentane); [α]D25 = –45.3° (c 0.6 
MeOH); IR (cm-1) ν 2928, 1819, 1741, 1703, 1249, 1069, 1018, 1003, 
836; 1H NMR (400 MHz, acetone-d6) δ 7.19 (d, J = 11.5 Hz, 1H), 6.64–
6.56 (m, 1H), 6.23–6.05 (m, 2H), 5.95 (s, 1H), 5.92 (ddd, J = 14.8, 10.3, 
4.5 Hz 1H), 5.77 (d, J = 7.0 Hz, 1H), 5.55 (dd, J = 8.3, 8.3 Hz, 1H), 5.49–
5.37 (m, 2H), 5.31–5.23 (m, 2H), 5.19 (d, J = 3.2 Hz, 1H), 5.17 (ap d, J = 
11.0 Hz 1H), 5.12–5.05 (m, 2H), 5.03 (dd, J = 9.6, 9.6 Hz, 1H), 4.67–4.56 
(m, 4H), 4.64 (s, 1H), 4.52 (dddd, J = 11.7, 5.9, 1.4, 1.4 Hz, 1H), 4.35 (d, 
J = 10.8 Hz, 1H), 4.36–4.34 (m, 1H), 4.27–4.20 (m, 1H), 3.90 (d, J = 10.1 
Hz, 1H), 3.76 (d, J = 9.8 Hz, 1H), 3.69 (ddd, J = 9.7, 9.7, 3.3, Hz, 1H), 3.55 
(d, J = 3.5 Hz, 1H), 3.54–3.47 (m, 1H) 3.52 (s, 3H), 2.92–2.76 (m, 3H), 
2.75–2.63 (m, 3H), 2.40 (ddd, J = 14.8, 10.3, 4.5 Hz, 1H), 2.32 (ddd, J = 
13.8, 7.6, 4.1 Hz, 1H), 2.02–1.94 (m, 1H), 1.91 (ap s, 3H), 1.87 (ap s, 
3H), 1.71 (ap s, 3H), 1.34 (d, J = 6.2 Hz, 3H), 1.22–1.14 (m, 19H), 0.91 
(s, 9H), 0.88 (s, 9H), 0.85 (t, J = 7.4 Hz, 3H), 0.09 (s, 3H), 0.09 (s, 3H), 
0.08 (s, 3H), 0.04 (s, 3H); 13C NMR (101 MHz, acetone-d6) δ 175.8, 
167.9, 166.5, 154.7, 153.9, 152.0, 145.2, 142.9, 140.0, 136.7, 136.5, 
136.0, 134.5, 134.2, 134.1, 128.7, 128.6, 127.8, 126.0, 125.4, 124.8, 
122.3, 118.8, 118.7, 102.2, 95.1, 93.4, 81.8, 77.9, 77.5, 76.4, 76.4, 75.4, 
75.0, 74.0, 73.2, 73.0, 72.4, 70.8, 69.2, 63.2, 61.7, 42.9, 38.1, 34.6, 
28.8, 27.1, 26.3, 26.2, 26.0, 25.6, 24.1, 20.9, 19.2, 19.0, 18.8, 18.6, 
18.4, 17.3, 15.2, 14.4, 13.9, 11.3, –4.1, –4.2, –4.8, –4.9; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C71H108Cl2O19Si2Na 1413.6293; found: 
1413.6254. 
 
Deprotection of Semisynthetic Fidaxomicin (1) 
 
Carbonate and allyl protected fidaxomicin (7b). To a solution of 
the fully protected, semisynthetic macrolide 7 (2.5 mg, 1.66 μmol) in 
THF (0.4 mL), 3HF·NEt3 (100 μL, excess) was added dropwise. The so-
lution was stirred for 26 h at 50 °C before it was quenched by the ad-
dition of sat. NaHCO3 (2 mL, Caution! Gas evolution). The aqueous 
layer was extracted with AcOEt (4 x 2 mL) and the combined organic 
layers were dried over MgSO4, filtered and concentrated. Purification 
by preparative TLC (acetone/pentane = 2/3) yielded the alcohol 7b 
(2.0 mg, > 99%). Analytical data matched those reported above. 
Allyl protected fidaxomicin (7a). To a solution of the carbonate and 
allyl protected semisynthetic 7b (8 mg, 7 µmol) in THF (0.2 mL) at 0 °C, 
a solution of NaH in ethylene glycol (20 μL, 0.5 mg/mL, 60% oil disper-
sion) was added. The mixture was stirred vigorously for 15 minutes 
and quenched with sat. NH4Cl (2 mL) and AcOEt (3 mL) was added. The 
layers were separated and the aqueous layer was extracted with Ac-
OEt (2 x 3 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated. Purification by column chromatography 
(AcOEt/PhMe = 2/3 - 1/1 - 3/2) gave starting material (7b, 1.0 mg, 
13%) and the allyl ether 7a as a mixture with minor side products, 3, 4 
and others. The impure 7a was further purified by RP-HPLC (A: 
H2O+0.1% HCOOH; Solvent B: MeCN+0.1% HCOOH; 1 mL/min; 
T = 20°C; B[%] (tR [min])= 65 (0 to 3); 90 (15); 100 (16)). The impure 
allylated fidaxomicin was dissolved in MeCN (0.15 mL) and separated 
in portions (100 μL). The 7a eluted at tR = 14.0 minutes and the sol-
vents were evaporated under reduced pressure to give pure 7a (3.6 
mg, 46%, 53% brsm) as an amorphous solid. Analytical data matched 
those reported above. 
Fidaxomicin (1). To a solution of the pure semisynthetic allyl pro-
tected pure fidaxomicin 7a (3.0 mg, 2.6 μmol) in THF (0.5 mL) at 0 °C, 
morpholine (0.5 µL in 10 µL THF) and Pd(PPh3)4 (0.3 mg, in 0.1 mL THF) 
were added and the reaction mixture was stirred at the same temper-
ature for 30 minutes. The reaction mixture was diluted with AcOEt (2 
mL) and quenched with sat. NH4Cl (2 mL). The layers were separated 
and the aqueous layer was extracted with AcOEt (3 x 2 mL). The com-
bined organic layers were dried over MgSO4, filtered and concen-
trated. Purification by column chromatography (acetone/pentane = 
2/3 - 1/1) yielded pure fidaxomicin 1 (2.4 mg, 86%). No migration of 
the isobutylate was observed under this mild reaction conditions; Rf = 
0.44 (MeOH/CH2Cl2 1/10); [α]D25 = –7.6° (c 0.96, MeOH); IR (cm-1) ν 
3452, 2974, 2933, 1703, 1643, 1584, 1370, 1312, 1242, 1199, 1146, 
1068, 1024, 900; 1H NMR (400 MHz, acetone-d6) δ 7.24 (dd, J = 11.5, 
0.8 Hz, 1H), 6.63 (dddd, J = 14.8, 11.6, 2.0, 1.0 Hz, 1H), 5.96 (ddd, J = 
14.6, 9.3, 4.6 Hz, 1H), 5.83 (s, 1H), 5.71–5.54 (m, 1H), 5.22 (dt, J = 10.6, 
1.5 Hz, 1H), 5.10 (t, J = 9.8 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 4.77 (d, J 
= 1.3 Hz, 1H), 4.75–4.71 (m, 1H), 4.68 (d, J = 0.8 Hz, 1H), 4.60 (d, J = 
11.5 Hz, 1H), 4.42 (d, J = 11.5 Hz, 1H), 4.26 (s, 1), 4.05–3.99 (m, 1H), 
3.95 (dd, J = 3.4, 1.2 Hz, 1H), 3.80 (dd, J = 9.9, 3.4 Hz, 1H), 3.75–3.73 
(m, 1H), 3.73–3.70 (m, 1H), 3.65–3.60 (m, 1H,), 3.59 (d, J = 2.5 Hz, 1H), 
3.52 (s, 3H), 3.01 (qd, J = 7.4, 2.0 Hz, 2H), 2.76 (dd, J = 14.4, 7.2 Hz, 1H), 
2.72–2.67 (m, 1H), 2.67–2.60 (m, 1H), 2.56 (sept, J = 7.0 Hz, 1H), 2.53–
2.46 (m, 1H), 2.46–2.38 (m, 1H), 1.93 (qdd, J = 10.5, 6.3, 1.9 Hz, 1H), 
1.81 (d, J = 1.3 Hz, 3H), 1.73 (d, J = 1.5 Hz, 3H), 1.65 (dd, J = 1.4, 0.7 Hz, 
3H), 1.31 (d, J = 6.2 Hz, 3H), 1.29–1.24 (m, 1H), 1.22 (t, J = 7.4 Hz, 3H), 
1.18 (d, J = 6.3 Hz, 3H), 1.16–1.12 (m, 9H), 1.09 (s, 3H), 0.83 (t, J = 7.5 
Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 178.4, 169.7, 169.1, 154.6, 
153.9, 146.2, 143.7, 141.9, 137.0, 137.0, 136.4, 134.6, 128.5, 126.9, 
125.6, 124.6, 114.8, 112.7, 108.8, 102.2, 97.2, 94.3, 82.5, 78.6, 76.9, 
75.9, 74.5, 73.5, 73.2, 72.8, 71.6, 70.6, 68.3, 63.9, 62.2, 42.5, 37.3, 
35.4, 28.7, 28.4, 26.9, 26.4, 20.3, 19.5, 19.1, 18.7, 18.1, 17.5, 15.4, 
14.5, 13.9, 11.3; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C52H74Cl2O18Na 1079.4144; found: 1079.4147. (see supporting infor-
mation for the detailed assignment of fidaxomicin) 
 
Total (de novo) Synthesis of Fidaxomicin (1) 
 
5-Ethyl-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
(20). To a solution of DIPA (0.35 mL, 2.5 mmol, 4.2 equiv) in THF 
(25 mL) at –78 °C was added n-BuLi (1.6 m in hexane; 1.57 mL, 
2.5 mmol, 4.2 equiv) slowly and it was stirred at 0 °C for 40 min before 
keto-dioxinone 1833a (221 mg, 1.2 mmol, 2.0 equiv) in THF (1.5 mL) 
was added. The resulting orange reaction mixture was stirred for 
100 min at –78 °C. Then propionyl imidazole 1733c (74 mg, 0.6 mmol) 
dissolved in THF (1.1 mL) was added. After stirring the reaction mix-
ture for 2.5 h at –78 °C, the reaction was quenched with sat. NH4Cl 
(20 mL). The medium was adjusted to pH = 3 using aqueous HCl (1 M), 
extracted with AcOEt (3 x 50 mL) and the combined organic layers 
were dried over MgSO4, filtered and concentrated. The yellow residue 
was dissolved in CH2Cl2 (15 mL) and Et3N (2 mL, excess). After stirring 
for 16 h, the mixture was acidified to pH = 1 using aqueous HCl (1 M) 
and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL), the com-
bined organic layers were dried over MgSO4, filtered and concen-
trated. Purification by column chromatography (Et2O/pentane = 1/2 
to 2/1) afforded the isopropylidene-protected resorcylate 20 
(76 mg, 57%) as a yellow crystalline solid; Rf = 0.45 (Et2O/pentane = 
1/2); m.p. = 138.0-140.0 °C; 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 
6.54 (d, J = 2.4 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 3.05 (q, J = 7.4 Hz, 2H), 
1.68 (s, 6H), 1.22 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 163.2, 
161.8, 159.3, 152.1, 112.6, 105.1, 103.8, 101.7, 27.8, 25.5 (2C), 14.9; 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C12H15O4 223.0965; Found 
223.0967; IR (cm-1) ν 3224, 3000, 2955, 2870, 1688, 1608, 1499, 1442, 
1294, 1213, 1154, 1048, 915, 840, 704. 
6,8-Dichloro-5-ethyl-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]di-
oxin-4-one (20a). To a solution of resorcylate 20 (500 mg, 2.3 mmol) 
in CH2Cl2 (25 mL) at room temperature, sulfuryl chloride (0.43 mL, 
5.3 mmol, 2.3 equiv) was added dropwise. The resulting yellow solu-
tion was heated to reflux for 1.5 h and subsequently the solvent was 
concentrated. The yellow residue was suspended in pentane (3 x 7 mL) 
and the supernatant was decanted off. The remaining solid was dried 
under HV to afford the dichloride 20a (639 mg, 98%) as a beige solid; 
 13 
Rf = 0.25 (pentane/Et2O = 3/1); m.p. = 172.5-173.5 °C; 1H NMR (400 
MHz, CDCl3) δ 6.47 (s, 1H), 3.30 (q, J = 7.4 Hz, 2H), 1.75 (s, 6H), 1.21 (t, 
J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 158.6, 153.3, 152.9, 145.9, 
116.5, 107.2, 106.3, 105.9, 25.6 (2C), 24.5, 13.3; HRMS (ESI-TOF) m/z: 
[M + H]+ Calcd for C12H11Cl2O4 289.0040; Found 289.0037; IR (cm-1) ν 
3287, 3001, 2974, 2950, 2881, 1716, 1584, 1561, 1437, 1280, 1192, 
1044, 786, 621. 
7-(Allyloxy)-6,8-dichloro-5-ethyl-2,2-dimethyl-4H-benzo[d][1,3]di-
oxin-4-one (21). To a suspension of resorcylate 20a (492 mg, 
1.7 mmol) and K2CO3 (701 mg, 5.1 mmol, 3.0 equiv) in DMF (5.0 mL), 
allyl bromide (0.44 mL, 5.1 mmol, 3.0 equiv) was added and the reac-
tion mixture was stirred at room temperature for 4 h. The reaction 
was quenched with H2O (50 mL) and sat. NaHCO3 (50 mL). The aque-
ous layer was extracted with Et2O (3 x 50 mL), the organic layers 
washed with H2O (50 mL) and brine (50 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated to afford the 
allyl-protected resorcylate 21 (534 mg, 95%) as a beige, crystalline 
compound; Rf = 0.74 (Et2O/pentane = 1/3); m.p. = 93.5-94.5 °C; 1H 
NMR (400 MHz, CDCl3) δ 6.15 (ddt, J = 17.1, 10.3, 6.0 Hz, 1H), 5.45 
(ddd, J = 17.1, 1.4, 2.9 Hz, 1H), 5.32 (ddd, J = 10.3, 2.4, 1.1 Hz, 1H), 4.63 
(dt, J = 6.0, 1.3 Hz, 2H), 3.30 (q, J = 7.4 Hz, 2H), 1.74 (s, 6H), 1.21 (t, J = 
7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 158.5, 156.9, 152.7, 146.2, 
132.5, 124.9, 119.3, 115.9, 109.9, 105.9, 74.6, 25.6 (2C), 24.5, 13.4; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H16Cl2O4Na 353.0318; 
Found 353.0312; IR (cm-1) ν 2990, 2943, 1733, 1573, 1380, 1277, 1231, 
1204, 1112, 1047, 911, 787.  
(2S,3S,4S,5S,6R)-2-methoxy-6-methyltetrahydro-2H-pyran-3,4,5-
triol (22).35 To a solution of Methyl 6-deoxy-6-iodo-α-
mannopyranoside 22a (3.59 g, 11.8 mmol) in MeOH (42 mL), DIPEA 
(6.19 mL, 35.4 mmol, 3.0 equiv) and Pd(OH)2 (0.83 g, , 1.2 mmol, 20% 
Wt on activated carbon) were added. The dark turbid mixture was de-
gassed with argon during 10 min, then hydrogen was bubbled through 
the suspension for 0.5 h, and the reaction mixture was subsequently 
stirred under a hydrogen atmosphere. The hydrogen atmosphere was 
exchanged by argon and the solution was filtered through Hyflo. The 
filtrate was concentrated and purified by column chromatography 
(MeOH/ CH2Cl2 = 1/10) to yield the rhamnoside 22 (2.19 g, quant.) as 
a colorless oil; The spectroscopic data were in good agreement with 
the literature.35 1H NMR (400 MHz, CD3OD) δ 4.56 (d, J = 1.7 Hz, 1H), 
3.78 (dd, J = 3.5, 1.7 Hz, 1H), 3.61 (dd, J = 9.4, 3.5 Hz, 1H), 3.57-3.48 
(m, 1H), 3.38 (pt, J = 9.5 Hz, 1H), 3.35 (s, 3H), 1.27 (d, J = 6.2 Hz, 3H); 
13C NMR (101 MHz, CD3OD,) δ 102.8, 74.0 , 72.4, 72.2, 69.6, 55.1, 18.0.  
(2R,3S,4S,5S,6S)-5,6-Dimethoxy-2-methyltetrahydro-2H-pyran-
3,4-diol (23). To a solution of D-rhamnoside 2235 (494 mg, 2.8 mmol) 
in MeOH (28 mL), 2,3-butadione (0.29 mL, 3.3 mmol, 1.2 equiv), tri-
methyl orthoformate (1.17 mL, 10.6 mmol, 3.8 equiv) and 10-cam-
phorsulfonic acid (41.1 mg, 0.16 mmol, 6 mol%) were added. The mix-
ture was heated in a sealed tube to 90 °C for 24 h. Then the reaction 
mixture was neutralized with Et3N and the solvent was removed under 
reduced pressure, yielding the protected intermediate 22b which was 
used in the next step without further purification. 
To the protected intermediate 22b in THF (17 mL) at 0 °C, NaH (60 
% dispersion in mineral oil, 223 mg, 5.6 mmol, 2.0 equiv) was added in 
portions. The mixture was allowed to warm to room temperature and 
was stirred for an additional 1 h. Then MeI (0.19 mL, 3.1 mmol, 1.1 
equiv) was added dropwise and the mixture was stirred for 3.5 h at 
room temperature. The reaction was quenched with sat. NH4Cl 
(20 mL), the solvent was removed under reduced pressure and the re-
maining aqueous suspension was diluted with H2O (40 mL). The mix-
ture was extracted with CH2Cl2 (3 x 50 mL) and the organic layers were 
washed with brine (30 mL), combined, dried over Na2SO4, filtered and 
concentrated. The methylated intermediate was used in the next step 
without further purification. 
To a solution of methylated intermediate in CH2Cl2 (30 mL), a mix-
ture of TFA/H2O (9:1, 2.4 mL) was added. The reaction was stirred for 
1 h while the mixture turned slightly yellow. The reaction was 
quenched with Et3N (2.5 mL), and then PhMe (10 mL) was added. The 
solvent was removed under reduced pressure. Azeotropic removal of 
Et3N was carried out twice with PhMe (5 mL). Purification by column 
chromatography (Et2O) afforded the desired product 23 (356 mg, 72% 
over three steps) as a colorless oil; Rf = 0.18 (Et2O); [α]D25 = +40.2° (c 
0.48, CHCl3); 1H NMR (400 MHz, CDCl3) δ 4.75 (d, J = 1.1 Hz, 1H), 3.72-
3.65 (m, 1H), 3.59 (dq, J = 9.3, 6.2 Hz, 1H), 3.47 (s, 3H), 3.45 (dd, J = 
3.9, 1.5 Hz, 1H), 3.37 (s, 3H), 3.38-3.32 (m, 1H) 2.50 (d, J = 2.7 Hz, 1H), 
2.43 (d, J = 10.4 Hz, 1H), 1.31 (d, J = 6.2 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 97.2, 80.2, 74.0, 71.5, 67.5, 58.8, 54.8, 17.5; HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C8H16O5Na 215.0890; Found 215.0889; IR (cm-
1) ν 3426, 2976, 2935, 2905, 2832, 1540, 1378, 1190, 1136, 1104 ,1046, 
966, 836, 807. 
(2R,3S,4S,5S,6R)-5-Methoxy-2-methyl-6-(phenylthio)tetrahydro-
2H-pyran-3,4-diol (24). To a solution of pyrannoside 23 (240 mg, 
1.3 mmol) in 1,2-dichloroethane (10 mL), tetrabutylammonium iodide 
(692 mg, 1.9 mmol, 1.45 equiv), ZnI (1.19 g, 3.8 mmol, 3.0 equiv) and 
trimethyl(phenylthio)silane (1.14 g, 6.2 mmol, 4.8 equiv) were added. 
The white turbid mixture was heated to 65 °C for 2.5 h. Then it was 
cooled to room temperature and a solution of TFA/H2O (9:1, 3 mL) was 
added. After stirring for 30 min, PhMe (5 mL) was added and concen-
trated. The residue was treated with Et2O (10 mL) and the biphasic 
mixture was stirred for 5 min. The etheral extract was decanted and 
the remaining oil was re-extracted twice in the same manner. The 
combined etheral extracts were concentrated and purified by column 
chromatography (Et2O) to afford the title compound 24 (247 mg, 73%) 
as a yellowish oil; Rf = 0.3 (Et2O); [α]D25 = +184.4° (c 0.47, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.35-7.30 (m, 2H), 7.30-
7.27 (m, 1H), 5.62 (ap s, 1H), 4.13 (dqd, J = 9.4, 6.2 Hz, 0.6, 1H), 3.77-
3.70 (m, 2H), 3.48-3.43 (m, 1H), 3.46 (s, 3H), 2.41 (d, J = 10.0 Hz, 1H), 
2.39 (d, J = 2.6 Hz, 1H), 1.32 (d, J = 6.2 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 134.4, 131.3 (2C), 129.1 (2C), 127.4, 84.0, 81.7, 74.3, 72.1, 
68.9, 58.1, 17.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C13H18O4SNa 
293.0818; Found 293.0817; IR (cm-1) ν 3523, 3296, 2976, 2932, 2898, 
2831, 1581, 1478, 1438, 1355, 1141, 1099, 1055, 1021, 839, 740, 690. 
(2R,3S,4S,5S,6R)-4-Hydroxy-5-methoxy-2-methyl-6-(phenyl-
thio)tetrahydro-2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hy-
droxybenzoate (26). To a solution of the rhamnose 24 (163 mg, 
0.60 mmol) and the resorcylate 21 (200 mg, 0.60 mmol, 1.0 equiv) in 
THF (6.0 mL) at 0 °C, NaH (60% dispersion in mineral oil, 114 mg, 
2.84 mmol, 4.7 equiv) was added in portions. The grey turbid mixture 
was stirred at room temperature for 16 h. The reaction was quenched 
with sat. NH4Cl (10 mL) and the aqueous layer was extracted with Et2O 
(3 x 10 mL), the combined organic layers were dried over MgSO4, fil-
tered and concentrated. Purification by column chromatography 
(TBME/cyclohexane = 1/3) afforded the desired ester 26 (272 mg, 
83%) as pale yellow oil; Rf = 0.1 (Et2O/pentane = 1/3); [α]D25 = +138.4° 
(c 1.25, CHCl3); 1H NMR (400 MHz, CDCl3) δ 10.29 (s, 1H), 7.44-7.40 (m, 
2H), 7.30-7.22 (m, 3H), 6.09 (ddt, J = 16.3, 10.3, 5.9 Hz, 2H), 5.60 (d, J 
= 0.7 Hz, 1H), 5.39 (ddd, J = 17.2, 3.0, 1.5 Hz, 1H), 5.24 (ddd, J = 10.3, 
2.5, 1.1, 1H), 5.19 (dd, J = 9.8, 9.8, 1H), 4.54 (ddd, J = 5.9, 1.2, 1.2 Hz, 
2H), 4.31 (dq, J = 9.8, 6.1 Hz, 1H), 3.96-3.87 (m, 1H), 3.78 (dd, J = 3.6, 
1.3 Hz, 1H), 3.44 (s, 3H), 3.02-2.94 (m, 2H), 2.47 (d, J = 10.9 Hz, 1H), 
1.23 (d, J = 6.3 Hz, 3H), 1.20 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 169.2, 155.5, 155.4, 142.5, 133.9, 132.7, 131.2 (2C), 129.2 
(2C), 127.7, 121.7, 119.1, 115.6, 112.4, 83.8, 81.6, 76.8, 74.3, 69.9, 
66.9, 58.0, 26.0, 17.5, 14.0; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C25H28Cl2O7SNa 565.0825; Found 565.0825; IR (cm-1) ν 2980, 2936, 




ethylbenzoate (26a). To a suspension of the rhamnose 26 (90 mg, 
0.17 mmol) and K2CO3 (69 mg, 0.50 mmol, 2.9 equiv) in DMF (2.0 mL), 
allyl bromide (22 µL, 0.25 mmol, 1.5 equiv) was added and the suspen-
sion was heated to 50 °C for 3 h. It was subsequently diluted with Et2O 
(5 mL), quenched with aqueous sat. NH4Cl (50 mL) and extracted with 
Et2O (3 x 20 mL). The organic layers were washed with brine (40 mL), 
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combined, dried over MgSO4, filtered and concentrated to afford the 
allyl ether 26a (93 mg, 96%) as a colorless oil; Rf = 0.3 (Et2O/pentane = 
1/3); [α]D25 = +111.1° (c 0.54, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.40-
7.36 (m, 2H), 7.26-7.17 (m, 3H), 6.07 (ddt, J = 17.3, 10.4, 5.9 Hz, 2H), 
5.97 (ddt, J = 17.2, 10.3, 5.9, 1H) 5.57 (d, J = 1.2 Hz, 1H), 5.36 (ddd, J = 
17.1, 1.5, 1.5 Hz, 1H), 5.30 (ddd, J = 17.1, 1.5, 1.5 Hz, 1H), 5.22 (ddd, J 
= 10.3, 2.6, 1.1 Hz, 1H), 5.17 (ddd, J = 10.3, 2.6, 1.1 Hz, 1H), 5.10 (dd, J 
= 9.7, 9.7 Hz, 1H), 4.52 (dddd, J = 11.6, 5.9, 1.4, 1.4 Hz, 1H) 4.48 (ddd, 
J = 5.9, 1.3, 1.3 Hz, 2H) 4.42 (dddd, J = 11.5, 6.0, 1.3, 1.3 Hz, 1H), 4.22 
(dq, J = 9.8, 6.2 Hz, 1H), 3.85 (dd, J = 9.8, 3.6 Hz, 1H), 3.73 (dd, J =3.6, 
1.4 Hz, 1H), 3.42 (s, 3H), 3.39 (q, J = 7.0 Hz, 2H) 2.83-2.66 (m, 2H), 1.25 
(d, J = 6.2 Hz, 3H), 1.14 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
166.5, 153.3, 151.1, 139.2, 134.1, 132.9, 132.9, 131.4 (2C), 129.3 (2C), 
127.7, 127.3, 125.7, 121.7, 119.1, 113.0, 84.2, 81.9, 76.6, 75.9, 74.4, 
70.2, 67.2, 58.3, 25.3, 17.6, 14.1; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd 
for C28H32Cl2O7SNa 605.1138; Found 605.1130; IR (cm-1) ν 3548, 2978, 
2936, 2883, 1736, 1570, 1402, 1314, 1246, 1099, 998, 929, 841, 742, 
692. 
(2R,3S,4S,5S)-4,6-dihydroxy-5-methoxy-2-methyltetrahydro-2H-
pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (26b). To a 
solution of thioglycoside 26a (17.5 mg, 0.03 mmol) in acetone (1.0 mL) 
and H2O (0.1 mL) at 0 °C, NBS (5.9 mg, 0.03 mmol, 1.0 equiv) was 
added. The orange reaction mixture was stirred at 0 °C for 15 min then 
it was warmed to room temperature. The colorless solution was 
treated with NBS in the same manner until full consumption of the 
starting material was observed by TLC. The reaction was quenched 
with sat. NaHCO3 (10 mL) extracted with CH2Cl2 (3 x 10 mL), dried over 
MgSO4, filtered and concentrated. Purification by column chromatog-
raphy (AcOEt/cyclohexane = 1/4 to 1/2) gave the desired pyranose 
26b (14.0 mg, 95%, α:β = 5:1) as a colourless oil of inseparable 
anomers; Rf = 0.18 (AcOEt/cyclohexane = 1/2); 1H NMR (400 MHz, 
CDCl3, major anomer) δ 6.15 (ddt, J = 16.4, 10.4, 5.9 Hz, 1H), 6.05 (ddt, 
J = 16.4, 10.4, 6.0 Hz, 1H), 5.44 (ddd, J = 17.1, 1.4, 1.4 Hz, 1H), 5.39 
(ddd, J = 17.1, 1.4, 1.4 Hz, 1H), 5.35 (s, 1H), 5.32 (ddd, J = 10.3. 1.2, 1.2 
Hz, 1H), 5.27 (ddd, J = 10.4, 1.3, 1.3 Hz, 1H), 5.09 (dd J = 9.8, 9.8 Hz, 
1H), 4.60 (dddd, J = 11.5, 5.9, 1.3, 1.3 Hz, 1H), 4.57 (ddd, J = 6.0, 1.3, 
1.3 Hz, 2H), 4.51 (dddd, J = 11.5, 6.1, 1.3, 1.3 Hz, 1H), 4.03 (dq, J = 9.8, 
6.2 Hz, 1H) 3.99 (dd, J = 9.8, 3.7 Hz, 1H), 3.58 (dd, J = 3.6, 1.5 Hz, 1H), 
3.53 (s, 3H), 2.89-2.73 (m, 2H), 1.30 (d, J = 6.2 Hz, 3H), 1.20 (t, J = 7.4 
Hz, 3H); 13C NMR (101 MHz, CDCl3, major anomer) δ 166.6, 153.2, 
151.1, 139.2, 132.9, 132.9, 127.4, 125.7, 121.7, 119.1, 119.0, 91.1, 
80.7, 75.6, 75.9, 74.5, 69.3, 66.1, 59.2, 25.3, 17.8, 14.1; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C22H28Cl2O8Na 513.1053; Found 
513.1052; IR (cm-1) ν 3442, 2936, 1734, 1567, 1460, 1403, 1315, 1248, 
1100, 1065, 1041, 995, 930, 798, 748. 
(2R,3S,4S,5S,6R)-4-Hydroxy-5-methoxy-2-methyl-6-((E)-2,2,2-tri-
fluoro-1-(phenylimino)ethoxy)tetrahydro-2H-pyran-3-yl 2,4-bis(al-
lyloxy)-3,5-dichloro-6-ethylbenzoate (27). To a solution of rhamnose 
26b (4.5 mg, 0.01 mmol) in acetone (0.3 mL, technical grade) at 0 °C 
was added K2CO3 (5.0 mg, 0.4 mmol, 40 equiv) and ClC(=NPh)CF3 
(1.7 µL, 0.01 mmol, 1.0 equiv) in acetone (0.1 mL). Then the reaction 
mixture was stirred at room temperature for 3 h. The suspension was 
diluted with PhMe (1 mL), filtered and concentrated. Purification by 
preparative TLC (AcOEt/cyclohexane = 1/4) afforded the acetimidate 
27 (6.0 mg, 98%) as a colorless oil; Rf = 0.5 (AcOEt/cyclohexane = 1/4); 
[α]D25 = +20.2° (c 0.07, CHCl3); 1H NMR (400 MHz, acetone-d6) δ 7.42-
7.32 (m, 2H), 7.18-7.12 (m, 1H), 6.99-6.89 (m, 2H), 6.24 (br, 1H), 6.23-
6.02 (m, 2H), 5.46 (ddd, J = 17.2, 1.6, 1.6 Hz, 1H), 5.40 (ddd, J = 17.2, 
1.6, 1.6 Hz, 1H), 5.31-5.23 (m, 2H), 5.19 (dd J = 10.0, 10.0 Hz, 1H), 4.68-
4.58 (m, 3H), 4.54 (dddd, J = 11.8, 5.7, 1.4, 1.4 Hz, 2H), 4.20 (d, J = 9.4, 
1H), 4.04-3.88 (m, 2H), 3.83 (br, 1H), 3.50 (br, 3H), 2.92-2.75 (m, 2H), 
1.35-1.26 (m, 3H), 1.17 (t, J = 7.4 Hz, 3H); HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C30H32Cl2F3NO8Na 684.1349; Found 684.1348; IR (cm-1) 
ν 3546, 2981, 2937, 1737, 1569, 1454, 1404, 1330, 1316, 1249, 1211, 
1164, 1118, 1024, 2012, 975, 929, 777, 752, 695. 
(3aS,4S,6R,6aS)-2,2-Dimethyl-6-vinyltetrahydrofuro[3,4-
d][1,3]dioxol-4-ol (28a). To a solution of iodo-mannopyranoside 28 
(4.42 g, 12.8 mmol) in MeOH (40 mL), zinc powder (8.40 g, 
128.0 mmol, 10 equiv) was added and the grey suspension was heated 
to 60 °C. Solid NH4Cl (150 mg, 2.8 mmol, 0.2 equiv) was added and it 
was stirred for 30 min. Then it was treated again with solid NH4Cl 
(150 mg, 2.8 mmol, 0.2 equiv). After stirring for 90 min it was allowed 
to cool to room temperature. The grey suspension was filtered 
through Celite, washed with CH2Cl2 (3 x 20 mL) and the solvent was 
concentrated. Purification by column chromatography (Et2O/pentane 
= 1/3) afforded the desired furanose 28a (2.2 g, 91%) as a colorless oil 
which crystallized at –20 °C; The spectroscopic data matched those 
reported in the literature.38a Rf = 0.6 (Et2O/pentane = 1/1); m.p. 
= 58.0-59.0 °C; [α]D25 = –28.7° (c 0.54, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 5.99 (ddd, J = 17.6, 10.4, 7.4 Hz, 1H), 5.42 (ddd, J = 17.4, 1.6, 1.1 Hz, 
1H), 5.41 (d, J = 2.3 Hz, 1H), 5.34 (ddd, J = 10.4, 1.6, 0.8 Hz, 1H), 4.73 
(dd, J = 5.8, 3.7 Hz, 1H), 4.64 (d, J = 5.8 Hz, 1H), 4.62-4.59 (m, 1H), 2.69 
(d, J = 2.3 Hz, 1H), 1.49-1.46 (m, 3H), 1.32 (d, J = 0.4 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 132.2, 119.3, 112.7, 101.1, 85.8, 81.6, 26.1, 24.9. 
 (3aS,4S,6R,6aS)-4-Methoxy-2,2-dimethyl-6-vinyltetrahydro-
furo[3,4-d][1,3]dioxole (29). To a solution of furanose 28a (1.00 g, 
5.45 mmol) in MeOH (10 mL) and 2,2-dimethoxypropane (5 mL), 10-
camphorsulfonic acid (250 mg, 1.1 mmol, 20 mol%) was added. The 
solution was heated to 55 °C for 18 h. Then, the dark solution was neu-
tralized with Et3N (solution turned bright yellow) and the solvents 
were carefully concentrated. The residue was treated with H2O 
(100 mL) and aqueous layer extracted with Et2O (3 x 50 mL). The com-
bined organic layers were dried over MgSO4, filtered and concen-
trated. Purification by Kugelrohr distillation afforded product 29 
(1.08 g, 99%) as a colorless liquid; The spectroscopic data matched 
those reported in the literature.38b Rf = 0.6 (Et2O/pentane = 1/3); b.p. 
= 130 °C (5.6 mbar); [α]D25 = +24.3° (c 0.5, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 5.99 (ddd, J = 17.3, 10.1, 7.4 Hz, 1H), 5.42 (ddd, J = 17.4, 1.7, 
1.1 Hz, 1H), 5.34 (ddd, J = 10.4, 1.5, 0.8 Hz, 1H), 4.91 (s, 1H), 4.68 (dd, 
J = 5.8, 3.7 Hz, 1H), 4.58 (d, J = 5.8 Hz, 1H), 4.39 (dd, J = 7.4, 3.7 Hz, 
1H), 3.35 (s, 3H), 1.47 (s, 3H), 1.31 (s, 3H); 13C NMR (101 MHz, CDCl3) 
δ 132.3, 119.1, 112.6, 107.2, 85.3, 81.5, 81.1, 54.7, 26.1, 24.9. 
Methyl (3aR,4S,6S,6aS)-6-methoxy-2,2-dimethyltetrahydro-
furo[3,4-d][1,3]dioxole-4-carboxylate (30) and (3aS,4S,6S,6aS)-6-
methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbalde-
hyde (31). To a solution of furanoside 29 (1.03 g, 5.14 mmol) in CH2Cl2 
(20 mL) and methanolic NaOH (5.0 mL, 2.5 m) was cooled to –78 °C. 
Then ozone was bubbled through the solution. The solution turned 
orange and faded to yellow after a while, after 1 h it turned deep blue. 
After 8 h, again methanolic NaOH (5.0 mL, 2.5 m) was added (solution 
turns yellow and turbid again which faded again after 45 minutes). Ad-
ditional methanolic NaOH (2.5 m) was added until full conversion to 
the ester (monitored by TLC). Then, N2 was bubbled through the solu-
tion for 15 minutes before it was diluted with CH2Cl2 (50 mL) and H2O 
(20 mL). The reaction mixture was allowed to warm to room temper-
ature then sat. NH4Cl (30 mL) was added. The layers were separated 
and the aqueous layer was extracted with CH2Cl2 (4 x 50 mL). The or-
ganic layers were dried with MgSO4, filtered and concentrated. Puri-
fication by column chromatography (Et2O/pentane = 1/3 - 1/2) af-
forded the desired ester 30 (0.740 g, 62%) as a colourless fluid, alde-
hyde 31 (110 mg, 11%) and ozonide mixture (46 mg); Aldehyde 31: 
The spectroscopic data matched to those reported in the literature.38c 
Rf = 0.1 (Et2O/pentane = 1/3); [α]D25 = +44.5° (c 1.2, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 9.66 (d, J = 1.2 Hz, 1H), 5.09 (s, 1H), 5.07 (dd, J = 
5.9, 4.3 Hz, 1H), 4.61 (d, J = 5.8 Hz, 1H), 4.37 (d, J = 4.3 Hz, 1H), 3.36 (s, 
3H), 1.43 (s, 3H), 1.29 (d, J = 0.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
197.9, 113.7, 108.0, 84.7, 84.1, 81.0, 55.2, 26.0, 24.7.; Methylester 30: 
Rf = 0.17 (Et2O/pentane = 1/3); [α]D25 = +23.5° (c 0.65, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 5.07 (s, 1H), 4.98 (dd, J = 5.8, 4.3 Hz, 1H), 4.60-4.55 
(m, 2H), 3.81 (s, 3H), 3.35 (s, 3H), 1.42 (s, 3H), 1.31-1.27 (m, 3H); 13C 
NMR (101 MHz, CDCl3) δ 167.9, 113.4, 107.5, 84.0, 80.6, 79.5, 55.1, 
52.2, 25.9, 25.1; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C10H16O6Na 
255.0839; Found 255.0840; IR (cm-1) ν 2990, 2942, 2839, 1769, 1739, 
1439, 1374, 1208, 1095, 1061, 967, 860, 775, 613. 
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Compound 30. To a solution of aldehyde 31 (795 mg, 3.9 mmol) in 
MeOH (24 mL) and water (4 mL) at room temperature was added solid 
NaHCO3 (5.30 g, 63 mmol). To this suspension under vigorous stirring 
was added Br2 (0.65 mL, 13 mmol, 3.25 equiv) and the mixture was 
heated to 40 °C. After stirring for 3 h again Br2 (50 μL, 1.0 mmol, 0.25 
equiv) was added and it was stirred for another 1 h. The reaction was 
quenched with sat. Na2S2O3 (50 mL) and the reaction mixture was di-
luted with water (50 mL), and extracted with AcOEt (3 x 70 mL). The 
combined organic layers were washed with water (50 mL) and with 
brine (50 mL), dried over MgSO4, filtered and concentrated to give de-
sired ester 30 (0.840 g, 92%) as a colourless fluid. 
2-((3aS,4S,6S,6aS)-6-Methoxy-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)propan-2-ol (32). To a solution of ester 30 (735 mg, 
3.2 mmol) in Et2O (28 mL), MeMgBr (3 M solution in Et2O, 3.2 mL, 
9.5 mmol, 2.4 equiv) was added dropwise at room temperature. Then 
it was heated to 35 °C for 30 min. The reaction was cooled to room 
temperature and carefully quenched with sat. NH4Cl (10 mL). Then 
H2O (30 mL) was added and the total was extracted with Et2O (3 x 20 
mL). The organic layers were dried over Na2SO4, filtered and concen-
trated. This gave the tertially alcohol 32 (721 mg, 99%) as a colorless 
oil; The spectroscopic data matched those reported for its enantiomer 
in the literature.65 Rf = 0.4 (Et2O/pentane = 1/1); [α]D25 = +84.0° (c 1.15, 
MeOH); 1H NMR (400 MHz, CDCl3) δ 5.01 (s, 1H), 4.86 (dd, J = 5.9, 3.4, 
Hz 1H), 4.58 (d, J = 5.9 Hz, 1H), 3.71 (d, J = 3.3 Hz, 1H), 3.56 (s, 1H), 
3.35 (s, 3H), 1.52 (s, 3H), 1.40 (s, 3H), 1.36 (s, 3H), 1.33 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 112.8, 106.6, 85.2, 82.9, 80.7, 70.9, 54.5, 27.3, 
27.3, 25.8, 24.2; IR (cm-1) ν 3525, 2979, 2937, 1465, 1374, 1209, 1153, 
1092, 1031, 964, 881, 854. 
(3S,4S,5S)-6-Methoxy-2,2-dimethyltetrahydro-2H-pyran-3,4,5-
triol (33). To a solution of furanoside 32 (210 mg, 0.90 mmol) in MeOH 
(2.0 mL), TFA (1.0 mL) was added. The colorless solution was heated 
in the microwave to 100 °C for 3 h. The reaction mixture was diluted 
with PhMe (10 mL), concentrated and the residue was submitted to 
column chromatography (CH2Cl2/MeOH = 20/1 to 10/1) to afford the 
desired pyranoside 33 and a mixture of acetonide deprotected 
furanoside 32a with starting material 32. The same protocol was ap-
plied twice to convert this mixture to the pyranoside 33. In this way 
the desired pyranoside 33 (141 mg, 81%) was obtained as a mixture of 
two inseparable anomers; Rf = 0.28 (CH2Cl2/MeOH = 10/1); 1H NMR 
(400 MHz, CD3OD α:β 2:1) δ 4.57 (d, J = 1.5 Hz, 1H), 4.54 (d, J = 1.0 Hz, 
0.5H), 3.85 (dd, J = 3.0, 1.0 Hz, 0.5H), 3.83-3.78 (m, 1H) 3.81 (s, 1H), 
3.63 (d, J = 9.1 Hz, 1H), 3.57 (dd, J = 10.0, 3.1 Hz, 0.5H), 3.52 (d, J = 10.0 
Hz, 0.5H), 3.45 (s, 1.5H), 3.37 (s, 3H), 1.29 (s, 1.5H), 1.28 (s, 6H), 1.18 
(s, 1.5H); 13C NMR (101 MHz, CD3OD α:β 2:1) δ 104.1, 98.4 (0.5C), 79.0, 
76.2 (0.5C), 74.8 (0.5C), 74.7, 72.8, 72.5 (0.5C), 71.9 (0.5C), 69.3, 56.9 
(0.5C), 55.8, 29.2, 28.7 (0.5C), 22.7, 18.5 (0.5C); HRMS (ESI-TOF) m/z: 
[M + Na]+ Calcd for C8H16O5Na 215.0890; Found 215.0890; IR (cm-1) ν 
3377, 2981, 2925, 2361, 1673, 1445, 1369, 1193, 1135, 1065, 1037, 
979, 803, 736. 
(3aS,4S,7S,7aS)-4-Methoxy-6,6-dimethyl-2-oxotetrahydro-4H-
[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (34). To a solution of novio-
side 33 (106 mg, 0.55 mmol) in 1,2-dichloroethane (5.0 mL), 1,1'-car-
bonyldiimidazole (98 mg, 0.61 mmol, 1.1 equiv) was added and the re-
action mixture was stirred at reflux for 3 h. Then, 1,1'-carbonyldiimid-
azole was added in portions until TLC indicated full consumption of 
the starting material. The reaction was quenched with aqueous HCl 
(1 M, 10 mL), extracted with CH2Cl2 (3 x 10 mL), the organic layers were 
dried over MgSO4, filtered and concentrated. Next, this residue was 
dissolved in CH2Cl2 (4.0 mL) and it was added Et3N (0.39 mL, 2.8 mmol, 
5.1 equiv) and isobutyryl chloride (0.17 mL, 1.65 mmol, 3.0 equiv). Af-
ter stirring for 1 h at room temperature it was quenched with H2O (10 
mL) and HCl (1 M, 10 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 10 mL) and the organic layers washed with aqueous Na-
HCO3 (20 mL), combined, dried over MgSO4, filtered and concen-
trated. Purification by column chromatography (Et2O/pentane = 1/2 
to Et2O) afforded the two anomers as white solids (α-34: 66 mg, 42%; 
β-34: 40 mg, 25%); α-34: Rf = 0.63 (Et2O/pentane = 1/1); m.p. = 89.0-
90.0 °C; [α]D25 = +18.5° (c 0.3, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.06 
(d, J = 7.6 Hz, 1H), 4.85 (d, J = 2.9 Hz, 1H), 4.72 (pt, J = 7.7 Hz, 1H), 4.62 
(dd, J = 7.8, 2.9 Hz, 1H), 3.40 (s, 3H), 2.56 (qq, J = 7.0 Hz, 1H), 1.22 (s, 
6H), 1.14 (d, J = 7.0 Hz, 3H), 1.14 (d, J = 7.0 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 175.6, 153.2, 97.3, 76.6, 75.4, 74.7, 72.0 56.1, 34.1, 26.9, 23.2, 
19.0, 18.8; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C13H21O7 289.1282; 
Found 289.1281; IR (cm-1) ν 2988, 1793, 1737, 1464, 1392, 1340, 1127, 
1087, 1026, 969, 818; β-34: Rf = 0.3 (Et2O/pentane = 1/1); m.p. = 
134.0-137.0 °C; [α]D25 = –101.9° (c 0.2, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 5.73-5.66 (m, 1H), 4.79-4.75 (m, 1H), 4.73-4.70 (m, 2H), 3.45 
(s, 3H), 2.61-2.49 (qq, J = 7.0 Hz, 1H), 1.21 (s, 3H), 1.14 (d, J = 7.0 Hz, 
3H), 1.14 (d, J = 7.0 Hz, 3H), 1.14 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
175.2, 153.9, 95.8, 75.7, 75.0, 72.3, 71.9, 56.2, 34.1, 28.7, 24.3, 19.1, 
18.8; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C13H21O7 289.1282; 
Found 289.1281; IR (cm-1) ν 2984, 1790, 1740, 1472, 1394, 1355, 1148, 
1048, 962, 807, 774. 
The experimental protocol for the synthesis of 35 is shown together 
with noviosylation with 43. The synthesis of known aldehyde 16 from 
36 and 37 is briefly described in supporting information. 
(S,E)-4-Benzyl-3-(2-methylhex-2-enoyl)oxazolidin-2-one (38).42 To 
a stirred solution of 2-methyl-2-hexenoic acid 38a (0.70 g, 5.46 mmol, 
prepared by a Wittig reaction between butanal and Ethyl 2-(tri-
phenylphosphoranylidene)propanoate and a subsequent hydrolysis) 
and Et3N (2.46 mL, 17.50 mmol, 3.2 equiv) in THF (30 mL) at -40 °C, 
PivCl (0.85 mL, 6.83 mmol, 1.25 equiv) was added and the resulting 
white slurry was stirred at -40 °C for 1.5 h. Next, flame dried LiCl (0.32 
g, 7.65 mmol, 1.4 equiv) and (S)-4-benzyloxazolidin-2-one (0.97 g, 
5.46 mmol, 1.0 equiv) were added and the cooling bath was removed 
and the reaction mixture was allowed to stir for 15 h at room temper-
ature. The reaction was quenched MeOH (5 mL) and sat. NH4Cl (60 
mL). The ensuing aqueous layer was extracted with Et2O (2 x 60 mL) 
and the combined organic layers were washed sequentially with sat. 
NaHCO3 (60 mL), brine (60 mL) and H2O (60 mL). The resulting organic 
layer was then dried over Na2SO4, filtered and concentrated. Purifica-
tion by column chromatography (AcOEt/pentane = 1/10 to 1/6) gave 
imide 3842 (1.25 g, 79%) as a white solid upon storage in the fridge; Rf 
= 0.73 (AcOEt/pentane = 1/2); m.p. = 40-41 °C; [α]D25 = +66.1° (c 0.53, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.31-7.16 (m, 3H), 7.16-7.09 (m, 
2H), 6.03 (tq, J = 7.3, 1.2 Hz, 1H), 4.64 (dddd, J = 9.2, 8.1, 5.6, 3.5 Hz, 
1H), 4.17 (dd, J = 8.9, 8.0 Hz, 1H), 4.07 (dd, J = 8.9, 5.6 Hz, 1H), 3.27 
(dd, J = 13.5, 3.5 Hz, 1H), 2.76 (dd, J = 13.5, 9.2 Hz, 1H), 2.24-1.96 (m, 
2H), 1.84 (d, J = 1.2 Hz, 3H), 1.42 (h, J = 7.4 Hz, 2H), 0.89 (t, J = 7.4 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 172.1, 153.3, 140.3, 135.3, 130.8, 
129.6 (2C), 129.0 (2C), 127.5, 66.5, 55.6, 37.7, 30.6, 21.9, 14.0, 13.7; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C17H21NO3Na 310.1414; 
Found 310.1415; IR (cm-1) ν 2960, 2931, 2872, 1782, 1678, 1455, 1389, 
1350, 1297, 1211, 1096, 1043, 902, 761, 704, 631. 
(S)-4-Benzyl-3-((1E,3E)-1-((tert-butyldimethylsilyl)oxy)-2-
methylhexa-1,3-dien-1-yl)oxazolidin-2-one (15). To a stirred solution 
of imide 3842 (9.5 g, 33.1 mmol) in THF (220 mL) at -78 °C, NaHMDS (2 
M in THF; 24.8 mL, 49.6 mmol, 1.5 equiv) was added and stirred for 2 
h. A solution of TBSCl (9.0 g, 59.5 mmol, 1.8 equiv) in THF (75 mL) was 
then added dropwise and the resulting mixture was stirred at -78 °C 
for 2 h. The reaction was quenched with sat. NH4Cl (300 mL) and the 
aqueous layer was extracted with Et2O (2 x 350 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated. Pu-
rification by column chromatography (Et2O/pentane = 1/8) gave a mix-
ture of silyl ketene aminal 15 and byproduct TBSOH. Azeotropic re-
moval of TBSOH with PhMe (3 x 15 mL) provided silyl ketene aminal 
15 (12.8 g, 97%) as a pale yellow oil; Rf = 0.38 (Et2O/pentane = 1/4); 
[α]D25 = -57.9° (c 1.52, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.35-7.27 
(m, 2H), 7.26-7.22 (m, 1H), 7.13 (br. d, J = 7.5 Hz, 2H), 6.14 (d, J = 15.6 
Hz, 1H), 5.68 (dt, J = 15.5, 6.7 Hz, 1H), 4.30-4.21 (m, 2H), 4.13 (br. s, 
1H), 3.16-3.06 (m, 1H), 2.72-2.56 (m, 1H), 2.28-2.01 (m, 2H), 1.82 (s, 
3H), 1.03 (t, J = 7.5 Hz, 3H), 0.99 (s, 9H), 0.21 (s, 3H), 0.14 (s, 3H); 13C 
NMR (126 MHz, CDCl3) δ 155.3, 135.8, 134.0, 132.1, 129.1 (2C), 129.0 
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(2C), 127.2, 125.9, 116.4, 67.9, 56.4, 38.9, 26.5, 25.8 (3C), 18.2, 14.2, 
12.5, -4.2, -4.8; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C23H35NO3SiNa 424.2278; Found 424.2281; IR (cm-1) ν 2958, 2930, 
2859, 1766, 1653, 1628, 1396, 1376, 1295, 1254, 1165, 1079, 1034, 
997, 841, 784, 632. 
(S)-4-Benzyl-3-((2E,4S,5S,6E)-4-ethyl-5-hydroxy-7-iodo-2,6-dime-
thylhepta-2,6-dienoyl)oxazolidin-2-one (39). To a solution of alde-
hyde 16 (7.58 mmol, 2.0 equiv) in CH2Cl2 (ca. 14 g of solution) at –78 
°C, TiCl4 (1 M, 3.79 mL, 3.79 mmol, 1.0 equiv) was slowly added and 
the resulting mixture was stirred for 20 mins at the same temperature 
to give an orange precipitate. A silyl ketene aminal 15 (1522 mg, 3.79 
mmol) in CH2Cl2 (4 mL) was then added dropwise at –78 °C using sy-
ringe pump over 20 min and stirred for 20 min. The resulting solution 
was then gradually warmed to –45 °C over 30 min and then stirred at 
–37 °C for 18 h (until the starting material consumed). During the 
course of the reaction, the color of the solution turned into orange-
red from brown and the mixture was quenched with the mixture of 
sat. Rochelle solution (15 mL) and sat. NaHCO3 (15 mL). The mixture 
was stirred for 30 min at room temperature and the resulting organic 
phase was separated. The remaining aqueous layer was extracted 
with Et2O (2 x 20 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated. Purification by column chromatog-
raphy (AcOEt/cyclohexane = 1/5 - 1/4 - 1/3) gave desired alcohol 39 
(1.39 g, 75%) as a pale yellow oil; Rf = 0.40 (AcOEt/pentane = 1/2); 
[α]D25 = +9.3° (c 0.59, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.36-7.25 (m, 
3H), 7.21-7.12 (m, 2H), 6.25-6.24 (m, 1H), 5.67 (dq, J = 10.4, 1.4 Hz, 
1H), 4.83 (tdd, J = 8.6, 6.7, 3.5 Hz, 1H), 4.33 (t, J = 8.8 Hz, 1H), 4.19 (dd, 
J = 9.0, 6.7 Hz, 1H), 3.89 (d, J = 9.0 Hz, 1H), 3.46 (br. s, 1H), 3.25 (dd, J 
= 13.7, 3.5 Hz, 1H), 2.94 (dd, J = 13.6, 8.6 Hz, 1H), 2.58 (tdd, J = 10.5, 
9.1, 3.5 Hz, 1H), 1.99 (d, J = 1.5 Hz, 3H), 1.87 (d, J = 1.1 Hz, 3H), 1.43-
1.30 (m, 1H), 1.16-1.01 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 171.3, 154.4, 147.6, 140.4, 134.8, 134.2, 129.7 (2C), 
129.1 (2C), 127.6, 80.5, 79.7, 66.4, 55.1, 45.9, 37.4, 24.0, 19.1, 14.3, 
12.1; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C21H26INO4Na 506.0799; 
Found 506.0800; IR (cm-1) ν 3495, 2961, 2929, 2872, 1766, 1682, 1454, 
1392, 1352, 1292, 1213, 1095, 1044, 911, 734, 704, 632. 
(1E,3R,4S,5E)-7-((S)-4-Benzyl-2-oxooxazolidin-3-yl)-4-ethyl-1-
iodo-2,6-dimethyl-7-oxohepta-1,5-dien-3-yl 4-nitrobenzoate (39a). 
To a solution of secondary alcohol 39 (400 mg, 0.83 mmol) in THF (25 
mL) at 0 °C, PPh3 (434 mg, 1.66 mmol, 2.0 equiv), p-nitrobenzoic acid 
(282 mg, 1.66 mmol, 2.0 equiv) and DEAD (40% in PhMe; 1.53 mL, 1.66 
mmol, 2.0 equiv) were added and stirred for 4.5 h. The reaction mix-
ture was concentrated and the residue was purified by column chro-
matography (AcOEt/pentane = 1/10, 1/5, 1/3) to give benzoyl ester 
39a (410 mg, 78%) as a colourless foam; Rf = 0.42 (AcOEt/pentane = 
1/4); [α]D25 = +4.6° (c 1.60, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.30 (d, 
J = 8.9 Hz, 2H), 8.23 (d, J = 8.9 Hz, 2H), 7.37-7.25 (m, 3H), 7.23-7.17 (m, 
2H), 6.48-6.44 (m, 1H), 5.61 (dq, J = 10.4, 1.2 Hz, 1H), 5.52 (d, J = 7.4 
Hz, 1H), 4.74-4.63 (m, 1H), 4.26 (t, J = 8.8 Hz, 1H), 4.17 (dd, J = 9.0, 4.9 
Hz, 1H), 3.32 (dd, J = 13.6, 3.4 Hz, 1H), 2.90-2.84 (m, 1H), 2.88 (dd, J = 
13.5, 9.2 Hz, 1H), 1.94 (d, J = 1.5 Hz, 3H), 1.91 (d, J = 1.2 Hz, 3H), 1.76-
1.67 (m, 1H), 1.43-1.30 (m, 1H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 171.3, 163.7, 152.8, 150.8, 143.8, 135.4, 135.2, 135.1, 
134.5, 131.0 (2C), 129.6 (2C), 129.1 (2C), 127.6, 123.8 (2C), 82.6, 80.7, 
66.6, 55.4, 42.7, 37.5, 24.2, 21.2, 14.5, 11.6; HRMS (ESI-TOF) m/z: [M 
+ Na]+ Calcd for C28H29IN2O7Na 655.0912; Found 655.0918; IR (cm-1) ν 
2964, 2930, 2875, 1784, 1724, 1681, 1607, 1526, 1348, 1267, 1212, 
1099, 1013, 872, 718, 703. 
(1E,3R,4S,5E)-4-Ethyl-7-hydroxy-1-iodo-2,6-dimethylhepta-1,5-
dien-3-yl 4-nitrobenzoate (40). and (2E,4S,5R,6E)-4-ethyl-7-iodo-2,6-
dimethylhepta-2,6-diene-1,5-diol (41). To a stirred solution of amide 
39a (white solid, 5.3 g, 8.38 mmol) in THF (110 mL) at 0 °C, NaBH4 (970 
mg, 25.1 mmol, 3.0 equiv) in water (35 mL) at 0 °C was added and 
stirred at 15 °C in the water bath. The reaction was monitored care-
fully by TLC (Et2O/pentane = 1/3) and it was quenched with sat. NH4Cl 
(100 mL) and the organic layer was separated. The aqueous layer was 
extracted with Et2O (2 x 100 mL). The combined organic layers were 
washed with brine (100 mL), dried over Na2SO4, filtered, and concen-
trated. Purification by column chromatography (Et2O/pentane = 1/6 - 
1/4 - 1/3 - 1/1.5 (product) - 1/1(diol and p-nitrobezyl alcohol) - 2/1) 
gave the desired p-nitrobenzoate 40 as a yellowish oil (3.02 g, 78%) 
and a diol 41* as a solid (0.94 g, obtained as a mixture with p-nitro-
bezyl alcohol, 22% based on the yield of product in the next 3 steps); 
Nitrobenzoate 40: [α]D25 = -8.2° (c 0.53, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 8.31 (d, J = 8.8 Hz, 2H), 8.21 (d, J = 8.9 Hz, 2H), 6.38-6.37 (m, 
1H), 5.42 (d, J = 8.5 Hz, 1H), 5.08 (dq, J = 10.4, 1.2 Hz, 1H), 4.03 (s, 2H), 
2.77 (tdd, J = 10.2, 8.6, 3.3 Hz, 1H), 1.84 (d, J = 1.2 Hz, 3H), 1.71 (d, J = 
1.4 Hz, 3H), 1.70-1.63 (m, 1H), 1.34-1.23 (m, 1H), 0.86 (t, J = 7.4 Hz, 
3H); 13C NMR (126 MHz, CDCl3) δ 163.8, 150.8, 144.6, 138.6, 135.5, 
130.9 (2C), 124.1, 123.8 (2C), 81.9, 81.7, 68.6, 41.9, 24.3, 20.7, 14.5, 
11.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C18H22INO5Na 482.0435; 
Found 482.0437; IR (cm-1) ν 3399, 2962, 2930, 1723, 1674, 1607, 1527, 
1457, 1409, 1347, 1270, 1101, 1014, 951, 874, 839, 783, 720. Diol 41: 
Rf = 0.30 (Et2O/pentane = 1/1); 1H NMR (400 MHz, CDCl3) δ 8.22 (d, J 
= 8.4 Hz)*, 7.54 (d, J = 8.4 Hz, 6H)*, 6.19 (s, 1H), 5.07 (d, J = 10.3 Hz, 
1H), 4.84 (s)*, 4.04 (d, J = 7.4 Hz, 1H), 4.01 (s, 2H), 2.48 – 2.38 (m, 1H), 
1.76 (s, 3H), 1.76 – 1.71 (m, 1H), 1.68 (s, 3H), 1.32 – 1.13 (m, 1H), 0.84 
(t, J = 7.4 Hz, 3H). *p-nitrobenzyl alcohol. 
(1E,3R,4S,5E)-7-((tert-butyldimethylsilyl)oxy)-4-ethyl-1-iodo-2,6-
dimethylhepta-1,5-dien-3-ol (41a). To a solution of diol 41 (940 mg, 
as a mixture with p-nitrobezyl alcohol, estimated ca. 1.8 mmol based 
on the previous reaction) in CH2Cl2 (35 mL) at 0 °C, imidazol (350 mg, 
5.15 mmol, 1.7 equiv) and TBSCl (690 mg, 4.6 mmol, 1.5 equiv) was 
added and stirred for 20 min at the same temperature. Full conversion 
was confirmed by TLC after 10 min. The reaction was quenched with 
sat. NH4Cl (25 mL) and organic layer was separated. The aqueous layer 
was extracted with Et2O (3 x 20 mL) and the combined organic layer 
was washed with brine (25 mL), dried over Na2SO4, filtered and con-
centrated. Purification by column chromatography (Et2O/pentane = 
1/20 (p-NO2BnOTBS) - 1/10 (product)) gave a desired secondary alco-
hol 41a (808 mg, 63% based on initial 940 mg, 22% from 39a) as a yel-
low oil; Rf = 0.30 (Et2O/pentane = 1/10); [α]D25 = +18.7° (c 1.11, CHCl3); 
IR (cm-1) ν 3380, 2956, 2930, 2858, 1254, 1076, 838, 777; 1H NMR (400 
MHz, CDCl3) δ 6.17 (p, J = 1.1 Hz, 1H), 5.06 (dq, J = 10.3, 1.5 Hz, 1H), 
4.01 (d, J = 7.5 Hz, 1H), 4.00 - 3.98 (m, 2H), 2.42 (tdd, J = 10.3, 7.4, 3.2 
Hz, 1H), 1.75 (d, J = 1.1 Hz, 3H), 1.75 - 1.64 (m, 1H), 1.59 (d, J = 1.4 Hz, 
3H), 1.25 - 1.11 (m, 1H), 0.90 (s, 9H), 0.82 (t, J = 7.4 Hz, 3H), 0.04 (s, 
6H); 13C NMR (101 MHz, CDCl3) δ 149.3, 137.0, 123.8, 79.9, 79.1, 68.2, 
43.3, 26.1, 24.0, 20.3, 18.5, 14.2, 11.7, –5.1; HRMS (ESI-Orbitrap) m/z: 
[M + Na]+ Calcd for C17H33IO2SiNa 447.1187; Found 447.1189. 
(1E,3R,4S,5E)-7-((tert-butyldimethylsilyl)oxy)-4-ethyl-1-iodo-2,6-
dimethylhepta-1,5-dien-3-yl 4-nitrobenzoate (41b). To a solution of 
alcohol 41a (808 mg, 1.9 mmol) in CH2Cl2 (20.0 mL) at 0 °C, DIPEA (1.1 
mL, 6.65 mmol, 3.5 equiv), PNBCl (1060 mg, 5.7 mmol, 3.0 equiv) and 
DMAP (115 mg, 0.95 mmol, 0.5 equiv) were added and stirred for 5 h 
at room temperature. The reaction mixture was added DIPEA (550 µL, 
3.3 mmol, 1.5 equiv) and PNBCl (530 mg, 2.8 mmol, 1.5 equiv) and 
stirred further 30 min. No starting material detected by TLC at this 
point and the reaction was quenched with sat. NH4Cl (20 mL) and the 
organic phase was separated. The resulting aqueous layer was ex-
tracted with CH2Cl2 (2 x 20 mL) and the combined organic layers were 
washed with sat. NaHCO3 (20 mL, to remove excess p-nitrobenzoic 
acid) and brine (20 mL), dried over Na2SO4, filtered, and concentrated 
to provide p-nitrobenzoate 41b, which was used in the next reaction 
without purification (1090 mg). For analytical purpose, the crude 
product could be purified by column chromatography (Et2O/pentane 
= 1/50 - 1/30 - 1/20) to give pure p-nitrobenzoate 41b; Rf = 0.4 
(Et2O/pentane = 1/20); [α]D24 = –12.6° (c 1.26, CHCl3); IR (cm-1) ν 2956, 
2930, 2957, 1728, 1530, 1268, 1113; 1H NMR (400 MHz, CDCl3) δ 8.29 
(d, J = 8.8 Hz, 2H), 8.20 (d, J = 8.8 Hz, 2H), 6.36 (s, 1H), 5.42 (d, J = 8.3 
Hz, 1H), 5.10 (dd, J = 10.4, 1.5 Hz, 1H), 4.00 (s, 2H), 2.77 (tdd, J = 10.0, 
8.3, 3.3 Hz, 1H), 1.84 (d, J = 1.2 Hz, 3H), 1.71 - 1.61 (m, 1H), 1.62 (d, J 
= 1.4 Hz, 3H), 1.33 - 1.20 (m, 1H), 0.88 (s, 9H), 0.85 (t, J = 7.4 Hz, 3H), 
 17 
0.04 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 163.7, 150.8, 144.5, 138.1, 
135.6, 130.9, 123.7, 121.9, 81.9, 81.7, 67.8, 41.8, 26.0, 24.5, 20.8, 18.5, 
14.2, 11.4, –5.1, –5.1. HRMS (ESI-Orbitrap) m/z: [M + Na]+ Calcd for 
C24H36INO5SiNa 596.1300; Found 596.1303. 
Compound 40. To the solution of TBS ether 41b (1.1 g, 1.9 mmol) in 
MeCN (30 mL, glass vial) at room temperature, HF (aq. 48%, 1.6 mL, 
39 mmol, 16 equiv) was added and stirred at the same temperature 
for 3 h. The reaction was quenched carefully with sat. NaHCO3 (cau-
tion! Gas evolution) at 0 °C and the aqueous layer was extracted with 
Et2O (3 x 50 mL). Combined organic layers were washed with brine 
(100 mL), dried over Na2SO4, filtered and concentrated. Purification by 
column chromatography (Et2O/pentane = 1/4 - 1/3) gave desired pri-
mary alcohol 40 (0.9 g, > 99% over 3 steps) as a pale, yellow oil. 
(1E,3R,4S,5E)-4-Ethyl-1-iodo-2,6-dimethyl-7-oxohepta-1,5-dien-3-
yl 4-nitrobenzoate (40a). To a stirred solution of primary alcohol 40 
(0.80 g, 1.74 mmol) in CH2Cl2 (115 mL), oven-dried activated MnO2 
(1.82 g, 20.90 mmol, 12 equiv) was added at room temperature and 
stirred for 18 h. The reaction mixture was filtered through a pad of 
Celite and washed with additional CH2Cl2 (50 mL). The filtrate was con-
centrated to give aldehyde 40a (0.79 g, 99%) as a yellow solid upon 
storage in the fridge. This material was used in the following step with-
out further purification; Rf = 0.26 (AcOEt/pentane = 1/9); m.p. = 92.5-
92.8 °C; [α]D25 = -1.7° (c 0.27, CHCl3); 1H NMR (500 MHz, CDCl3) δ 9.43 
(s, 1H), 8.32 (d, J = 8.9 Hz, 2H), 8.21 (d, J = 8.9 Hz, 2H), 6.51-6.50 (m, 
1H), 6.13 (dq, J = 10.4, 1.2 Hz, 1H), 5.58 (d, J = 8.3 Hz, 1H), 3.10 (tdd, J 
= 10.1, 8.3, 3.4 Hz, 1H), 1.84 (d, J = 1.2 Hz, 3H), 1.81 (d, J = 1.4 Hz, 3H), 
1.83-1.77 (m, 1H), 1.51-1.39 (m, 1H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR 
(126 MHz, CDCl3) δ 194.8, 163.6, 150.9 (2C), 143.7, 141.8, 135.1, 130.9 
(2C), 123.9 (2C), 83.2, 80.5, 43.2, 24.1, 20.5, 11.5, 10.1; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C18H20INO5Na 480.0278; Found 
480.0281; IR (cm-1) ν 3112, 3059, 2961, 2921, 2857, 1721, 1675, 1645, 
1607, 1525, 1457, 1409, 1349, 1266, 1203, 1103, 1036, 1016, 951, 875, 
839, 784, 721. 
(1E,3R,4S,5E,7S)-4-Ethyl-7-hydroxy-1-iodo-2,6-dimethyldeca-
1,5,9-trien-3-yl 4-nitrobenzoate (40b). To a stirred solution of alde-
hyde 40a (190 mg, 0.42 mmol) in Et2O (16 mL) at -78 °C, freshly pre-
pared (-)-Ipc2B(allyl) (0.19 M in Et2O; 3.28 mL, 0.62 mmol, 1.5 equiv) 
was added dropwise and stirring was continued for 1.5 h at -78 °C. 
The reaction was quenched with NaBO3·4H2O (1.5 g) in H2O (30 mL) 
and additional Et2O (35 mL) was added. The resulting mixture was 
warmed to room temperature and stirred further for 30 min. The 
aqueous layer was extracted with Et2O (2 x 25 mL) and the combined 
organic layers were dried over MgSO4, filtered and concentrated. Pu-
rification by column chromatography (Et2O/pentane = 1/8 to 1/5) gave 
the secondary alcohol 40b (145 mg, 70%, d.r = 20:1) as a colourless oil. 
At this point, the separation of isopinocampheol from the desired 40b 
was difficult in large scale. Therefore, the material was used in the 
next TBS protection after removal of the undesired diastereomer. The 
yield over two steps were comparable to the yield described here; Rf 
= 0.31 (Et2O/pentane = 3/7); [α]D25 = -17.4° (c 0.73, CHCl3); 1H NMR 
(500 MHz, CDCl3) δ 8.30 (d, J = 8.9 Hz, 2H), 8.21 (d, J = 8.9 Hz, 2H), 6.40-
6.38 (m, 1H), 5.72 (ddt, J = 17.4, 10.3, 7.1 Hz, 1H), 5.43 (d, J = 8.8 Hz, 
1H), 5.21-4.99 (m, 3H), 4.06 (t, J = 6.7 Hz, 1H), 2.83-2.65 (m, 1H), 2.42-
2.16 (m, 2H), 1.83 (d, J = 1.2 Hz, 3H), 1.67 (d, J = 1.4 Hz, 3H), 1.66-1.63 
(m, 1H), 1.30-1.21 (m, 1H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 163.8, 150.8, 144.5, 140.2, 135.5, 134.3, 130.9 (2C), 124.1, 
123.8 (2C), 118.4, 82.3, 81.9, 75.7, 41.8, 40.0, 24.4, 20.4, 13.2, 11.5; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C21H26INO5Na 522.0748; 
Found 522.0751; IR (cm-1) ν 3551, 2961, 2929, 2873, 1725, 1608, 1528, 
1455, 1347, 1267, 1101, 1014, 912, 873, 783, 720, 634. 
(1E,3R,4S,5E,7S)-7-((tert-Butyldimethylsilyl)oxy)-4-ethyl-1-iodo-
2,6-dimethyldeca-1,5,9-trien-3-yl 4-nitrobenzoate (42). To a solution 
of alcohol 40b (30 mg, 0.06 mmol) in CH2Cl2 (1.5 mL) at 0 °C, 2,6-
lutidine (15 µL, 0.13 mmol, 2.0 equiv) and TBSOTf (17 µL, 0.07 mmol, 
1.1 equiv) were added and the resulting mixture was stirred for 1 h at 
room temperature. The reaction was quenched with sat. NH4Cl (10 
mL) and the ensuing aqueous layer was extracted with CH2Cl2 (2 x 10 
mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated. Purification by column chromatography (Et2O/pentane 
= 1/30) gave silyl-ether 42 (34.2 mg, 93%) as a colourless oil; Rf = 0.54 
(Et2O/pentane = 1/19); [α]D25 = -2.8° (c 0.50, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 8.30 (d, J = 9.0 Hz, 2H), 8.20 (d, J = 9.0 Hz, 2H), 6.47-6.38 
(m, 1H), 5.70 (ddt, J = 17.2, 10.2, 7.1 Hz, 1H), 5.45 (d, J = 8.6 Hz, 1H), 
5.10-4.93 (m, 3H), 4.00 (t, J = 6.4 Hz, 1H), 2.82-2.65 (m, 1H), 2.33-2.17 
(m, 2H), 1.84 (d, J = 1.1 Hz, 3H), 1.70-1.62 (m, 1H), 1.63 (d, J = 1.4 Hz, 
3H), 1.30-1.21 (m, 1H), 0.88 (s, 9H), 0.84 (t, J = 7.4 Hz, 3H), 0.01 (s, 3H), 
-0.02 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.8, 150.8, 144.4, 141.0, 
135.7, 135.3, 130.9 (2C), 123.8 (2C), 123.2, 116.7, 82.8, 81.8, 77.5, 
41.7, 41.6, 26.0 (3C), 24.7, 20.4, 18.3, 12.7, 11.3, -4.3, -4.7; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C27H40INO5SiNa 636.1613; Found 
636.1608; IR (cm-1) ν 2942, 2930, 2857, 1727, 1608, 1529, 1463, 1346, 
1266, 1099, 1089, 1014, 914, 836, 778, 719, 632. 
(1E,3R,4S,5E,7S)-7-((tert-butyldimethylsilyl)oxy)-4-ethyl-1-iodo-
2,6-dimethyldeca-1,5,9-trien-3-ol (43). To a solution of benzoyl ester 
42 (155 mg, 0.25 mmol) in CH2Cl2 (5.0 mL) at –78 °C, DIBAL (1.2 M in 
PhMe, 450 µL, 0.54 mmol, 2.2 equiv) was added, and the reaction mix-
ture was stirred for 30 min at the same temperature. Then it was 
warmed to –40 °C and stirred for additional 30 min. The reaction mix-
ture was first treated with AcOEt (0.5 mL) and then with aqueous sat. 
Rochelle salt (5.0 mL) and stirred vigorously at room temperature for 
2 h. The organic layer was separated and the aqueous layer was ex-
tracted with Et2O (2 x 10 mL). The organic layers were washed with 
brine (15 mL), dried over Na2SO4, filtered, and concentrated under re-
duced pressure. Purification by silica gel column chromatography 
(Et2O/pentane = 1/25 to 1/20 to 1/15) gave alcohol 43 (119 mg, > 99%) 
as a colorless oil; Rf = 0.50 (Et2O/pentane = 1/9); [α]D25 = +20.8° (c 0.54, 
CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.24-6.19 (m, 2H), 5.72 (ddt, J = 
17.3, 10.2, 7.1 Hz, 1H), 5.02 (d, J = 17.1 Hz, 1H), 4.99 (d, J = 9.8 Hz, 1H), 
4.05-3.98 (m, 2H), 3.99 (d, J = 6.1 Hz, 1H), 2.42 (tdd, J = 10.0, 7.6, 3.2 
Hz, 1H), 2.30-2.17 (m, 2H), 1.75 (d, J = 1.2 Hz, 3H), 1.73 (s, 1H), 1.59 (d, 
J = 1.5 Hz, 3H), 1.17 (ddd, J = 13.4, 9.8, 7.4 Hz, 1H), 0.88 (s, 9H), 0.82 
(t, J = 7.5 Hz, 3H), 0.02 (s, 3H), -0.01 (s, 3H); 13C NMR (126 MHz, CDCl3) 
δ 149.4, 139.9, 135.6, 124.8, 116.6, 78.0, 79.6, 77.7, 43.2, 41.7, 26.0 
(3C), 24.3, 19.9, 18.3, 12.6, 11.5, -4.3, -4.7; HRMS (ESI-TOF) m/z: [M 
+ Na]+ Calcd for C20H37IO2SiNa 487.1500; Found 487.1499; IR (cm-1) ν 
3389, 3076, 2956, 2930, 2857, 1640, 1615, 1463, 1387, 1254, 1076, 
1005, 913, 836, 776, 673. 
(5S,8S,9R,E)-5-Allyl-8,11,11-triethyl-9-((E)-1-iodoprop-1-en-2-yl)-
2,2,3,3,6-pentamethyl-4,10-dioxa-3,11-disilatridec-6-ene (44). To a 
solution of nitrobenzoyl ester 42 (380 mg, 0.62 mmol) in MeOH (15 
mL) and THF (5 mL) at 0 °C, K2CO3 (94 mg, 0.68 mmol, 1.1 equiv) in H2O 
(1.5 mL) was added and stirring continued for 30 min at room temper-
ature. The reaction was quenched with sat. NaHCO3 (30 mL) and the 
resulting aqueous layer was extracted with Et2O (2 x 35 mL). The com-
bined organic layers were dried over Na2SO4, filtered and concen-
trated to give a residue, which was used in the following step without 
further purification. 
To a stirred solution of intermediate 43 (crude, 0.62 mmol) in CH2Cl2 
(12 mL) at 0 °C, 2,6-lutidine (0.14 mL, 1.24 mmol, 2.0 equiv) and 
TESOTf (0.17 mL, 0.74 mmol, 1.2 equiv) were added and the resulting 
mixture was stirred for 15 min at room temperature. The reaction was 
quenched with sat. NH4Cl (30 mL) and the ensuing aqueous layer was 
extracted with CH2Cl2 (2 x 30 mL). The combined organic layers were 
dried over Na2SO4, filtered and concentrated. Purification by column 
chromatography (Et2O/pentane = 1/99) gave silyl ether 44 (340 mg, 
95% over two steps) as a colourless oil; Rf = 0.67 (Et2O/pentane = 
1/99); [α]D25 = +30.6° (c 0.32, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.11-
6.05 (m, 1H), 5.72 (ddt, J = 17.2, 10.1, 7.1 Hz, 1H), 5.05-4.94 (m, 2H), 
4.93-4.85 (m, 1H), 3.95 (t, J = 6.2 Hz, 1H), 3.91 (d, J = 8.3 Hz, 1H), 2.35 
(dtd, J = 10.0, 8.4, 3.2 Hz, 1H), 2.30-2.15 (m, 2H), 1.85-1.75 (m, 1H), 
1.70 (d, J = 1.1 Hz, 3H), 1.56 (d, J = 1.4 Hz, 3H), 1.12-1.01 (m, 1H), 0.93 
(t, J = 7.9 Hz, 9H), 0.88 (s, 9H), 0.82-0.75 (t, J = 8.1 Hz, 3H), 0.56 (q, J = 
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7.9 Hz, 6H), 0.01 (s, 3H), -0.02 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
150.2, 139.3, 135.9, 125.0, 116.4, 81.0, 79.0, 77.9, 44.2, 42.1, 26.0 
(3C), 24.8, 19.5, 18.4, 12.6, 11.5, 7.0 (3C), 4.9 (3C), -4.16, -4.72; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C26H51IO2Si2Na 601.2364; Found 
601.2362; IR (cm-1) ν 2955, 2878, 1628, 1461, 1414, 1377, 1251, 1068, 
1004, 912, 835, 775, 739, 669. 
Ethyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxypent-4-
enoate (47). To a stirred solution of freshly prepared LDA (12 mmol, 
3.5 equiv) in THF (35 mL) at -78 °C, hydroxyl-ester 45 (400 mg, 3.4 
mmol) in THF (5 mL) was added dropwise and stirred for 1.5 h. Acro-
lein (0.34 mL, 5.08 mmol, 1.5 equiv) in THF (4 mL) was then added 
dropwise and stirred further for 1.5 h. The reaction was quenched 
with sat. NH4Cl (60 mL) and the resulting aqueous layer was extracted 
with Et2O (2 x 50 mL) and AcOEt (2 x 50 mL, Et2O was not enough polar 
to extract diol 46). The combined organic layers were dried over 
MgSO4, filtered and concentrated to give diol 46 (591 mg) as a yellow 
oil, which was used in the following step without further purification. 
To a stirred solution of diol 46 (3.4 mmol), Et3N (0.86 mL, 6.10 
mmol, 1.8 equiv), and Me2SnCl2 (154 mg, 0.68 mmol, 20 mol%) in 
CH2Cl2 (25 mL) at room temperature, TBSCl (920 mg, 6.10 mmol, 1.8 
equiv) was added and stirred for 6 h. The reaction was quenched with 
sat. NH4Cl (50 mL) and the resulting aqueous layer was extracted with 
CH2Cl2 (2 x 40 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated. Purification by column chromatog-
raphy (Et2O/pentane = 1/10 to 3/7) gave secondary alcohol 47 (733 
mg, 75% over two steps, d.r = 3:2) as a yellow oil; Rf = 0.14 (Et2O/pen-
tane = 1/9); 1H NMR (500 MHz, CDCl3) δ 5.89 (ddd, J = 10.5, 5.8, 2.2 Hz, 
0.4H) 5.86 (ddd, J = 10.5, 5.8, 2.2 Hz, 0.6H), 5.35 (q, J = 1.6 Hz, 0.6H), 
5.31 (q, J = 1.6 Hz, 0.4H), 5.22-5.14 (m, 1H), 4.53 (tt, J = 5.8, 1.3 Hz, 
0.6H), 4.46 (tt, J = 5.3, 1.2 Hz, 0.4H), 4.16 (q, J = 7.1 Hz, 1.2H), 4.16 (qd, 
J = 7.1, 0.7 Hz, 0.8H), 3.98 (d, J = 6.0 Hz, 1H), 3.92 (dd, J = 10.0, 6.5 Hz, 
0.4H), 3.89 (dd, J = 10.0, 6.1 Hz, 0.6H), 3.27 (br. s, 1H), 2.74 (q, J = 5.7 
Hz, 0.4 H), 2.70 (q, J = 6.0 Hz, 0.6H), 1.26 (t, J = 7.1 Hz, 3H), 0.88 (s, 
5.4H), 0.87 (s, 3.6H), 0.07 (s, 1.8H), 0.06 (s, 1.8H), 0.04 (s, 1.2H), 0.04 
(s, 1.2H); 13C NMR (126 MHz, CDCl3) δ 173.0, 172.2, 138.0, 137.9, 
116.4, 116.3, 72.9, 71.4, 62.1, 62.0, 60.9, 60.8, 52.9, 52.8, 25.9 (3C), 
18.3, 18.2, 14.4, -5.49, -5.50 (as a mixture of diastereoisomers); 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C14H28O4SiNa 311.1649; 
Found 311.1653; IR (cm-1) ν 3484, 2955, 2932, 2887, 2858, 1733, 1470, 
1379, 1256, 1185, 1108, 1031, 925, 894, 838, 778. 
(E)-Ethyl 2-((tert-butyldimethylsilyloxy)methyl)penta-2,4-dieno-
ate (48). To a stirred solution of alcohol 47 (550 mg, 1.91 mmol) in 
CH2Cl2 (30 mL) at room temperature, triethylamine (0.54 mL, 3.81 
mmol, 2.0 equiv), DMAP (23.5 mg, 0.19 mmol, 10 mol%) and Ac2O 
(0.36 mL, 3.81 mmol, 2.0 equiv) were added and stirred for 2.5 h. The 
reaction was quenched with sat. NaHCO3 (60 mL) and the ensuing 
aqueous layer was extracted with CH2Cl2 (100 mL). The organic layer 
was then washed with sat. NH4Cl (60 mL), dried over MgSO4, filtered 
and concentrated to give acetate 47a (655 mg) as a yellow oil. This 
material was used in the following step without further purification. 
To a stirred solution of acetate 47a (1.91 mmol) in CH2Cl2 (30 mL) 
at room temperature, DBU (2.28 mL, 15.30 mmol, 8 equiv) was added 
and stirred for 18 h. The reaction was quenched with sat. NH4Cl (120 
mL) and the ensuing aqueous layer was extracted with CH2Cl2 (150 
mL). The organic layer was then washed with sat. NaHCO3 (120 mL), 
dried over MgSO4, filtered and concentrated. Purification by column 
chromatography (Et2O/pentane = 1/10) gave (E,E)-dienoate 48 (401 
mg, 78% over two steps) as a yellow oil and (Z, E)-dienoate 48 (72 mg, 
14% over two steps) as a yellow oil. The product 48 should be stored 
at –20 °C in a flozen benzene. The decomspotion of the compound was 
observed within 1 month at 4 °C; (E,E)-Dienoate 48: Rf = 0.36 
(Et2O/pentane = 1/19); 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 11.4 
Hz, 1H), 6.88 (ddd, J = 16.8, 11.4, 10.0 Hz, 1H), 5.66-5.56 (m, 1H), 5.51 
(dd, J = 10.0, 1.1 Hz, 1H), 4.50 (s, 2H), 4.23 (q, J = 7.1 Hz, 2H), 1.31 (t, J 
= 7.1 Hz, 3H), 0.89 (s, 9H), 0.08 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 
167.5, 141.5, 132.3, 131.3, 125.8, 60.8, 57.7, 26.0 (3C), 18.5, 14.5, -5.1 
(2C); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C14H26O3SiNa 293.1543; 
Found 293.1547; IR (cm-1) ν 2943, 2932, 2858, 1711, 1635, 1595, 1469, 
1378, 1248, 1179, 1074, 1003, 920, 838, 778; (Z, E)-Dienoate 48: Rf = 
0.43 (Et2O/pentane = 1/19); 1H NMR (400 MHz, CDCl3) δ 7.38 (ddd, J = 
16.9, 11.3, 10.0 Hz, 1H), 6.73-6.67 (m, 1H), 5.52-5.43 (m, 1H), 5.45-
5.37 (m, 1H), 4.38 (br. d, J = 1.0 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 1.32 
(t, J = 7.1 Hz, 3H), 0.93 (s, 9H), 0.09 (s, 6H); 13C NMR (101 MHz, CDCl3) 
δ 166.3, 138.2, 133.5, 130.5, 124.2, 62.9, 60.5, 26.0 (3C), 18.5, 14.4, 
-5.2 (2C); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C14H26O3SiNa 
293.1543; Found 293.1545; IR (cm-1) ν 2943, 2931, 2894, 2858, 1718, 
1638, 1594, 1467, 1388, 1378, 1318, 1253, 1215, 1181, 1129, 1072, 
1002, 925, 838, 776, 679, 632. 
(E)-2-((tert-Butyldimethylsilyloxy)methyl)penta-2,4-dienoic acid 
(49). To a stirred solution of (E,E)-dienoate 49 (300 mg, 1.11 mmol) in 
CH2Cl2 (10 mL) at -78 °C, DIBAL (1 M in CH2Cl2; 2.77 mL, 2.77 mmol, 2.5 
equiv) was added dropwise and stirring continued for 1.5 h at -10 °C. 
The reaction was quenched with sat. NH4Cl (30 mL) and the resulting 
aqueous layer was extracted with Et2O (2 x 30 mL). HCl (1 M; 10 mL) 
was added to the aqueous layer and re-extracted with Et2O (20 mL). 
The combined organic layers were dried over MgSO4, filtered and con-
centrated to give the corresponding primary alcohol 48a. This material 
was used in the following step without further purification. 
To a stirred solution of crude primary alcohol 48a (1.11 mmol) in 
CH2Cl2 (20 mL), oven-dried activated MnO2 (1.45 g, 16.60 mmol, 15 
equiv) was added and stirred for 18 h at room temperature. The reac-
tion mixture was filtered through a pad of Celite and washed with ad-
ditional CH2Cl2 (30 mL). The filtrate was concentrated to give aldehyde 
48b (251 mg) as a yellow liquid. This material was used in the following 
step without further purification. 
To a stirred solution of crude aldehyde 48b (251 mg) in t-BuOH (25 
mL) and H2O (25 mL) at 0 °C, NaClO2 (627 mg, 5.55 mmol, 5 eq), KH2PO4 
(906 mg, 6.66 mmol, 6 eq) and 2-methyl-2-butene (2.8 mL, 33.3 mmol, 
30 eq) were added and stirring continued for 1 h at 10 °C. The reaction 
was slowly warmed to room temperature and further stirred for 3.5 h. 
H2O (35 mL) was then added and the aqueous layer was extracted with 
Et2O (3 x 40 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated. Purification by column chromatography 
(Et2O/pentane = 1/6 to 1/5) gave carboxylic acid 49 (188 mg, 70% over 
three steps) as an off-white solid. This compound should be used in 
the next reaction within few days due to the side product formation 
probably via spontaneous TBS deprotection and / or (hetero) Diels Al-
der reactions; Rf = 0.19 (Et2O/pentane = 3/7); m.p. = 56.5-57.0 °C; 1H 
NMR (400 MHz, CDCl3) δ 11.30 (br. s, 1H), 7.35 (d, J = 11.5 Hz, 1H), 6.86 
(ddd, J = 16.8, 11.5, 10.0 Hz, 1H), 5.75-5.64 (m, 1H), 5.61-5.57 (m, 1H), 
4.53 (s, 2H), 0.90 (s, 9H), 0.11 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 
171.9, 143.4, 131.8, 129.7, 127.4, 57.8, 26.0 (3C), 18.5, -5.2 (2C); 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C12H22O3SiNa 265.1230; 
Found 265.1233; IR (cm-1) ν 2939, 2928, 2895, 2856, 1672, 1431, 1344, 
1253, 1062, 998, 926, 836, 775, 677, 666. 
tert-Butyldimethyl((R)-1-((S)-oxiran-2-yl)ethoxy)silane (50).52b, 52c 
To a stirred solution of secondary alcohol 50a52a (250 mg, 2.84 mmol) 
in CH2Cl2 (10 mL) at 0 °C, imidazole (429 mg, 6.24 mmol, 2.2 equiv) and 
TBSCl (0.74 mL, 4.26 mmol, 1.5 equiv) were added and the resulting 
mixture was stirred at room temperature for 2 h. The reaction was 
quenched with sat. NH4Cl (25 mL) and the resulting aqueous layer was 
extracted with CH2Cl2 (2 x 25 mL). The combined organic layers were 
dried over Na2SO4, filtered and concentrated. Purification by column 
chromatography (Et2O/pentane = 1/99 to 1/19) gave silyl-ether 50 
(535 mg, 93%) as a colourless oil; The spectroscopic data matched 
those reported in the literature.52 Rf = 0.22 (Et2O/pentane = 1/99); 
[α]D25 = -20.7° (c 0.35, CHCl3); 1H NMR (400 MHz, CDCl3) δ 3.72 (qd, J 
= 6.3, 4.4 Hz, 1H), 2.85 (td, J = 4.1, 2.6 Hz, 1H), 2.70 (dd, J = 5.4, 3.9 Hz, 
1H), 2.65 (dd, J = 5.4, 2.6 Hz, 1H), 1.23 (d, J = 6.3 Hz, 3H), 0.87 (s, 9H), 
0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 67.8, 55.8, 44.9, 
25.9 (3C), 21.0, 18.3, -4.6, -4.7; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd 
for C10H22O2SiNa 225.1281; Found 225.1278; IR (cm-1) ν 2956, 2931, 
 19 
2888, 2858, 1472, 1373, 1252, 1167, 1107, 995, 957, 899, 832, 775, 
739, 666, 628. 
(2R,3S)-2-((tert-Butyldimethylsilyl)oxy)hept-5-yn-3-ol (50a). To a 
stirred solution of n-BuLi (1.6 M in hexane; 0.74 mL, 1.19 mmol, 3.0 
equiv) in THF (2.5 mL) at -78 °C, propyne gas was bubbled through the 
reaction mixture using a balloon for 1 h. A milky white slurry was 
formed at which point, epoxide 50 (80 mg, 0.40 mmol) in THF (0.5 mL) 
was added dropwise followed by BF3·Et2O (0.05 mL, 0.42 mmol, 1.05 
equiv). The stirring was continued at -30 °C for 30 min, and then at 0 
°C for 1.5 h. The reaction was quenched with sat. NH4Cl (15 mL) and 
the resulting aqueous layer was extracted with Et2O (2 x 20 mL). The 
combined organic layers were dried over MgSO4, filtered and concen-
trated. Purification by column chromatography (Et2O/pentane = 1/9) 
afforded alkyne 50a (85 mg, 90%) as a colourless oil; Rf = 0.55 
(Et2O/pentane = 1/4); [α]D25 = -30.1° (c 0.40, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 3.84 (qd, J = 6.2, 4.8 Hz, 1H), 3.57 (ddd, J = 6.9, 5.8, 4.8 
Hz, 1H), 2.44-2.24 (m, 2H), 2.16 (br. s, 1H), 1.79 (t, J = 2.6 Hz, 3H), 1.13 
(d, J = 6.2 Hz, 3H), 0.89 (s, 9H), 0.08 (s, 6H); 13C NMR (101 MHz, CDCl3) 
δ 78.0, 75.4, 74.2, 70.4, 25.9 (3C), 23.0, 18.2, 18.1, 3.7, -4.3, -4.8; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C13H26O2SiNa 265.1594; 
Found 265.1592; IR (cm-1) ν 3455, 2941, 2930, 2858, 1463, 1372, 1253, 
1136, 1085, 1006, 975, 908, 833, 775, 667, 629. 
(2R,3S,E)-2-(tert-Butyldimethylsilyloxy)-6-(tributylstannyl)hept-5-
en-3-ol (52) and regioisomer (53). Tricyclohexylphosphine (60 mg, 
0.21 mmol, 10 mol%) was added to Pd(OAc)2 (23 mg, 0.10 mmol, 5 
mol%) in hexane (25 mL) and stirred for 20 min at room temperature 
until the solids were dissolved. Alkyne 28 (500 mg, 2.06 mmol) in hex-
ane (7 mL) was then added slowly followed by dropwise addition of 
Bu3SnH (2.22 mL, 8.24 mmol, 4.0 equiv) over 3 min. The ensuing dark-
orange solution was stirred for additional 20 min. The reaction mix-
ture was concentrated and column chromatography (oven-dried SiO2, 
neutralized with Et3N/pentane 1/9 prior to use, Et2O/pentane = 0/1 to 
1/9) gave vinyl stannane 52 (554 mg, 51%) as a pale yellow oil. The 
regioisomer 53 was isolated (494 mg, 45%) as a pale yellow oil; Vinyl 
stannane 52: Rf = 0.30 (Et2O/pentane = 1/20); [α]D25 = -11.3° (c 0.33, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.56 (tq, J = 6.9, 1.9 Hz, 1H), 3.79 
(qd, J = 6.2, 3.9 Hz, 1H), 3.66-3.53 (m, 1H), 2.34-2.25 (m, 2H), 2.14 (d, 
J = 2.9 Hz, 1H), 1.93-1.76 (m, 3H), 1.55-1.41 (m, 6H), 1.38-1.21 (m, 6H), 
1.11 (d, J = 6.2 Hz, 3H), 0.91-0.85 (m, 15 H), 0.90 (s, 9H), 0.07 (s, 2 x 
3H); 13C NMR (101 MHz, CDCl3) δ 141.5, 136.1, 75.2, 70.9, 31.2, 29.3 
(3C), 27.5 (3C), 26.0 (3C), 19.5, 18.2, 17.3, 13.9 (3C), 9.3 (3C), -4.3, 
-4.7; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C25H54O2SiSnNa 
557.2811; Found 557.2806; IR (cm-1) ν 3581, 2956, 2927, 2856, 1462, 
1378, 1336, 1253, 1188, 1141, 1077, 1004, 975, 939, 834, 775, 667; 
Regioisomer 53: Rf = 0.50 (Et2O/pentane = 1/20); [α]D25 = -9.7° (c 0.33, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.93-5.71 (m, 1H), 3.75 (qd, J = 6.2, 
4.4 Hz, 1H), 3.46-3.36 (m, 1H), 2.47 (dd, J = 13.5, 10.7 Hz, 1H), 2.39-
2.30 (m, 1H), 1.96 (d, J = 2.6 Hz, 1H), 1.76-1.71 (m, 3H), 1.53-1.41 (m, 
6H), 1.38-1.23 (m, 6H), 1.15 (d, J = 6.2 Hz, 3H), 0.91-0.85 (m, 15 H), 
0.90 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
141.8, 137.7, 75.5, 71.6, 35.6, 29.3 (3C), 27.6 (3C), 26.0 (3C), 18.6, 
18.2, 14.9, 13.8 (3C), 10.0 (3C), -4.2, -4.7; HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C25H54O2SiSnNa 557.2811; Found 557.2803; IR (cm-1) ν 
3578, 2955, 2927, 2856, 1462, 1377, 1337, 1254, 1198, 1143, 1084, 
1004, 835, 776, 669. 
(2R,3S,Z)-2-((tert-butyldimethylsilyl)oxy)-6-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)hept-5-en-3-ol (54).17 To a 10 mL two necked 
flask, CuCl (2 mg, 0.02 mmol, 5 mol%), PPh3 (6,5 mg, 0,025 mmol, 6 
mol%) and KOt-Bu (9.3 mg, 0.083 mmol, 20 mol%) were added, sus-
pended in THF (2.0 mL) and stirred at room temperature for 0.5 h 
forming a brown to black solution. A solution of B2pin2 (115 mg, 0.453 
mmol, 1.1 equiv) in dry THF (2 mL) was added and the reaction mixture 
was stirred for additional 10 min. Next, the reaction mixture was 
cooled to 0 °C and a solution of alkyne 51 (100 mg, 0.412 mmol) in 
MeOH (33.4 µL, 0.824 mmol, 2.0 equiv) and THF (1.5 mL) was added. 
The reaction was warmed to room temperature and stirred for 16 h. 
The reaction mixture was filtered through Celite with Et2O and the fil-
trate was concentrated. Purification by column chromatography 
(Et2O/pentane = 1/8 - 1/6 - 1/4, Caution! The boronate can decom-
pose on the silica gel. Perform chromatography as quick as possible.) 
provided the desired boronic ester 54 (140 mg, 91%) as a colourless 
oil; Rf = 0.35 (Et2O/pentane = 1/4); [α]D25 = –13.2° (c 0.62, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ 6.37 (tq, J = 6.7, 1.5 Hz, 1H), 3.77 (qd, J = 6.2, 
3.8 Hz, 1H), 3.64-3.59 (m, 1H), 2.26 (ap d, J = 10.0 Hz, 1H), 2.24 (ap d, 
J = 10.0 Hz, 1H), 2.12 (d, J = 3.5 Hz, 1H), 1.69 (s, 3H), 1.24 (s, 12H), 1.09 
(d, J = 6.3 Hz, 3H), 0.87 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 142.1, 128.3, 83.3 (2C), 74.9, 71.2, 31.7, 25.9 (3C), 24.9 
(4C), 18.2, 17.5, 14.3, -4.3, -4.7; HMBC (δ H: 1.69 ppm, δ C: 128.3 ppm); 
11B NMR (128 MHz, CDCl3) δ 29.9; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd 
for C19H39BO4SiNa 393.2603; Found 393.2604; IR (cm-1) ν 3479, 2977, 
2956, 2931, 2888, 2858, 1633, 1463, 1369, 1310, 1254, 1214, 1143, 
1083, 975, 833, 775, 667. 
(2R,3S,Z)-2-((tert-butyldimethylsilyl)oxy)-6-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)hept-5-en-3-yl (E)-2-(((tert-butyldimethylsi-
lyl)oxy)methyl)penta-2,4-dienoate (55). To a stirred solution of car-
boxylic acid 49 (40 mg, 0.17 mmol, 1.2 equiv) in PhH (1.5 mL) at room 
temperature, Et3N (49 µL, 0.35 mmol, 2.0 equiv) and 2,4,6-trichloro-
benzoyl chloride (29 µL, 0.18 mmol, 1.25 equiv) were added and 
stirred for 1.5 h. To this mixture, alcohol 54 (51 mg, 0.14 mmol) and 
DMAP (17 mg, 0.14 mmol, 0.8 equiv) in PhH (1.5 mL) were added and 
stirred for 7 h at room temperature. The reaction was quenched with 
sat. NH4Cl (10 mL) and the aqueous layer was extracted with Et2O (3 x 
10 mL). The combined organic layers were washed with aqueous sat. 
NaHCO3 (15 mL) and brine (15 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification by silica gel chro-
matography (Et2O/pentane = 1/40 to 1/30 to 1/20) gave the desired 
ester 55 (50 mg, 61%) as a colorless oil; Rf = 0.40 (Et2O/pentane = 
1/12); [α]D25 = –43.5° (c 1.08, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.20 
(d, J = 11.4 Hz, 1H), 6.92 (ddd, J = 16.9, 11.5, 10.0 Hz, 1H), 6.33 (ddt, J 
= 7.1, 5.3, 1.8 Hz, 1H), 5.56 (ddd, J = 16.9, 1.8, 0.8 Hz, 1H), 5.48 (dd, J 
= 10.0, 1.8 Hz, 1H), 4.88 (dt, J = 7.9, 4.6 Hz, 1H), 4.49 (d, J = 1.5 Hz, 2H), 
3.97 (qd, J = 6.3, 4.0 Hz, 1H), 2.58-2.44 (m, 2H), 1.69 (s, 3H), 1.22 (s, 
12H), 1.15 (d, J = 6.4 Hz, 3H), 0.87 (s, 9H), 0.87 (s, 9H), 0.06 (s, 6H), 0.02 
(s, 3H), 0.01 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 166.9, 141.6, 141.4, 
132.6, 131.3, 129.3, 125.6, 83.2 (2C), 77.8, 69.4, 57.9, 28.6, 26.0 (3C), 
25.9 (3C), 24.92 (2C), 24.89 (2C), 20.1, 18.5, 18.1, 14.2, -4.30, -4.7, 
-5.1 (2C); HMBC (δ H: 1.69 ppm, δ C: 129.3 ppm); 11B NMR (128 MHz, 
CDCl3) δ 29.6; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C31H59BO6Si2Na 
617.3835; Found 617.3839; IR (cm-1) ν 2930, 2887, 2858, 1706, 1634, 
1370, 1305, 1370, 1145, 1072, 834, 775, 668. 
(5R,6S,8E,10E,12R,13S,14E,16S)-16-Allyl-13-ethyl-
2,2,3,3,5,9,11,15,18,18,19,19-dodecamethyl-12-((triethylsilyl)oxy)-
4,17-dioxa-3,18-disilaicosa-8,10,14-trien-6-ol (56). A degassed solu-
tion of vinyl stannane 52 (266 mg, 0.50 mmol, 1.7 equiv) and vinyl io-
dide 44 (165 mg, 0.29 mmol) in DMF (10 mL) was added to a flask con-
taining [Ph2PO2]-[NBu4]+ (pre-dried with heat gun, 520 mg, 1.13 mmol, 
3.9 equiv) at room temperature. After stirring for 5 min, CuTC (163 
mg, 0.86 mmol, 3.0 equiv) was introduced followed by Pd(PPh3)4 (231 
mg, 0.20 mmol, 70 mol%). The resulting brown-black mixture was 
stirred for 1 h at room temperature. The reaction was quenched with 
H2O (60 mL) and the resulting aqueous layer was extracted with Et2O 
(2 x 35 mL). The combined organic layers were dried over Na2SO4, fil-
tered and concentrated. Purification by column chromatography 
(Et2O/pentane = 1/99 - 1/50 - 1/15 - 1/8) afforded diene 56 (152 mg, 
77%) as a pale yellow oil; Rf = 0.35 (Et2O/pentane = 1/24); [α]D25 = 
+11.7° (c 0.27, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.78-5.67 (m, 1H), 
5.72 (s, 1H), 5.31-5.27 (m, 1H), 5.00-4.93 (m, 3H), 3.95 (t, J = 6.3 Hz, 
1H), 3.85-3.75 (m, 1H), 3.75 (d, J = 8.1 Hz, 1H), 3.62-3.52 (m, 1H), 2.45-
2.31 (m, 1H), 2.30-2.14 (m, 4H), 2.13 (br. s, 1H), 1.87-1.74 (m, 1H), 1.73 
(s, 3H), 1.67 (d, J = 1.2 Hz, 3H), 1.56 (d, J = 1.4 Hz, 3H), 1.13-1.09 (m, 
1H), 1.11 (d, J = 6.3 Hz, 3H), 0.94 (t, J = 7.9 Hz, 9H), 0.89 (s, 9H), 0.86 
(s, 9H), 0.79 (t, J = 7.4 Hz, 3H), 0.58 (q, J = 8.0 Hz, 6H), 0.07 (s, 3H), 0.06 
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(s, 3H), -0.01 (s, 3H), -0.06 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 138.1, 
137.1, 136.1, 134.8, 130.6, 126.0, 125.5, 116.2, 82.9, 78.0, 75.3, 71.0, 
44.1, 42.2, 31.3, 26.0 (6C), 24.8, 18.3, 18.2, 17.4, 17.3, 13.6, 12.6, 11.6, 
7.1 (3C), 5.1 (3C), -4.3, -4.5, -4.7, -4.9; HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C39H78O4Si3Na 717.5100; Found 717.5098; IR (cm-1) ν 
3583, 2955, 2944, 2878, 1642, 1462, 1384, 1253, 1072, 1006, 911, 835, 




thylsilyl)oxy)methyl)penta-2,4-dienoate (57). To a stirred solution of 
carboxylic acid 49 (101 mg, 0.42 mmol, 1.9 equiv) in PhMe (4 mL) at 
room temperature, Et3N (0.15 mL, 1.04 mmol, 2.5 equiv) and 2,4,6-
trichlorobenzoyl chloride (64 µL, 0.409 mmol, 1.95 equiv) were added 
and stirred for 1 h, forming white suspension. To a solution of alcohol 
56 (145 mg, 0.21 mmol) and DMAP (76 mg, 0.63 mmol, 1.5 equiv) in 
PhMe (2.5 mL), suspension was added dropwise and the mixture was 
stirred for 1.5 h at room temperature. The reaction was quenched 
with sat. NH4Cl (25 mL) and the resulting aqueous layer was extracted 
with Et2O (2 x 25 mL). The combined organic layers were washed with 
sat. NaHCO3 (40 mL), dried over Na2SO4, filtered and concentrated. 
Purification by column chromatography (Et2O/pentane = 1/99) af-
forded polyene 57 (165 mg, 86%) as a colourless oil; Rf = 0.13 
(Et2O/pentane = 1/99); [α]D25 = -21.0° (c 0.56, CHCl3); 1H NMR (500 
MHz, CDCl3) δ 7.20 (d, J = 11.4 Hz, 1H), 6.92 (ddd, J = 16.9, 11.4, 10.0 
Hz, 1H), 5.77-5.67 (m, 1H), 5.66 (s, 1H), 5.55 (dd, J = 16.9 Hz, 1.1, 1H), 
5.49 (dd, J = 10.1, 1.5 Hz, 1H), 5.23 (t, J = 7.2 Hz, 1H), 5.02-4.90 (m, 3H), 
4.91-4.84 (m, 1H), 4.51 (d, J = 12.2 Hz, 1H), 4.47 (d, J = 12.2 Hz, 1H), 
4.02-3.88 (m, 2H), 3.72 (d, J = 7.9 Hz, 1H), 2.44 (t, J = 7.0 Hz, 2H), 2.40-
2.30 (m, 1H), 2.26-2.13 (m, 2H), 1.83-1.73 (m, 1H), 1.70 (s, 3H), 1.60 
(d, J = 1.3 Hz, 3H), 1.54 (d, J = 1.3 Hz, 3H), 1.16 (d, J = 6.3 Hz, 3H), 1.12-
1.02 (m, 1H), 0.91 (t, J = 7.9 Hz, 9H), 0.88 (s, 9H), 0.88 (s, 9H), 0.86 (s, 
9H), 0.78 (t, J = 7.4 Hz, 3H), 0.55 (q, J = 7.7 Hz, 6H), 0.07 (s, 2 x 3H), 0.03 
(s, 2 x 3H), -0.02 (s, 3H), -0.07 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
166.8, 141.5, 138.1, 137.0, 136.1, 134.6, 132.5, 131.3, 130.4, 126.1, 
125.5, 124.9, 116.2, 82.7, 78.0, 77.9, 69.4, 57.9, 44.0, 42.2, 28.4, 26.0 
(3C), 25.98 (3C), 25.9 (3C), 24.7, 19.9, 18.5, 18.3, 18.2, 17.4, 13.5, 12.6, 
11.6, 7.1 (3C), 5.1 (3C), -4.3, -4.5, -4.7, -4.9, -5.11, -5.14; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C51H98O6Si4Na 941.6333; Found 
941.6332; IR (cm-1) ν 2955, 2944, 2881, 2870, 1709, 1463, 1378, 1252, 




lyl)oxy)oxacyclooctadeca-3,5,9,13,15-pentaen-2-one (58). To a 
stirred degassed solution of olefin 57 (90 mg, 0.10 mmol) in PhMe (22 
mL), second generation Grubbs catalyst (12.7 mg, 15 mol%) was added 
and the resulting mixture was stirred at 40 °C (µw) for 10 min (full con-
version, E/Z = 2/3). The reaction was then heated at 100 °C for 18 h 
(E/Z = 2/1). The solvent was removed by evaporation under reduced 
pressure and the residue was purified by column chromatography 
(Et2O/pentane = 1/99) to give macrocycle (E)-58 (52 mg, 60%) and (Z)-
58 (26.4 mg, 30%). Z-isomer was resubmitted to aforementioned 
isomerization conditions to give both macrocycles in E/Z = 2/1; Rf = 
0.67 (Et2O/pentane = 1/49); [α]D25 = +27.2° (c 0.35, CHCl3); 1H NMR 
(500 MHz, CDCl3) δ 7.01 (d, J = 11.5 Hz, 1H), 6.58-6.41 (m, 1H), 5.79-
5.70 (m, 1H), 5.70 (s, 1H), 5.38 (t, J = 8.2 Hz, 1H), 5.13 (dt, J = 10.5, 1.6 
Hz, 1H), 4.73-4.62 (m, 1H), 4.46 (d, J = 12.1 Hz, 1H), 4.37 (d, J = 12.0 
Hz, 1H), 4.17 (br. s, 1H), 4.11-4.01 (m, 1H), 3.76 (d, J = 9.4 Hz, 1H), 2.75-
2.66 (m, 1H), 2.60-2.45 (m, 2H), 2.35 (ddd, J = 13.9, 9.0, 4.4 Hz, 1H), 
2.27 (ddd, J = 14.6, 9.8, 4.2 Hz, 1H), 1.95-1.84 (m, 1H), 1.73 (d, J = 1.4 
Hz, 3H), 1.67 (s, 3H), 1.56 (s, 3H), 1.24-1.16 (m, 1H), 1.14 (d, J = 6.1 Hz, 
3H), 0.94 (t, J = 7.9 Hz, 9H), 0.88 (s, 9H), 0.87 (s, 9H), 0.87 (s, 9H), 0.81 
(t, J = 7.4 Hz, 3H), 0.59 (q, J = 7.9 Hz, 6H), 0.07 (s, 3H), 0.06 (s, 3H), 0.05 
(s, 3H), 0.02 (s, 3H), 0.00 (s, 3H), -0.01 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 167.7, 143.0, 140.9, 136.5, 135.9, 134.5, 132.4, 127.8, 127.5, 
124.9, 124.7, 83.8, 77.0, 73.2, 68.1, 57.7, 43.6, 37.3, 27.2, 26.1 (3C), 
25.94 (3C), 25.92 (3C), 25.8, 21.0, 18.5, 18.3, 18.1, 17.2, 15.0, 12.7, 
10.9, 7.2 (3C), 5.2 (3C), -4.1, -4.7, -4.91, -4.95, -5.1, -5.2; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C49H94O6Si4Na 913.6020; Found 
913.6015; IR (cm-1) ν 2955, 2943, 2858, 1706, 1645, 1463, 1377, 1252, 
1071, 1006, 900, 837, 777, 680, 632. 
Isomerization of (Z)-58 to (E)-58. To a solution of (Z)-58 (30 mg, 34 
µmol) in degassed PhMe (7.5 mL, microwave sealed tube), second 
generation Grubbs catalyst (4.33 mg, 15 mol%) was added and the re-
sulting mixture was stirred at 100 °C for 16 h. The solvent was evapo-
rated and 1H NMR showed the formation of desired E isomer (E:Z = ca. 
2:1). The residue was purified by column chromatography (Et2O/pen-
tane = 1/100) to give the desired (E)-58 (13 mg, 43%, very pure ample) 
and (5.5 mg, 18%, acceptable purity for next reaction), and (Z)-58 (7 





3,5,9,13,15-pentaen-2-one (10). To a stirred solution of protected 
macrocycle (E)-58 (25 mg, 0.03 mmol) in THF/MeCN (1:1, 5 mL) at 0 
°C, 3HF·NEt3 (0.15 mL, 0.84 mmol, excess) was added dropwise and 
stirring was continued for 8 h at room temperature. The reaction was 
quenched with sat. NaHCO3 (15 mL) and the resulting aqueous layer 
was extracted with Et2O (2 x 15 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated. Purification by column 
chromatography (Et2O/pentane = 1/5 to 1/3) afforded diol 10 (12 mg, 
65%) as a colourless oil, and primary alcohol 59 (7 mg, 32%) as a col-
ourless oil; Diol 10: Rf = 0.50 (Et2O/pentane = 2/3); [α]D25 = +17.2° (c 
0.48, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.97 (d, J = 11.6 Hz, 1H), 6.34 
(ddd, J = 14.8, 11.6, 1.5 Hz, 1H), 5.87 (s, 1H), 5.79 (ddd, J = 14.7, 10.1, 
4.5 Hz, 1H), 5.48-5.37 (m, 1H), 5.13 (dt, J = 10.6, 1.6 Hz, 1H), 4.63 (ddd, 
J = 7.5, 5.2, 4.3 Hz, 1H), 4.39 (d, J = 12.7 Hz, 1H), 4.32 (d, J = 12.6 Hz, 
1H), 4.22-4.13 (m, 2H), 3.82 (d, J = 9.6 Hz, 1H), 2.83 (dt, J = 14.3, 8.2 
Hz, 1H), 2.66-2.44 (m, 3H, include 1 x OH), 2.38-2.15 (m, 2H), 1.99-1.90 
(m, 1H), 1.80 (d, J = 1.3 Hz, 3H), 1.79 (s, 3H), 1.61 (s, 3H), 1.23-1.19 (m, 
1H), 1.15 (d, J = 6.3 Hz, 3H), 0.88 (s, 9H), 0.86 (s, 9H), 0.84 (t, J = 7.2 Hz, 
3H), 0.04 (s, 3H), 0.03 (s, 3H), 0.01 (s, 3H), -0.01 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 168.7, 142.3, 141.6, 136.5, 136.1, 134.9, 133.1, 127.4, 
127.1, 126.6, 124.8, 83.2, 77.6, 73.2, 68.1, 57.6, 42.7, 37.6, 26.4, 25.9 
(3C), 25.88 (3C) 25.8, 20.7, 18.4, 18.1, 17.1, 15.1, 12.7, 11.0, -4.3, -4.6, 
-4.91, -4.93; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C37H66O6Si2Na 
685.4290; Found 685.4292; IR (cm-1) ν 3424, 2954, 2930, 2857, 1688, 
1643, 1462, 1443, 1377, 1297, 1254, 1205, 1146, 1107, 1070, 1007, 
973, 938, 900, 837, 775, 676; Secondary alcohol 59: Rf = 0.46 
(Et2O/pentane = 1/4); [α]D25 = -5.3° (c 0.38, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 6.95 (d, J = 11.4 Hz, 1H), 6.69-6.37 (m, 1H), 5.86 (s, 1H), 5.71 
(ddd, J = 14.8, 10.0, 4.6 Hz, 1H), 5.42 (t, J = 8.2 Hz, 1H), 5.12 (dt, J = 
10.3, 1.4 Hz, 1H), 4.64 (ddd, J = 7.4, 5.2, 4.1 Hz, 1H), 4.45 (d, J = 11.9 
Hz, 1H), 4.35 (d, J = 12.0 Hz, 1H), 4.17 (br. s, 1H), 4.15-4.09 (m, 1H), 
3.81 (d, J = 9.7 Hz, 1H), 2.79 (dt, J = 15.8, 8.1 Hz, 1H), 2.59-2.47 (m, 2H), 
2.33-2.22 (m, 2H), 1.98-1.90 (m, 1H), 1.80 (d, J = 1.3 Hz, 3H), 1.78 (s, 
3H), 1.60 (s, 3H), 1.23-1.18 (m, 1H), 1.15 (d, J = 6.2 Hz, 3H), 0.88 (s, 
18H), 0.86 (s, 9H), 0.84 (t, J = 7.1 Hz, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.04 
(s, 3H), 0.03 (s, 3H), 0.02 (s, 3H), -0.01 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 168.0, 142.4, 140.1, 136.5, 135.9, 135.0, 133.2, 128.3, 127.9, 
126.8, 124.8, 83.3, 77.0, 73.2, 68.4, 57.7, 42.8, 37.6, 26.7, 26.1 (3C), 
26.0 (3C), 25.9 (3C), 25.8, 20.8, 18.5, 18.4, 18.1, 17.1, 15.1, 12.7, 11.0, 
-4.2, -4.5, -4.9, -5.0, -5.1, -5.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd 
for C43H80O6Si3Na 799.5155; Found 799.5144; IR (cm-1) ν 3500, 2954, 
2930, 2857, 1703, 1644, 1463, 1376, 1252, 1203, 1146, 1103, 1072, 







zoate (61). A mixture of primary alcohol 10 (3.2 mg, 4.83 µmol) and 
acetimidate 27 (3.2 mg, 4.83 µmol, 1.0 equiv) in PhMe (1 mL) was co-
evaporated and dried. Next, the residue obtained was dissolved in 
CH2Cl2 (0.4 mL) and MS 4Å was added. The white suspension was 
stirred for 0.5 h at room temperature before it was cooled to –78 °C. 
To this mixture was added TBSOTf (a 50 µL CH2Cl2 stock solution, 0.48 
µmol, 10 mol%) dropwise and the reaction mixture was stirred at –78 
°C for 2 h before it was warmed to –50 °C and stirred for 1h. No con-
version was observed. Additional amount of TBSOTf (a 50 µL CH2Cl2 
stock solution, 0.48 µmol, 10 mol%) was added dropwise and the re-
action mixture was slowly warmed to –20 °C. The reaction was 
quenched with diluted Et3N in CH2Cl2 (2 mL), filtered and evaporated. 
1H NMR showed anomeric ratio to be β:α = 3/1. Purification by column 
chromatography (PhMe/AcOEt = 12/1) provided desired glycoside as 
a mixture with impurities. The obtained residue was further purified 
by preparative thin layer chromatography (PhMe/AcOEt = 8/1) to pro-
vide desired rather pure β-rhamnoside 61 (0.9 mg, 16%). 
Although the relatively good site selectivity observed, the separa-
tion between diol 10 and desired β-61 was difficult on the silica gel 
column chromatography. As we obtained bis-glycosylated side prod-
uct (confirmed by HRMS and NMRs, not shown) with the extra equiv-
alence of glycosyl donor 27, exactly 1.0 eq of 27 had to be used. Alt-
hough the desired β-61 could also be synthesized under the similar 
condition using glycosyl sulfoxide prepared from 26, however, the re-
producibility and product yield  was similarly low and the product was 
always contaminated with unknown aromatic side products: Condi-
tions: glycosyl sulfoxide (4.0 equiv), Tf2O (2.5 equiv), 2,6-di-tert-butyl-
4-methylpyridine (5.0 equiv), Et2O, MS 4Å, –90 to –80 °C, 2 h; primary 
alcohol 10, –90 to –80 °C, 2.5 h, β:α = 2/1, β-61: 10-20%; Rf = β-61: 
0.55, α-61: 0.4 (AcOEt/cyclohexane = 1:4); 1H NMR (500 MHz, ace-
tone-d6) δ 7.17 (d, J = 11.5 Hz, 1H), 6.58 (dd, J = 14.4, 12.2 Hz, 1H), 6.17 
(ddt, J = 17.7, 11.8, 6.4 Hz, 1H), 6.08 (ddd, J = 16.3, 11.2, 5.3 Hz, 1H), 
5.92 (ddd, J = 15.0, 10.2, 4.4 Hz, 1H), 5.46 (dd, J = 17.2, 1.4 Hz, 1H), 
5.46 (s, 1H), 5.41 (dd, J = 17.2, 1.4 Hz, 1H), 5.28 (d, J = 10.4 Hz, 1H), 
5.25 (d, J = 10.4 Hz, 1H), 5.20 (d, J = 10.6 Hz, 1H), 5.03 (t, J = 9.7 Hz, 
1H), 4.62 (m, 6H), 4.57 (d, J = 11.1 Hz, 1H), 4.52 (dd, J = 11.8, 5.8 Hz, 
1H), 4.35 (d, J = 11.1 Hz, 1H), 4.34 (s, 1H), 4.29 – 4.20 (m, 1H), 3.91 (d, 
J = 10.0 Hz, 1H), 3.74 (s, 1H), 3.73 – 3.66 (m, 2H), 3.55 (d, J = 3.4 Hz, 
1fH), 3.52 (s, 3H), 3.51 – 3.45 (m, 1H), 2.70 (d, J = 14.7 Hz, 1H), 2.52 (d, 
J = 8.7 Hz, 1H), 2.38 (ddd, J = 14.7, 10.4, 4.4 Hz, 1H), 2.30 (dd, J = 14.0, 
7.7 Hz, 1H), 1.84 (s, 3H), 1.83 (s, 3H), 1.68 (s, 3H), 1.34 (d, J = 6.2 Hz, 
3H), 1.17 (s, 3H), 1.16 – 1.15 (m, 7H), 0.91 (d, J = 2.7 Hz, 9H), 0.88 (s, 
9H), 0.86 – 0.82 (m, 3H), 0.08 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H), 0.03 (s, 
3H); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C59H92Cl2O13Si2Na 





ate (62). To a solution of pyranose 34 (40 mg, 0.14 mmol, 1.6 equiv) 
in CH2Cl2 (1.0 mL) under dark was added 33% HBr in AcOH (1.0 mL) at 
0 °C and the resulting colorless, slightly orange solution was stirred at 
room temperature under dark for 2 h before it was cooled to 0 °C, 
diluted with CH2Cl2 (3 mL) and quenched with ice water (5 mL). Layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 
mL) and combined organic layers were washed with sat. NaHCO3 (10 
mL). The separated organic layer was dried over Na2SO4, filtered and 
concentrated in cold water bath to provide desired glycosyl bromide 
35 as a brown oil. Additional amount of pyranose 34 (30 mg, 0.11 
mmol, 1.2 equiv) was subjected to the same condition to prepare ad-
ditional amount of glycosyl bromide 35 and combined, and used in the 
next glycosylation (total 2.8 eq glycosyl bromide was used as a starting 
material. The glycosyl bromide 35 was isolated as a mixture with gly-
cosyl acetate). 
A solution of alcohol 43 (41 mg, 86.7 µmol) in PhH (1.5 mL) was 
concentrated and dried before use. Next, this was dissolved in CH2Cl2 
(1.0 mL) and MS 3A (powder, 100 mg) was added and stirred for 90 
minutes, before HgO (124 mg, 0.56 mmol, 6.5 equiv) and HgBr2 (4.5 
mg, 13 µmol, 0.15 equiv) were added and the orange suspension was 
stirred for 30 minutes. Then the glycosyl bromide in CH2Cl2 (0.5 mL) 
was added dropwise for 20 min and stirred for 50 min. Then it was 
diluted with CHCl3 (5 mL) and quenched with NaHCO3 (3 mL). Organic 
layer was separated and filtered over silica gel pad. The filtrate was 
washed with NaHCO3 (15 mL), organic layer dried over Na2SO4, filtered 
and concentrated under reduced pressure. 1H NMR showed anomeric 
ratio to be β:α = 3:1. Purification by column chromatography (Ac-
OEt/cyclohexane = 1/15 - 1/10 - 1/8) gave alcohol starting material 43, 
α-62 and pure β-62 (33.6 mg, 54%); β-62: Rf = 0.38 (AcOEt/cyclohex-
ane = 1/4); [α]D25 = –23.1° (c 0.22, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
6.22 (d, J = 0.9 Hz, 1H), 5.79 (ap dd, 1H) 5.75-5.62 (m, 1H), 5.03-4.97 
(m, 3H), 4.86 (d, J = 10.5 Hz, 1H), 4.79-4.76 (m, 2H), 3.94 (dd, J = 6.1, 
6.1 Hz, 1H), 3.82 (d, J = 9.3 Hz, 1H), 2.62 (hept, J = 7.0 Hz, 1H), 2.58-
2.48 (m, 1H), 2.27-2.14 (m, 2H), 1.92-1.78 (m, 1H), 1.78 (d, J = 0.9, 3H), 
1.57 (d, J = 1.2, 3H), 1.21 (d, J = 6.9, 6H), 1.16 (s, 3H), 1.14 (s, 3H), 0.87 
(s, 9H) 0.81 (t, J = 7.4, 3H), 0.01 (s, 3H), -0.03 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 175.2, 153.8, 147.6, 140.0, 135.6, 123.6, 116.5, 95.3, 
89.8, 81.6, 75.7, 75.1, 72.1, 71.8, 42.6, 42.0, 34.1, 28.0, 26.0 (3C), 25.6, 
28.8, 24.3, 19.8, 19.1, 18.8, 18.3, 12.8, 11.2, -4.2, -4.7; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C32H53IO8SiNa 743.2447; Found 
743.2445; IR (cm-1) ν 2954, 2929, 2856, 1818, 1749, 1468, 1389, 1253, 
1145, 1091, 1074, 1034, 915, 837, 775; α-62: Rf = 0.56 (AcOEt/cyclo-
hexane = 1/4); [α]D25 = +31.6° (c 0.8, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 6.23 (d, J = 1.0 Hz, 1H), 5.70 (dddd, J = 17.2, 10.2, 7.1, 7.1 Hz, 1H), 
5.13 (d, J = 8.3 Hz, 1H), 5.04-4.98 (m, 2H), 4.90 (ap d, J = 10.5 Hz, 1H), 
4.78 (dd, J = 8.3, 8.3 Hz, 1H), 4.78 (d, J = 5.2 Hz, 1H), 4.66 (dd, J = 8.4, 
5.2 Hz, 1H), 4.06 (d, J = 9.2 Hz, 1H), 3.95 (dd, J = 6.1, 6.1 Hz, 1H), 2.63 
(hept, J = 7.0 Hz, 1H), 2.53-2.45 (m, 1H), 2.27-2.15 (m, 2H), 1.85-1.76 
(m, 1H), 1.67 (d, J = 1.1 Hz, 3H), 1.57 (d, J = 1.3 Hz, 3H), 1.25 (s, 3H), 
1.24 (s, 3H), 1.21 (d, J = 1.3 Hz, 3H), 1.20 (d, J = 1.3 Hz, 3H), 1.18-1.10 
(m, 1H), 0.88 (s, 9H), 0.80 (t, J = 7.4 Hz, 3H), 0.01 (s, 3H), -0.02 (s, 3H); 
13C NMR (101 MHz, CDCl3) δ 175.5, 153.2, 145.4, 139.8, 135.5, 123.7, 
116.4, 91.8, 83.9, 82.3, 77.5, 76.6, 75.6, 74.8, 72.0, 41.9, 41.5, 33.9, 
25.9 (3C), 25.8, 25.0, 23.8, 18.9, 18.7, 18.7, 18.2, 12.5, 10.9, -4.28, 
-4.85; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C32H53IO8SiNa 
743.2447; Found 743.2451; IR (cm-1) ν 2954, 2931, 2858, 1831, 1748, 





(((tert-butyldimethylsilyl)oxy)methyl)penta-2,4-dienoate (63). To a 
solution of iodide 62 (16.5 mg, 23 µmol) and boronate 55 (22.5 mg, 34 
µmol, 1.7 equiv) in degassed THF (600 µL) and degassed H2O (150 µL) 
at 0 °C, Pd(PPh3)4 (5.4 mg, 20 mol%) was added and stirred for 5 min. 
Then the stock solution of TlOEt* (45 µL, ca. 4.5 mg, 18 µmol, 1.6 
equiv) was added dropwise for 2 min at room temperature. After stir-
ring for 30 min at the same temperature, the reaction mixture was 
diluted with Et2O (5 mL) and quenched with brine (5 mL) and aqueous 
sat. NH4Cl (5 mL). The aqueous layer was extracted with Et2O (3 x 10 
mL). The combined organic layers were washed with brine (20 mL), 
dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification by column chromatography (Et2O/pentane = 1/6 to 1/4) 
gave polyene 63 (20 mg, 82%) as a colorless oil. *A water stock solu-
tion of TlOEt was prepared as follows: To a vial under Ar, TlOEt (12.0 
mg) and degassed H2O (120 µL) were added and stirred until all the 
residue completely dissolved. Later it was found that the dropwise ad-
dition of TlOEt into the reaction mixture over 10-15 min at room tem-
perature gives the better yield using different substrate; Rf = 0.43 (Ac-
OEt/cyclohexane = 1/4); [α]D25 = –48.5° (c 0.57, CHCl3); 1H NMR (500 
MHz, CDCl3) δ 7.20 (d, J = 11.4 Hz, 1H), 6.92 (ddd, J = 16.9, 11.4, 9.9 Hz, 
 22 
1H), 5.85-5.79 (m, 1H), 5.74 (s, 1H), 5.69 (ddt, J = 17.2, 10.1, 7.2 Hz, 
1H), 5.56 (dd, J = 16.8, 1.0 Hz, 1H), 5.50 (dd, J = 10.1, 1.7 Hz, 1H), 5.32 
(t, J = 7.3 Hz, 1H), 5.03 (d, J = 1.7 Hz, 1H), 4.97 (dd, J = 17.2, 2.2 Hz, 1H), 
4.93-4.92 (m, 1H), 4.92 (dd, J = 19.2, 2.2 Hz, 1H), 4.89-4.81 (m, 1H), 
4.76 (d, J = 1.2 Hz, 1H), 4.75 (d, J = 1.9 Hz, 1H), 4.51 (d, J = 12.2 Hz, 1H), 
4.47 (d, J = 12.2 Hz, 1H), 3.98-3.90 (m, 2H), 3.66 (d, J = 8.9 Hz, 1H), 
2.65-2.56 (m, 1H), 2.56-2.37 (m, 3H), 2.18 (t, J = 6.9 Hz, 2H), 1.86-1.77 
(m, 1H), 1.74 (d, J = 1.3 Hz, 3H), 1.71 (d, J = 1.2 Hz, 3H), 1.62-1.56 (m, 
1H), 1.56 (d, J = 1.3 Hz, 3H), 1.21 (s, 3H), 1.20 (s, 3H), 1.16 (s, 3H), 1.15 
(d, J = 5.0 Hz, 3H), 1.12 (s, 3H), 0.88 (s, 9H), 0.88 (s, 9H), 0.85 (s, 9H), 
0.80 (t, J = 7.4 Hz, 3H), 0.07 (s, 3H), 0.07 (s, 3H), 0.03 (s, 3H), 0.02 (s, 
3H), -0.03 (s, 3H), -0.09 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 175.2, 
166.8, 153.9, 141.5, 138.8, 135.8, 134.3, 133.8, 133.6, 132.5, 131.3, 
126.5, 125.7, 124.8, 116.3, 94.1, 92.1, 78.1, 77.7, 75.8, 74.9, 72.3, 72.0, 
69.5, 57.9, 42.3, 42.0, 34.1, 28.4, 28.2, 26.1 (3C), 26.0 (3C), 25.9 (3C), 
24.7, 24.3, 20.0, 19.1, 18.8, 18.5, 18.3, 18.1, 17.2, 13.8, 12.7, 11.3, 
-4.3, -4.5, -4.7, -4.9, -5.10, -5.12; HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C57H100O12Si3Na 1083.6415; Found 1083.6417; IR (cm-1) ν 







(64). To an alkene 63 (11.7 mg, 11 µmol) in PhMe (2.0 mL), second 
generation Grubbs catalyst (1.05 mg, 2.2 µmol, 20 mol%) was added 
and the resulting mixture was stirred at 100 °C in a preheated oil bath 
for 3 h. The reaction mixture was filtered through Celite or a pad of 
silica gel and resulting filtrate was concentrated. Crude 1H NMR 
showed E/Z = ca. 2/1. Purification by short silica gel column chroma-
tography (Et2O/pentane = 1/4) followed by preparative TLC (Et2O/pen-
tane = 1/4, ca. 5 mg sample was loaded on 0.5 mm, 20 cm x 20 cm 
preparative TLC plate from Merck and 4 times elevation was needed 
for a good separation) gave desired (E)-macrocycle 64 (7.8 mg, 68%) 
and (Z)-macrocycle 64 as a mixture; (E)-64: Rf = 0.20 (Et2O/pentane = 
1/4); [α]D25 = –42.5° (c 0.41, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.97 
(d, J = 11.5 Hz, 1H), 6.48 (ddd, J = 14.8, 11.4, 1.4 Hz, 1H), 5.85-5.80 (m, 
2H), 5.71 (ddd, J = 14.8, 10.0, 4.5 Hz, 1H), 5.44 (t, J = 8.3 Hz, 1H), 5.11 
– 5.03 (m, 2H), 4.80-4.74 (m, 2H), 4.68-4.62 (m, 1H), 4.45 (d, J = 12.0 
Hz, 1H), 4.35 (d, J = 12.0 Hz, 1H), 4.16 (br, 1H), 4.10 (p, J = 6.1 Hz, 1H), 
3.67 (d, J = 9.8 Hz, 1H), 2.82-2.72 (m, 1H), 2.69-2.62 (m, 1H), 2.66-2.58 
(m, 1H), 2.55 (dt, J = 15.0, 2.4 Hz, 1H), 2.32-2.22 (m, 2H), 1.89 (dt, J = 
7.4, 4.5 Hz, 1H), 1.83 (s, 3H), 1.76 (s, 3H), 1.60 (m, 1H), 1.59 (s, 3H), 
1.22-1.20 (m, 9H), 1.14 (d, J = 6.2 Hz, 3H), 1.13 (s, 3H), 0.88 (s, 18H), 
0.85 (s, 9H), 0.82 (t, J = 7.4 Hz, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.04 (s, 
3H), 0.02 (s, 3H), 0.02 (s, 3H), -0.02 (s, 3H); 13C NMR (126 MHz, CDCl3) 
δ 175.3, 167.9, 154.0, 142.6, 140.4, 135.8, 135.4, 133.1, 128.2, 127.8, 
126.9, 125.7, 124.0, 93.6, 93.1, 77.1, 75.7, 75.0, 73.2, 72.4, 72.1, 68.4, 
57.6, 42.0, 37.5, 34.1, 28.4, 26.9, 26.1 (3C), 26.0 (3C), 25.9 (3C), 25.4, 
24.2, 20.8, 19.1, 18.8, 18.5, 18.3, 18.1, 17.0, 15.1, 13.4, 10.9, -4.1, 
-4.5, -4.9, -5.0, -5.1, -5.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C55H96O12Si3Na 1055.6102; Found 1055.6104; IR (cm-1) ν 2930, 2857, 
1820, 1751, 1703, 1645, 1465, 1252, 1145, 1072, 1004, 838, 776. 
Isomerization of (Z)-64 to (E)-64. To a degassed solution of (Z)-64 
(7.9 mg, 7.5 µmol) in PhMe (1.5 mL), second generation Grubbs cata-
lyst (1.3 mg, 1.5 µmol, 20 mol%) was added using Schlenk technique 
and the resulting mixture was heated to 100 °C in a pre-heated oil bath 
for 11 h. After cooling to room temperature, the reaction mixture was 
diluted with Et2O (3.0 mL) and H2O (3.0 mL). The organic layer was 
separated and the resulting aqueous layer was extracted by Et2O (2 x 
10 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated under reduced pressure. 1H NMR analysis revealed 
the desired product formation as a 2:1 (E/Z) mixture at C4-C5 olefin. 
Purification by preparative TLC (Et2O/pentane = 1/4, 3 times eleva-





4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (64a). To a solution of 
macrolide 64 (8.0 mg, 8 µmol) in THF/MeCN 1:1 (1.0 mL) at 0 °C, 
3HF·NEt3 (50 µL, 0.31 mmol, excess) was added dropwise. The reac-
tion mixture was stirred at room temperature for 8 h, then it was 
quenched with aqueous sat. NaHCO3 (5 mL), extracted with CH2Cl2 (3 
x 2 mL), dried over MgSO4, filtered and concentrated. Purification by 
preparative TLC (AcOEt/cyclohexane = 1/4) afforded the alcohol 64a 
(3.5 mg, 49%) as a colorless oil and recovered starting material 64 (2.5 
mg, 40%) which was subjected to the same reaction conditions to ob-
tain 64a. As is mentioned above, the TBS deprotection had to be 
stopped before reaching full conversion due to the competing TBS 
cleavage at C18 position; The alcohol was used in the next steps with-







lyloxy)-3,5-dichloro-6-ethylbenzoate (Fully protected fidaxomicin, 7). 
To a solution of alcohol 64a (2.8 mg, 4 µmol) and acetimidate 
27 (3.0 mg, 3 µmol, 1.15 equiv) in CH2Cl2 (0.3 mL) molecular sieves 4Å 
(30 mg) was added and the white suspension was stirred for 30 min. 
Then, it was cooled to –78 °C and TBSOTf (0.15 µL, 20 mol%) in CH2Cl2 
(50 µL) was added dropwise. The reaction mixture was then warmed 
to –50 °C and subsequently warmed to –30 °C within 1 h. The reaction 
mixture was diluted with CH2Cl2 (1 mL), quenched with a drop of Et3N, 
filtered through cotton and concentrated. The anomeric ratio was de-
termined to be α:β = 1:4 by 1H NMR of this crude mixture. Purification 
by preparative TLC (AcOEt/cyclohexane = 1/4) afforded the desired β-
rhamnoside 7 (β-7: 3.3 mg, 62%) as a mixture with a tiny amount of 
inseparable impurity; β-7: Rf = 0.32 (AcOEt/cyclohexane = 1/4); 1H 
NMR (400 MHz, acetone-d6,) δ 7.19 (d, J = 11.5 Hz, 1H), 6.64-6.56 (m, 
1H), 6.23-6.05 (m, 2H), 5.95 (s, 1H), 5.92 (ddd, J = 14.8, 10.3, 4.5 Hz 
1H), 5.77 (d, J = 7.0 Hz, 1H), 5.55 (dd, J = 8.3, 8.3 Hz, 1H), 5.49-5.37 (m, 
2H), 5.31-5.23 (m, 2H), 5.19 (d, J = 3.2 Hz, 1H), 5.17 (ap d, J = 11.0 Hz 
1H), 5.12-5.05 (m, 2H), 5.03 (dd, J = 9.6, 9.6 Hz, 1H), 4.67-4.56 (m, 4H), 
4.64 (s, 1H), 4.52 (dddd, J = 11.7, 5.9, 1.4, 1.4 Hz, 1H), 4.35 (d, J = 10.8 
Hz, 1H), 4.36-4.34 (m, 1H), 4.27-4.20 (m, 1H), 3.90 (d, J = 10.1 Hz, 1H), 
3.76 (d, J = 9.8 Hz, 1H), 3.69 (ddd, J = 9.7, 9.7, 3.3, Hz, 1H), 3.55 (d, J = 
3.5 Hz, 1H), 3.54-3.47 (m, 1H) 3.52 (s, 3H), 2.92-2.76 (m, 3H), 2.75-2.63 
(m, 3H), 2.40 (ddd, J = 14.8, 10.3, 4.5 Hz, 1H), 2.32 (ddd, J = 13.8, 7.6, 
4.1 Hz, 1H), 2.02-1.94 (m, 1H), 1.91 (ap s, 3H), 1.87 (ap s, 3H), 1.71 (ap 
s, 3H), 1.34 (d, J = 6.2 Hz, 3H), 1.22-1.14 (m, 19H), 0.91 (s, 9H), 0.88 (s, 
9H), 0.85 (t, J = 7.4 Hz, 3H), 0.09 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H), 0.04 
(s, 3H); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C71H108Cl2O19Si2Na 
1413.6293; Found 1413.6276. HRMS (ESI-TOF) m/z: [M + NH4]+ Calcd 
for C71H112Cl2O19Si2N 1408.6739; Found 1408.6725. (See supporting in-
formation for the comparison of 1H NMR experiments between sem-
isynthetic and totally synthetic sample.) 
Carbonate and allyl protected fidaxomicin (7b). To a solution of the 
totally synthetic macrolide 7 (3.0 mg, 2.15 μmol) in THF (0.5 mL), 
3HF·NEt3 (50 μL, excess) was added dropwise. The solution was stirred 
for 48 h at 50 °C before it was quenched by the addition of sat. NaHCO3 
(3 mL, Caution! Gas evolution). The aqueous layer was extracted with 
AcOEt (4 x 2 mL) and the combined organic layers were dried over 
MgSO4, filtered and concentrated. Purification by preparative TLC (ac-
etone/pentane = 2/3) yielded the alcohol 7b (21.5 mg, 60%). Analyti-
cal data matched those reported above. 1H NMR (400 MHz, acetone-
d6) δ 7.19 (d, J = 11.4 Hz, 1H), 6.62 (dd, J = 15.1, 11.4 Hz, 1H), 6.22 – 
6.11 (m, 1H), 6.13 – 6.03 (m, 1H), 6.01 – 5.90 (m, 1H), 5.93 (s, 1H), 5.74 
(d, J = 6.9 Hz, 1H), 5.61 (t, J = 8.2 Hz, 1H), 5.46 (dq, J = 16.9, 1.5 Hz, 1H), 
5.45 – 5.36 (m, 1H), 5.33 – 5.25 (m, 1H), 5.29 – 5.21 (m, 1H), 5.18 (dt, 
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J = 10.3, 1.5 Hz, 1H), 5.18 (d, J = 3.1 Hz, 1H), 5.11 (dd, J = 8.7, 3.2 Hz, 
1H), 5.05 (dd, J = 9.2, 6.4 Hz, 1H), 5.03 (t, J = 9.7 Hz, 1H), 4.74 – 4.66 
(m, 1H), 4.65 (s, 1H), 4.63 – 4.58 (m, 3H), 4.59 (m, 1H), 4.57 – 4.47 (m, 
1H), 4.39 (d, J = 11.4 Hz, 1H), 4.26 (s, 1H), 4.08 – 3.98 (m, 2H), 3.83 – 
3.76 (m, 2H), 3.75 – 3.65 (m, 1H), 3.61 – 3.55 (m, 1H), 3.52 (s, 3H), 3.54 
– 3.49 (m, 1H), 2.87 (dd, J = 13.5, 7.5 Hz, 3H), 2.75 (t, J = 8.2 Hz, 3H), 
2.72 – 2.64 (m, 2H), 2.50 (ddd, J = 14.8, 9.5, 4.4 Hz, 1H), 2.40 (ddd, J = 
13.7, 8.3, 4.3 Hz, 1H), 1.89 (d, J = 1.3 Hz, 3H), 1.79 (d, J = 1.4 Hz, 3H), 
1.68 (s, 3H), 1.33 (d, J = 6.2 Hz, 3H), 1.23 – 1.13 (m, 16H), 0.82 (t, J = 
7.4 Hz, 3H); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C59H80Cl2O19Na 
1185.4563; found: 1185.4570. 
Fidaxomicin (1). To a solution of the totally synthetic carbonate 7b 
(0.9 mg, 0.8 μmol) in CH2Cl2 (0.2 mL), a drop of Barton’s base (ca. mg) 
and a drop of H2O (ca. 13 mg) were added. The mixture was stirred 
vigorously for 1.5 h before it was diluted with AcOEt (2.0 mL) and 
quenched with sat. NH4Cl (2 mL). The layers were separated and the 
aqueous layer was extracted with AcOEt (3 x 2 mL). The combined or-
ganic layers were dried with MgSO4, filtered and concentrated. Purifi-
cation by preparative TLC (MeOH/PhMe = 1/5) gave the allylether 7a 
(0.4 mg) with minor impurities; To a solution of the fully protected fi-
daxomicin 7a (crude, 0.4 mg) in THF (0.2 mL) at 0 °C, morpholine (0.3 
µL, 3.6 mmol) in CH2Cl2 (10 µL) and Pd(PPh3)4 (0.14 mg, 10 mol%) were 
added and the reaction mixture was stirred at this temperature for 20 
minutes. The reaction was quenched with sat. NH4Cl (2 mL), extracted 
with AcOEt (4 x 2 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated. Purification by preparative TLC 
(MeOH/CH2Cl2 = 1/10) yielded totally synthetic fidaxomicin (0.4 mg) as 
a colourless oil with minor impurities. The compound was further pu-
rified by RP-HPLC (A: H2O+0.1% HCOOH; Solvent B: MeCN+0.1% 
HCOOH; 1 mL/min; T = 20°C; B[%] (tR [min])= 50 (0 to 3); 65 (15); 
100 (16)). The impure fidaxomicin was dissolved in MeCN (0.15 mL) 
and separated in portions (3 x 50 μL). Fidaxomicin (1) eluted at tR = 
12.3 minutes and the solvents were evaporated under a constant 
stream of nitrogen yielding fidaxomicin contaminated with formate 
(ca. 0.1 mg 10% over 2 steps, calculated from a UV-standard curve of 
an authentic sample of fidaxomicin by linear regression analysis); 1H 
NMR (600 MHz equipped with cryo-platform, CD3OD, containing 
HCOO– from final RP-HPLC purification) δ 8.55 (s, HCOO–), 7.23 (d, J = 
11.5 Hz, 1H), 6.60 (dd, J = 14.9, 11.8 Hz, 1H), 5.95 (ddd, J = 14.7, 9.5, 
4.8 Hz, 1H), 5.83 (s, 1H), 5.57 (ap t, J = 8.2 Hz, 1H), 5.14 (ap d, J = 10.7, 
1H), 5.13 (dd, J = 9.7 Hz, 1H), 5.02 (d, J = 10.2 Hz, 1H), 4.74–4.70 (m, 
1H), 4.71 (s, 1H), 4.64 (s, 1H), 4.61 (d, J = 11.6 Hz, 1H), 4.44 (d, J = 11.6 
Hz, 1H), 4.22 (ap s, 1H), 4.02 (p, J = 6.3 Hz, 1H), 3.92 (dd, J = 3.2, 1.2 
Hz, 1H), 3.75 (ddd, J = 13.9, 10.2, 3.3 Hz, 1H) 3.71 (d, J = 9.7 Hz 1H), 
3.58–3.52 (m, 2H) 3.54 (s, 3H), 3.15–3.06 (m, 1H), 3.04–2.95 (m, 1H), 
2.76–2.66 (m, 3H), 2.60 (hept, J = 7.0 Hz, 1H), 2.49 (ddd, J = 14.9, 9.5, 
4.4 Hz, 1H), 2.43 (ddd, J = 13.8, 8.8, 4.5 Hz, 1H), 2.05–1.98 (m, 1H), 
1.82 (d, J = 1.3 Hz, 3H), 1.76 (ap s, 3H), 1.66 (ap s, 3H), 1.32–1.27 (m, 
4H), 1.22–1.15 (m, 12H), 1.15 (s, 3H), 1.13 (s, 3H), 0.88 (t, J = 7.4 Hz, 
3H); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C52H74Cl2O18Na 
1079.4144; found: 1079.4151. (The observed overall yield (10%) for 
these transformations can be explained by difficulties in the purifica-
tion of the final synthetic product on a small scale (compare with sem-
isynthetic approach). This low value is also partially explained by the 
impurity of 7 contaminated after the rhamnosylation reaction, which 
was difficult to remove by simple column chromatographic purifica-
tion. Although the purity of semisynthetic sample 7 is much higher 
than that of fully synthetic 7, we concluded synthetic 7 is pure enough 
for further transformations. The contaminant of 7 was successfully re-
moved after RP-HPLC at the end of synthesis. The identity of the syn-
thetic compound was confirmed by co-injection of synthetic and au-
thentic material on RP-HPLC and 1H NMR analysis. The retention time 
of both compounds was identical for both compounds and co-injec-
tion showed only single peak. However, the 1H NMR spectrum of syn-
thetic 1 did not match completely to those of natural 1 (at most 0.2 
ppm difference observed, especially around the resorcylate segment 
(ethyl group) and rhamnose segment (C4´ hydrogen atom and C6´ hy-
drogen atoms)) probably due to the formate salt formation (see pKa 
experiment). Therefore, identity of the compounds was confirmed in 
1H NMR by mixing equimolar amounts of synthetic 1 and natural 1, the 
1H NMR spectrum clearly showed a single set of peaks. See supporting 
information for the detailed comparison in 1H NMR experiments be-
tween natural 1 and totally synthetic 1.) 
 
Total Synthesis of Tiacumicin A (2) 
 
(3aS,4S,7S,7aS)-4-methoxy-6,6-dimethyl-2-oxotetrahydro-4H-
[1,3]dioxolo[4,5-c]pyran-7-yl acetate (α-33b) and (3aS,4R,7S,7aS)-4-
methoxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]py-
ran-7-yl acetate (β-33b). To a solution of triol 33 (200 mg, 1.04 mmol) 
in THF (30 mL) at 50 °C was added 1,1-carbodiimidazol (590 mg, 3.64 
mmol, 3.5 equiv, addition of ca. 100 mg every 30 min) was added por-
tion wise over 3.5 h. Then 6N HCl (3.0 mL) was added and stirred for 2 
h at room temperature, during which time UV active side product at 
low Rf value (checked by TLC: AcOEt/cyclohexane 1/1) have disap-
peared and two non-UV active desired products at high Rf left. Then it 
was extracted with AcOEt three times, washed with brine, dried over 
Na2SO4, filtered and concentrated. The obtained carbonate 33a was 
used in the next reaction without further purification. 
To a solution of carbonate 33a (crude, 1.04 mmol) in CH2Cl2 (5 mL) 
at room temperature was added Ac2O (2 mL, 20 equiv) and pyridine (2 
mL, 25 equiv) and stirred at room temperature for 5 h. The reaction 
was quenched with water (40 mL), extracted with CH2Cl2 (3 x 10mL). 
The combined organic layers were added 1N HCl (50 mL) and the re-
sulting aqueous phase was extracted again (50 mL, 10 mL). The com-
bined organic layers were washed with brine, dried over Na2SO4, fil-
tered and concentrated. Purification by silica gel column chromatog-
raphy (AcOEt/cyclohexane = 1/5 - 1/4 - 1/3 - 1/2) gave desired α and 
β glycoside 33b as a separable isomer (total 190 mg, 70% over 2 steps); 
β-33b: Rf = 0.45 (AcOEt/PhMe = 1/3); IR (cm-1) ν 2983, 1806, 1745, 
1223, 1171, 1042; [α]D26  = –91.6° (c 1.10, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 5.81 – 5.72 (m, 1H), 4.83 (d, J = 1.9 Hz, 1H), 4.81 – 4.75 (m, 
2H), 3.52 (s, 3H), 2.14 (s, 3H), 1.28 (s, 3H), 1.20 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 169.2, 153.9, 95.8, 75.7, 75.0, 72.6, 71.9, 56.2, 28.9, 
24.2, 21.0; HRMS (ESI) m/z: [M + Na]+ Calcd for Calcd for C11H16O7Na 
283.07882; Found 283.0793; α-33b: Rf = 0.6 (AcOEt/PhMe = 1/3); 
[α]D26  = +21.6° (c 0.82, CHCl3); IR (cm-1) ν 2987, 1827, 1809, 1748, 1223, 
1082, 1035; 1H NMR (400 MHz, CDCl3) δ 5.11 (d, J = 7.7 Hz, 1H), 4.91 
(d, J = 3.0 Hz, 1H), 4.78 (t, J = 7.7 Hz, 1H), 4.68 (dd, J = 7.8, 3.0 Hz, 1H), 
3.46 (s, 3H), 2.13 (s, 3H), 1.28 (d, J = 2.6 Hz, 6H); 13C NMR (63 MHz, 
CDCl3) δ 169.6, 153.2, 97.3, 76.7, 75.4, 74.7, 72.4, 56.1, 26.7, 23.1, 
20.9; HRMS (ESI) m/z: [M + Na]+ Calcd for C11H16O7Na 283.0788; Found 
283.0790. 
(R)-hept-5-yn-3-ol (65a). To a stirred solution of propyne (ca. 3% in 
heptane 63 mL, 31.9 mmol, 3.5 equiv) in 120 mL of THF at –78 °C was 
added n-BuLi (1.6 M, 11.5 mL, 18.2 mmol, 2.0 equiv) and stirred at –
78 °C. The reaction mixture was heated up to –30 °C and continued to 
stirred for 15 min and cooled again to –78 °C. Commercially available 
optically active epoxide 65 (800 µL, 9.1 mmol, 99% ee) was added drop 
wise followed by BF3·OEt2 (1210 µL, 9.56 mmol, 1.05 equiv). Stirring 
was continued at –78 °C for 10 min and heated up to –10 °C gradually 
over 2 h. Reaction was quenched with sat. NH4Cl (50 mL) and stirred 
for 15 min. Organic layer was separated and the resulting aqueous 
layer was extracted with Et2O 2 times. Combined organic layer was 
washed with brine, dried over Na2SO4, filtered and evaporated slowly 
up to 100 mbar at 40 °C gave heptane solution of alcohol. Purification 
by silica gel chromatography (Et2O/pentane = 0/10 - 1/9 - 1/7.5 - 1/5) 
gave alcohol 65a (540 mg, 53%) as a color less liquid; Rf = 0.25 
(Et2O/pentane = 1/6); [α]D25 = –12.3° (c 1.34, CHCl3); IR (cm-1) ν 3369 
(br), 2964, 2922, 1461, 1103, 1019, 976; 1H NMR (400 MHz, CDCl3) δ 
3.68 – 3.55 (m, 1H), 2.42 – 2.33 (m, 1H), 2.29 – 2.17 (m, 1H), 1.93 (d, J 
= 4.2 Hz, 1H), 1.80 (t, J = 2.6 Hz, 1H), 1.59 – 1.47 (m, J = 7.5 Hz, 2H), 
0.95 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 78.5, 75.4, 71.7, 
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29.2, 27.4, 10.1, 3.7; HRMS (APCI-TOF) m/z: [M + H]+ Calcd for C7H13O 
113.0961; Found 113.0971. 
(R,Z)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hept-5-en-3-
ol (66). A suspension of CuCl (11 mg, 0.11 mmol, 5 mol%), PPh3 (35 
mg, 0.13 mmol, 6 mol%) and KOt-Bu (50 mg, 0.45 mmol, 20 mol%) in 
THF (1.5 mL) was stirred at room temperature for 30 min forming a 
brown solution. A solution of B2Pin2 (620 mg, 2.45 mmol, 1.1 equiv) in 
THF (2 mL) was added and the reaction mixture and stirred for further 
10 min forming a black solution. The reaction mixture was cooled to 0 
°C and a solution of alkyne 65a (235 mg, 2.09 mmol) in THF (1.0 mL) 
were added. The reaction was warmed to room temperature and 
stirred for 16 h. Then MeOH (180 µL, 4.46 mmol, 2.0 equiv) was added 
and continued stirring for more 10 h. The reaction mixture was filtered 
through Celite and washed with Et2O. Purification by flash column 
chromatography (Et2O/pentane = 1/6 - 1/5 -1/3) yielded the product 
boronic ester 66 (432 mg, 86%) as a colorless oil; Rf = 0.34 (Et2O/pen-
tane = 1/4); [α]D25 = –11.0° (c 0.316, CHCl3); IR (cm-1) ν 3409 (br), 2977, 
2931, 1370, 1301, 1138; 1H NMR (400 MHz, CDCl3) δ 6.35 (tt, J = 7.2, 
1.6 Hz, 1H), 3.69 – 3.58 (m, 1H), 2.32 (t, J = 6.8 Hz, 2H), 1.71 (s, 3H), 
1.57 – 1.41 (m, 2H), 1.26 (d, J = 1.6 Hz, 12H), 0.96 (td, J = 7.4, 1.4 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 140.7, 82.4, 71.8, 35.5, 28.9, 24.0, 
13.4, 9.2; 11B NMR (128 MHz, CDCl3) δ 30.4; HMBC (δ H: 1.71 ppm, δ C: 
129.6 ppm); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C13H25BO3Na 
263.1789; Found 263.1787. 
 (R,Z)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hept-5-en-3-
yl (E)-2-methylpenta-2,4-dienoate (68). To a stirred solution of the 
known carboxylic acid 6764 (76 mg, 0.68 mmol, 1.3 equiv, see support-
ing information for the synthesis of 67) in PhMe (6 mL), Et3N (210 µL, 
1.46 mmol, 2.8 equiv) and 2,4,6-trihlorobenzoyl chloride (110 µL, 0.68 
mmol, 1.3 equiv) was added successively and stirred at room temper-
ature for 1.5 h. To the reaction mixture, PhMe (5 mL) solution of alco-
hol 66 (125 mg, 0.52 mmol, 1.0 equiv) and DMAP (83 mg, 0.68 mmol, 
1.3 equiv) was added and continued to stir for 5 h. Reaction was 
quested with sat. NH4Cl and aqueous layer was extracted with Et2O, 
washed with brine. Organic phase was dried over Na2SO4, filtered, and 
concentrated under the reduced pressure. Purification by silica gel 
chromatography (Et2O/pentane = 1/30 - 1/20) gave desired ester 68 
(140 mg, 81%) as a color less oil; Rf = 0.30 (Et2O/pentane = 1/20); [α]D25 
= –13.3° (c 1.47, CHCl3); IR (cm-1) ν 2976, 2934, 1706, 1370, 1306, 1247, 
1143, 1100; 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 11.3 Hz, 1H), 6.64 
(ddd, J = 16.8, 11.4, 10.1 Hz, 1H), 6.28 (td, J = 7.2, 1.8 Hz, 1H), 5.54 (d, 
J = 17.3 Hz, 1H), 5.42 (d, J = 10.1 Hz, 1H), 4.96 - 4.87 (m, 1H), 2.46 (ddd, 
J = 7.0, 5.8, 1.0 Hz, 1H), 2.44 - 2.35 (m, 1H), 1.93 (d, J = 1.4 Hz, 3H), 
1.69 (s, 3H), 1.68 - 1.55 (m, 2H), 1.24 (s, 12H), 0.90 (t, J = 7.4 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 168.1, 140.4, 138.1, 132.4, 128.6, 124.0, 
83.3, 75.2, 32.9, 26.7, 24.9, 24.9, 14.3, 12.9, 9.8; 11B NMR (128 MHz, 
CDCl3) δ 29.9; HMBC (δ H: 1.69 ppm, δ C: 129.7 ppm); HRMS (ESI-TOF) 




(70). To a solution of methyl novioside 33c (124 mg, 0.476 mmol, 1.8 
equiv) in CH2Cl2 (4.0 mL) under dark at 0 °C was added HBr (33% in 
AcOH, 2 mL). The colorless, slightly orange solution was warmed up to 
room temperature and stirred for 100 min then AcBr (a drop) was 
added and stirred further 1 h. The reaction mixture was diluted with 
CH2Cl2 (5 mL) and quenched with ice water (4 mL). Layers were sepa-
rated and the aqueous layer was re-extracted using CH2Cl2 (5 mL). Ob-
tained organic layer was washed with sat. NaHCO3 and dried over 
MgSO4, filtered and concentrated under reduced pressure without 
heating (water bath) giving glycosyl bromide 69 as a rather dark oil. An 
alcohol 43 (122 mg, 0.263 mmol) solution in PhH was azeotroped and 
dried before use. It was then dissolved in CH2Cl2 (1.5 mL) and MS 3Å 
(powder, 240 mg) was added. After stirring for 100 minutes, HgO (450 
mg, 2.1 mmol, 8 equiv) and HgBr2 (8 mg, 0.026 mmol, 10 mol%) were 
added and the orange suspension was stirred for 0.5 h. Then the gly-
cosyl bromide 69 in CH2Cl2 (3.0 mL) was slowly added over 25 min and 
stirred for overnight. After the reaction mixture was diluted with 
CHCl3, it was filtered through Celite. Organic layer was separated and 
extracted with CHCl3/NaHCO3/sat. Rochelle and Na2S2O3 solution. 
Then organic layer was dried over Na2SO4, and concentrated under re-
duced pressure after addition of 1 drop of Et3N. Purification by column 
chromatography (AcOEt/cyclohexane = 1/15 (sm) - 1/10 - 1/6 - 1/4 (β-
anomer) then 1/1 (acetylated sugar recovery)) gave alcohol starting 
material, acetylated sugar, and desired β-glycoside 70 (80.3 mg, 44%); 
Rf = 0.60 (Et2O/pentane = 1/1); IR (cm-1) ν 2931, 1813, 1223, 1167, 
1093, 1073, 1043, 1007, 836, 775; [α]D25 = –33.0° (c 0.58, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ 6.22 (d, J = 1.2 Hz, 1H), 5.80 - 5.74 (m, 1H), 
5.70 (ddt, J = 17.3, 10.2, 7.1 Hz, 1H), 5.03 - 4.99 (m, 2H), 4.99 - 4.97 (m, 
3H), 4.87 (dt, J = 10.6, 1.3 Hz, 1H), 4.80 - 4.75 (m, 2H), 3.95 (t, J = 6.1 
Hz, 1H), 3.84 (d, J = 9.1 Hz, 1H), 2.50 (qd, J = 9.6, 3.1 Hz, 1H), 2.21 (tdd, 
J = 7.0, 5.6, 1.3 Hz, 2H), 2.14 (s, 3H), 1.84 (ddd, J = 13.2, 7.6, 3.1 Hz, 
1H), 1.78 (d, J = 1.1 Hz, 3H), 1.57 (d, J = 1.4 Hz, 3H), 1.17 (s, 3H), 1.14 
(s, 3H), 1.14 - 1.10 (m, 1H), 0.88 (s, 9H), 0.81 (t, J = 7.4 Hz, 3H), 0.01 (s, 
3H), –0.02 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 169.2, 153.7, 147.5, 
140.1, 135.6, 123.7, 116.6, 95.2, 89.5, 81.6, 77.4, 75.6, 75.1, 72.1, 72.1, 
42.7, 42.0, 28.0, 26.0, 24.7, 24.2, 21.0, 19.9, 18.3, 12.8, 11.3, –4.2, –





5,7,11,15-tetraen-3-yl (E)-2-methylpenta-2,4-dienoate (71). To an io-
dide 70 (25.9 mg, 63 µmol) and bronate 68 (22 mg, 64 µmol, 1.7 equiv) 
in dry THF (1.0 mL) and degassed water (200 µL) at 0 °C, Pd(PPh3)4 (4.0 
mg, 3.7 mmol, 10 mol%) was added. Next, the stock solution of TlOEt* 
(ca. 140 µL solution, 56 µmol, 1.5 equiv) was added dropwise for 1 min 
(better to add TlOEt slowly, preferably over ca. 10 min.). Reaction was 
monitored by TLC. After stirring for 20 min at room temperature, the 
reaction mixture was diluted with Et2O (2 mL), AcOEt (2 mL), sat. NH4Cl 
(2 mL) and water (1 mL). The aqueous layer was extracted with AcOEt 
(2 x 10 mL). The combined organic layers were dried over Na2SO4, fil-
tered, and evaporated. Purification by silica gel column chromatog-
raphy (Et2O/pentane = 1/6 - 1/4 - 1/2) gave desired alkene 71 (25.5 
mg, 88%) as an oil. *TlOEt stock solution; To TlOEt (41.8 mg, a clear 
colourless to bit brown liquid) in a HPLC vial tube under Ar was added 
degassed water (400 µL) and it was dissolved prior to use; Rf = 0.70 
(Et2O/pentane = 1/1); IR (cm-1) ν 2930, 2857, 1815, 1706, 1251, 1172, 
1095, 1005, 837; [α]D25 = –64.6° (c 0.105, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 7.14 (dd, J = 11.3, 1.4 Hz, 1H), 6.65 (ddd, J = 16.8, 11.3, 10.1 
Hz, 1H), 5.87 - 5.79 (m, 1H), 5.77 (s, 1H), 5.76 - 5.63 (m, 1H), 5.55 (d, J 
= 16.8 Hz, 1H), 5.44 (d, J = 10.8 Hz, 1H), 5.33 (t, J = 7.4 Hz, 1H), 5.04 
(dd, J = 2.5, 1.3 Hz, 1H), 4.97 (ddd, J = 17.2, 2.5, 1.2 Hz, 1H), 4.94 (ddt, 
J = 10.2, 2.3, 1.1 Hz, 2H), 4.89 (dt, J = 12.4, 6.4 Hz, 1H), 4.79 - 4.74 (m, 
2H), 3.93 (t, J = 6.1 Hz, 1H), 3.68 (d, J = 9.0 Hz, 1H), 2.52 (qd, J = 9.5, 
3.2 Hz, 1H), 2.45 - 2.31 (m, 2H), 2.20 - 2.16 (m, 2H), 2.12 (s, 3H), 1.94 
(d, J = 1.4 Hz, 3H), 1.88 - 1.77 (m, 1H), 1.74 (dd, J = 6.5, 1.3 Hz, 6H), 
1.67 - 1.59 (m, 3H), 1.57 (d, J = 1.3 Hz, 3H), 1.25 (s, 3H), 1.17 (s, 3H), 
1.12 (s, 3H), 0.90 (t, J = 7.4 Hz, 3H), 0.85 (s, 9H), 0.81 (t, J = 7.4 Hz, 3H), 
–0.03 (s, 3H), –0.08 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 169.1, 168.1, 
153.9, 138.9, 138.2, 135.8, 134.6, 134.1, 133.5, 132.4, 128.6, 125.8, 
124.7, 124.1, 116.3, 94.2, 92.0, 77.6, 75.7, 75.6, 74.9, 72.3, 42.5, 42.0, 
32.5, 28.1, 26.6, 26.0, 24.7, 24.3, 21.0, 18.3, 17.3, 13.9, 12.9, 12.8, 
11.4, 9.9, –4.5, –4.9; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 




2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl acetate (71a). To 
an alkene 71 (4.0 mg, 9.5 µmol) in PhMe (1.0 mL), second generation 
Grubbs catalyst (0.86 mg, 1.0 µmol, 20 mol%) was added at 0 °C and 
the resulting mixture was stirred at 100 °C in a preheated oil bath for 
90 min. The reaction mixture was diluted with Et2O (3 mL) and brine 
(5 mL) and separated. Organic layer was dried over Na2SO4, filtered 
 25 
and concentrated. Purification by silica gel column chromatography 
(Et2O/pentane = 1/3) gave desired macrocycle as a mixture of E and Z 
isomer (E:Z = 1:0.8 determined by 1H NMR). Further purification by 
HPLC with DAICEL Chiral-IA (Eluant: n-hexane/IPA = 99/1) gave desired 
(E)-macrocycle 71a (1.6 mg, 42%); Rf = 0.3 (Et2O/pentane = 1/1); IR 
(cm-1) ν 2958, 2930, 1815, 1701, 1371, 1253, 1224, 1167, 1097, 1044; 
[α]D25 = +49.8° (c 0.32, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.01 (d, J = 
11.4 Hz, 1H), 6.25 (dd, J = 15.1, 11.3 Hz, 1H), 5.83 (m, 1H), 5.78 (s, 1H), 
5.71 (ddd, J = 14.6, 9.0, 5.0 Hz, 1H), 5.48 (d, J = 8.0 Hz, 1H), 5.16 (d, J = 
10.4 Hz, 1H), 5.09 (s, 1H), 4.86 (td, J = 6.9, 3.3 Hz, 1H), 4.78 (dd, J = 4.4, 
1.6 Hz, 2H), 4.19 (br, 1H), 3.72 (d, J = 9.8 Hz, 1H), 2.67 (qd, J = 11.4, 
10.0, 3.2 Hz, 2H), 2.57 (m, 1H), 2.52 (m, 1H), 2.38 - 2.19 (m, 2H), 2.13 
(s, 3H), 1.85 (m, 1H), 1.85 (s, 3H), 1.81 (s, 3H), 1.84 - 1.62 (m, 2H), 1.64 
(s, 3H), 1.57 (s, 3H), 1.23 (s, 3H), 1.15 (s, 3H), 0.95 (t, J = 7.5 Hz, 3H), 
0.87 (s, 9H), 0.83 (t, J = 7.4 Hz, 3H), 0.03 (s, 3H), –0.01 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 169.2, 169.0, 153.9, 140.5, 138.7, 135.6, 135.2, 
134.9, 134.0, 127.9, 124.9, 124.3, 123.6, 94.2, 92.7, 77.4, 75.7, 74.9, 
74.6, 73.0, 72.4, 41.6, 37.1, 31.3, 30.5, 29.9, 28.2, 26.2, 25.9, 25.5, 
24.2, 21.0, 18.3, 17.0, 14.8, 13.0, 12.2, 10.7, 10.4, –4.9, –5.0; HRMS 





[1,3]dioxolo[4,5-c]pyran-7-yl acetate (71b). To a TBS ether 71a (5.2 
mg, 7.0 µmol) in THF (0.65 mL) in a glass sealed tube (PP tube is rec-
ommended), 3HF·NEt3 (0.35 mL, 2.05 mmol, excess) was added and 
stirred at room temperature for 2 h and at 50 °C for 24 h. The reaction 
mixture was diluted with AcOEt (1 mL) and carefully quenched with 
sat. NaHCO3 (caution! Gas evolution.). The aqueous layer was further 
diluted with water (10 mL) and extracted with AcOEt (3 x 10 mL), dried 
over Na2SO4, filtered and concentrated. Purification by column chro-
matography (AcOEt/cyclohexane = 1/3 - 2/3) gave desired alcohol 71b 
as a white solid (4.3 mg, 98%); Rf = 0.35 (AcOEt/cyclohexane = 2/3), Rf 
= 0.6 (Et2O only); 1H NMR (500 MHz, CDCl3) δ 6.96 (d, J = 11.3 Hz, 1H), 
6.39 (ddd, J = 15.0, 11.3, 1.6 Hz, 1H), 5.84 - 5.80 (m, 2H), 5.64 (td, J = 
10.4, 5.2 Hz, 1H), 5.45 (t, J = 8.1 Hz, 1H), 5.07 (s, 1H), 4.99 (d, J = 10.5 
Hz, 1H), 4.82 – 4.74 (m, 3H), 4.23 (s, 1H), 3.72 (d, J = 9.8 Hz, 1H), 2.73 
- 2.66 (m, 2H), 2.48 - 2.32 (m, 3H), 2.13 (s, 3H), 1.90 (m, 1H), 1.88 (s, 
3H), 1.85 (s, 3H), 1.80 (m, 1H), 1.74 (s, 3H), 1.69 (m, 1H), 1.66 (s, 3H), 
1.50 (m, 1H), 1.26 (m, 1H), 1.20 (s, 3H), 1.14 (s, 3H), 0.95 (t, J = 7.5 Hz, 
3H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 169.2, 169.0, 
153.9, 139.0, 136.6, 136.3, 135.3, 135.1, 133.7, 129.8, 126.8, 126.2, 
123.0, 94.4, 92.7, 75.7, 75.1, 74.9, 72.7, 72.4, 42.1, 36.6, 31.8, 29.9, 
28.1, 26.8, 25.4, 24.2, 21.0, 17.2, 15.2, 13.4, 12.5, 11.0, 10.1; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C35H50O10Na 653.3296; Found 
653.3292. 
Tiacumicin A (2). To the solution of carbonate protected tiacumicin 
A (71b) (10.2 mg, 16.2 µmol) in THF (2000 µL) and ethylene glycol (100 
µL), a stock solution (25 µL, prepared from 1.5 mg NaH in 1.5 mL eth-
ylene glycol) was added at 0 °C and the reaction mixture was stirred 
for 10 min at the same temperature. Then, stock solution (10 µL) was 
added and stirred for 30 min resulting in slightly yellowish solution and 
the reaction mixture was first diluted with AcOEt (2 mL) and water (2 
mL). The aqueous layer was extracted with AcOEt (3 x 5 mL). The com-
bined organic layers were dried over Na2SO4, filtered and concen-
trated under reduced pressure. UPLC MS analysis showed desired 
molecule ion as a Na+ adduct. Purification of crude mixture with re-
versed phase HPLC without formic acid lead to the isolation of desired 
tiacumicin A (2) as a slow eluting entity (tR = 26 min, 1.80 mg, 18.4%) 
on the RP-HPLC (A: H2O; Solvent B: MeCN; 20 mL/min; T = 20 °C; B[%] 
(tR [min])=35 (0 to 0.5); 70 (30); 90 (35), Phenomenox Gemini column 
5 µm NX-C18 110, 250 x 21.2 mm). This hydrolysis also led to the iso-
lation of dacetyl tiacumicin A (tR = 18 min, 0.91 mg, 10.0%), 2`-acety-
lated product (tR = 23 min, 0.33 mg, 3.5%), 3`-acetylated product (tR = 
24 min, 0.72 mg, 7.4%) and recovery of starting material (tR = 36 min, 
2.76 mg, 27%); Tiacumicin A (1) Rf = 0.15 (Et2O only); IR (cm-1) ν 3484, 
2969, 2928, 1735, 1700, 1643, 1369, 1249, 1166, 1046, 1006, 899, 802, 
752; [α]D25 = +59.0° (c 0.205, CHCl3) [lit.12a [α]D25 = +128.2º (c 1.19, 
MeOH)]; 1H NMR (500 MHz, CDCl3) δ 7.00 (d, J = 11.3 Hz, 1H), 6.40 (dd, 
J = 14.7, 11.8 Hz, 1H), 5.75 (s, 1H), 5.65 (ddd, J = 14.8, 10.2, 4.5 Hz, 1H), 
5.46 (t, J = 8.3 Hz, 1H), 5.01 (d, J = 10.0 Hz, 1H), 4.83 (p, J = 6.2 Hz, 1H), 
4.67 (s, 1H), 4.24 (s, 1H), 4.01 (s, 1H), 3.66 (d, J = 9.3 Hz, 1H), 2.77 – 
2.67 (m, 3H), 2.52 (ddd, J = 13.8, 9.0, 4.3 Hz, 1H), 2.50 – 2.38 (m, 3H), 
2.31 (dt, J = 13.7, 6.5 Hz, 1H), 2.11 (s, 3H), 1.89 (s, 4H), 1.84 (dd, J = 
14.1, 7.0 Hz, 1H), 1.80 (s, 4H), 1.69 (s, 3H), 1.65 (s, 3H), 1.33 – 1.24 (m, 
1H), 1.18 (s, 3H), 1.11 (s, 3H), 0.96 (t, J = 7.5 Hz, 3H), 0.86 (t, J = 7.4 Hz, 
3H); 13C NMR (126 MHz, CDCl3) δ 171.22, 168.80, 139.11, 136.63, 
136.33, 135.46, 134.39, 134.26, 129.75, 126.14, 125.80, 122.83, 94.89, 
92.76, 75.28, 74.91, 73.52, 72.64, 71.67, 70.24, 41.34, 36.61, 31.50, 
28.20, 26.60, 26.19, 21.22, 18.41, 17.23, 15.07, 13.43, 12.41, 11.00, 
10.17; HRMS (ESI-Orbitrap) m/z: [M + Na]+ Calcd for C34H52O9Na 
627.3504; Found 627.3504. See supporting information for the com-
parison of 1H and 13C NMR experiments between natural and totally 
synthetic tiacumicin A. Although the results obtained was reproduci-
ble (same experiment was repeated 3 times with 10 - 12 mg of starting 
material), the migration of the acyl group was not avoided. To get the 
best yield, the reaction should be stopped before full consumption of 
the starting material. 
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